

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2004, 10:46:57 ; Search time 123 Seconds

(without alignments)  
20.674 Million cell updates/sec

Title: US-10-706-475-10

Perfect score: 43

Sequence: 1 SLMMITQX 9

Scoring table:

BLOSUM62XX

Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 50 summaries

Database : A Geneseq\_29Jan04:\*

- 1: Geneseqp1980s:\*
- 2: Geneseqp1990s:\*
- 3: Geneseqp2000s:\*
- 4: Geneseqp2001s:\*
- 5: Geneseqp2002s:\*
- 6: Geneseqp2003as:\*
- 7: Geneseqp2003bs:\*
- 8: Geneseqp2004s:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	43	100.0	9	4	AAB85306	Aab85306 HLA-A2 bi
2	43	100.0	10	4	AAB85314	Aab85314 HLA-A2 bi
3	42	97.7	9	2	AAW62586	Aaw62586 Cancer as
4	42	97.7	9	2	AAW01762	Aay01762 Exemplary
5	42	97.7	9	3	AAW52432	Aay52432 Human tum
6	42	97.7	9	3	AAB22791	Aay22791 NY-ESO-1
7	42	97.7	9	3	AAW78470	Aay78470 NY-ESO-1
8	42	97.7	9	3	AAB02631	Aab02631 Tumour as
9	42	97.7	9	3	AAW08703	Aab08703 Antigenic
10	42	97.7	9	4	AAE02120	Aae02120 NY-ESO-1
11	42	97.7	9	4	AAB69948	Aab69948 Human NY-
12	42	97.7	9	4	AAW67166	Aag67166 Cancer te
13	42	97.7	9	4	AAU01537	Aau01537 Cytolytic
14	42	97.7	9	4	AAB31329	Aab31329 Exemplary
15	42	97.7	9	4	AAB85299	Aab85299 HLA-A2 bi
16	42	97.7	9	4	AAB85315	Aab85315 HLA-A2 bi
17	42	97.7	9	4	AAB85304	Aab85304 HLA-A2 bi
18	42	97.7	9	4	AAB85303	Aab85303 HLA-A2 bi
19	42	97.7	9	4	AAB85305	Aab85305 HLA-A2 bi
20	42	97.7	9	4	AAB85308	Aab85308 HLA-A2 bi
21	42	97.7	9	4	AAW82017	Aab82017 HLA- bind
22	42	97.7	9	4	AAW06850	Aae06850 Human NY-
23	42	97.7	9	5	AAE26809	Aae26809 Human HLA
24	42	97.7	9	5	AAE26808	Aae26808 Human HLA
25	42	97.7	9	5	AAO21430	Aao21430 HLA-A2 re

26	42	97.7	9	6	ABP74313	Abp74313 Human NY-
27	42	97.7	9	6	ABU64813	Abu64813 Human NY-
28	42	97.7	9	6	ADA19553	Ada19553 Human can
29	42	97.7	9	7	ADC09172	Adc09172 Epitope w
30	42	97.7	9	7	ADD35560	Add35560 Human NY-
31	42	97.7	10	2	AAW06006	Aay06006 Human can
32	42	97.7	10	4	AAB85310	Aab85310 HLA-A2 bi
33	42	97.7	10	4	AAB85313	Aab85313 HLA-A2 bi
34	42	97.7	10	4	AAB85312	Aab85312 HLA-A2 bi
35	42	97.7	10	4	AAB85309	Aab85309 HLA-A2 bi
36	42	97.7	10	4	AAB85311	Aab85311 HLA-A2 bi
37	42	97.7	10	4	AAB85307	Aab85307 HLA-A2 bi
38	42	97.7	11	2	AAW62585	Aaw62585 Cancer as
39	42	97.7	11	2	AAW01761	Aay01761 Exemplary
40	42	97.7	11	3	AAW52431	Aay52431 Human tum
41	42	97.7	11	3	AAB22790	Aab22790 NY-ESO-1
42	42	97.7	11	3	AAW78469	Aay78469 NY-ESO-1
43	42	97.7	11	3	AAB02630	Aab02630 Tumour as
44	42	97.7	11	3	AAW08702	Aab08702 Antigenic
45	42	97.7	11	4	AAE02119	Aae02119 NY-ESO-1
46	42	97.7	11	4	AAB69947	Aab69947 Human NY-
47	42	97.7	11	4	AAW67165	Aag67165 Cancer te
48	42	97.7	11	4	AAU01536	Aau01536 Cytolytic
49	42	97.7	11	4	AAB31327	Aab31327 Exemplary
50	42	97.7	11	4	AAB31328	Aab31328 Exemplary

## ALIGNMENTS

RESULT 1

AAB85306

ID AAB85306 standard; peptide; 9 AA.

AC AAB85306;

DT 17-SEP-2001 (first entry)

DE HLA-A2 binding NY-ESO-1 peptide.

KW NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;  
KW HLA-A2; T-cell sorter; tumor; immune tetramer.

OS Homo sapiens.

FH Key Location/Qualifiers

FT Misc-difference 9 /label= Ala, Val, Leu, Ile, Pro, Phe, Met, Trp or Gly  
FT /note= "can be any amino acid, preferably one with a non-  
polar side chain such as those residues indicated above"

WO200136453-A2.

25-MAY-2001

08-NOV-2000; 2000WO-US042010.

15-NOV-1999; 99US-00440621.

25-FEB-2000; 2000US-00514036.

29-SEP-2000; 2000US-00676005.

(LUDW-) LUDWIG INST CANCER RES.

(UYOX-) UNIV OXFORD.

Valmori D, Cerottini J, Romero P, Cerundolo V;

WPI; 2001-451454/48.

Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell  
presents human leukocyte antigen-A2 molecule on its surface, binds to  
human leukocyte antigen molecules and provokes lysis by cytolytic T  
cells.

PS Claim 1; Page 25; 38pp; English.

XX The invention provides NY-ESO-1 peptide derivatives which bind to human

CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells

CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an

CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide

CC derivatives are useful for determining if a cell presents an HLA-A2

CC molecule on its surface, by contacting a sample containing the cell with

CC the peptide or its derivative, and determining binding between them,

CC where the binding is indicative of HLA-A2 on the surface of the cell. The

CC NY-ESO-1 peptides and analogues are useful therapeutically, for

CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1

CC in connection with the pathology, as well as diagnostically, i.e. to

CC determine if HLA-A2 positive cells are present, or if relevant CTLs are

CC present. They are also useful for determining the presence of CTLs in a

CC sample. The peptides are useful as T-cell sorters, when incorporated into

CC immune tetramers. The present sequence represents a NY-ESO-1 peptide that

CC can bind to HLA-A2 molecule

XX Sequence 9 AA;

SQ Query Match 100.0%; Score 43; DB 4; Length 9;

Best Local Similarity 100.0%; Pred. NO. 1.4e+06;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQX 9

DB 1 SLLMWITQX 9

RESULT 2

AAB85314

ID AAB85314 standard; peptide; 10 AA.

XX AC AAB85314;

XX 17-SEP-2001 (first entry)

XX HLA-A2 binding NY-ESO-1 peptide.

XX NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;

XX HLA-A2; T-cell sorter; tumor; immune tetramer.

XX Homo sapiens.

XX Key Location/Qualifiers

XX Misc-difference 9 /label= Ala or Cys

XX Misc-difference 10 /label= Val, Phe, Ile or Leu

XX /note= "can be any amino acid, preferably one indicated above"

XX WO200136453-A2.

XX 25-MAY-2001

XX 08-NOV-2000; 2000WO-US042010.

XX 15-NOV-1999; 99US-00440621.

XX 25-FEB-2000; 2000US-00514036.

XX 29-SEP-2000; 2000US-00676005.

XX (LUDW-) LUDWIG INST CANCER RES.

XX (UYOX-) UNIV OXFORD.

XX Valmori D, Cerottini J, Romero P, Cerundolo V;

XX WPI; 2001-451454/48.

XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell

XX presents human leukocyte antigen-A2 molecule on its surface, binds to

XX human leukocyte antigen molecules and provokes lysis by cytolytic T

PT cells.

PS Disclosure; Page 36; 38pp; English.

CC The invention provides NY-ESO-1 peptide derivatives which bind to human

CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells

CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an

CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide

CC derivatives are useful for determining if a cell presents an HLA-A2

CC molecule on its surface, by contacting a sample containing the cell with

CC the peptide or its derivative, and determining binding between them,

CC where the binding is indicative of HLA-A2 on the surface of the cell. The

CC NY-ESO-1 peptides and analogues are useful therapeutically, for

CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1

CC in connection with the pathology, as well as diagnostically, i.e. to

CC determine if HLA-A2 positive cells are present, or if relevant CTLs are

CC present. They are also useful for determining the presence of CTLs in a

CC sample. The peptides are useful as T-cell sorters, when incorporated into

CC immune tetramers. The present sequence represents a NY-ESO-1 peptide that

CC can bind to HLA-A2 molecule

XX Sequence 10 AA;

SQ Query Match 100.0%; Score 43; DB 4; Length 10;

Best Local Similarity 100.0%; Pred. NO. 0.4; Indels 0; Gaps 0;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQX 9

DB 1 SLLMWITQX 9

RESULT 3

AAW62586

ID AAW62586 standard; peptide; 9 AA.

XX AC AAW62586;

XX 17-SEP-1998 (first entry)

XX Cancer associated antigen peptide.

XX Cancer associated antigen; NY-ESO-1; regression; progression; onset;

XX cancer; treatment; diagnosis.

XX Synthetic.

XX Homo sapiens.

XX WO9814464-A1.

XX 09-APR-1998.

XX 15-SEP-1997; 97WO-US016335.

XX 03-OCT-1996; 96US-00725182.

XX (LUDW-) LUDWIG INST CANCER RES.

XX Chen Y, Scanlan M, Gure A, Old LJ, Jager E, Knuth A;

XX Drijfhout JW;

XX WPI; 1998-286417/25.

XX New isolated cancer associated antigen - is used to develop products for

XX the diagnosis and treatment of cancers and for monitoring cancer therapy.

XX Claim 33; Page 17; 49pp; English.

XX Peptides AAW62586-87 are derived from cancer associated antigen NY-ESO-1,

XX and are stimulators of cytotoxic T-cells. The specification describes a

XX method for determining regression, progression of onset of a cancerous

XX condition, comprising monitoring a sample from a patient with the

XX cancerous condition for a parameter selected from NY-ESO-1 protein, a

CC peptide derived from NY-ESO-1 protein and cytolytic T cells specific for  
CC the peptide and an MHC molecule with which it non-covalently complexes.  
CC Methods for the treatment of a cancerous condition are also described.  
CC The NY-ESO-1 protein and peptides derived from it can be used for  
CC diagnosis and treatment of cancers and to monitor the efficacy of a  
CC therapeutic regime  
XX Sequence 9 AA;

Query Match 97.7%; Score 42; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
Db 1 SLLMWITQ 8

## RESULT 4

AA01762  
ID AAY01762 standard; peptide; 9 AA.

XX  
AC AAY01762;

XX 25-JUN-1999 (first entry)

XX Exemplary antigenic peptide derived from NY-ESO-1.

XX MAGE-3; tumour associated gene; human leucocyte antigen Class II;  
XX autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;  
XX osteosarcoma; leukemia; carcinoma.

XX Homo sapiens.

XX WO9914326-A1.

XX 25-MAR-1999.

XX 04-SEP-1998; 98WO-US018601.

XX 12-SEP-1997; 97US-00928615.

XX (LUDW-) LUDWIG INST CANCER RES.

XX (UYVR-) UNIV VRIJE BRUSSEL.

XX Thielemans K, Heirman C, Corthals J, Chaux P, Stroobant V;

XX Boon-Falleur T, Van Der Bruggen P, Luiten R;

XX WPI; 1999-244031/20.

XX Isolated peptides that bind to human leucocyte antigen class II  
XX molecules.

XX Disclosure; Page 29; 88pp; English.

XX The present sequence represents an exemplary tumour associated peptide  
XX antigen. The specification describes a MAGE-3 tumour associated gene.  
XX Peptides (AA01721-25) that bind human leucocyte antigen (HLA) Class II  
XX molecules can be derived from the MAGE-3 protein. These peptides and  
XX autologous CD4+ cells that bind to a complex of MAGE-3 peptide and HLA  
XX Class II, are used to treat MAGE-3 related diseases, particularly cancers  
XX (e.g. melanoma, osteosarcoma, leukemia and various forms of carcinoma).  
XX The peptides are also used to produce specific antibodies. Detection of  
XX the peptides, e.g. in binding assays, particularly with antibodies, is  
XX used for diagnosis of such diseases

XX Sequence 9 AA;

Query Match 97.7%; Score 42; DB 2; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8

Db 1 SLLMWITQ 8

## RESULT 5

AA02432  
ID AAY52432 standard; peptide; 9 AA.

XX  
AC AAY52432;

XX 15-FEB-2000 (first entry)

XX Human tumour antigen NY-ESO-1 peptide #5.

XX Cancer; tumour; antigen; MHC; major histocompatibility complex; Class I;  
XX T-cell; cytotoxic; stimulation; proliferation; treatment; diagnosis;  
XX prevention; melanoma; breast cancer; ovarian cancer; prostate cancer;  
XX hepatoma; thyroid cancer; bladder cancer; lung cancer; lymphoma.

XX Synthetic.

XX Homo sapiens.

XX WO9953938-A1.

XX 28-OCT-1999.

XX 24-MAR-1999; 99WO-US006875.

XX 17-APR-1998; 98US-00062422.

XX 02-OCT-1998; 98US-00165546.

XX (LUDW-) LUDWIG INST CANCER RES.

XX Stockert E, Jager E, Chen Y, Scanlan M, Alexander K, Old LJ;

XX Gure A, Ritter G;

XX WPI; 2000-038483/03.

XX Novel peptides which bind to MHC class I and MHC class II molecules,  
XX useful for therapeutic and diagnostic purposes.

XX Claim 60; Page 18; 49pp; English.

XX Peptides #4-#7 (AAY52431-Y52434) are peptides derived from the human  
XX tumour antigen, NY-ESO-1 (AAY52430) which contain the motif LLMWIT  
XX (AAY52441). These sequences can bind to MHC (major histocompatibility  
XX Class I HLA-A2 molecules, thereby stimulating proliferation of cytotoxic  
XX T-cells. cDNA encoding NY-ESO-1 was initially isolated from an oesophagus  
XX squamous cell cancer cDNA library. Tissue localisation studies revealed  
XX it to be expressed at high levels in normal ovary and testis but not in  
XX normal colon, kidney, liver, brain, oesophagus and skin. It was expressed  
XX in certain tumours and tumour cell lines with some degree of frequency -  
XX these included melanoma specimens and cell lines, and breast and bladder  
XX cancer specimens, with expression in other tumour types being sporadic.  
XX These NY-ESO-1-derived peptides may be used in methods and compositions  
XX used for the treatment, diagnosis and prevention of cancers (such as  
XX melanoma, breast cancer, prostate cancer, lung cancer, hepatoma, ovarian  
XX cancer, thyroid cancer, bladder cancer, or lymphoma) and to stimulate the  
XX proliferation of T cells

XX Sequence 9 AA;

Query Match 97.7%; Score 42; DB 3; Length 9;  
Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8

Db 1 SLLMWITQ 8

## RESULT 6

AA022791

ID AAB22791 standard; peptide; 9 AA.  
 AC AAB22791;  
 XX  
 DT 22-DEC-2000 (first entry)  
 DE NY-ESO-1 peptide epitope, SEQ ID NO:2.  
 XX  
 KW NY-ESO-1; epitope; CTL response; cytotoxic T lymphocyte; vaccine;  
 KW immunogenic; adjuvant coadministration; microbial infection;  
 KW tuberculosis; HIV; hepatitis B virus; hepatitis C virus; cancer.  
 XX  
 OS Unidentified.  
 XX  
 FN WO200048630-A1.  
 XX  
 PD 24-AUG-2000.  
 XX  
 PF 17-FEB-2000; 2000WO-AU000110.  
 XX  
 PR 17-FEB-1999; 99AU-00008735.  
 XX  
 PR 27-JUL-1999; 99AU-00001861.  
 XX  
 PA (CSLC-) CSL LTD.  
 XX  
 PI Cox JC, Drane DP;  
 XX  
 DR WPI; 2000-571930/53.  
 XX  
 XX Immunogenic complexes comprising negatively charged organic carrier  
 PT adjuvants and positively charged antigens for use as vaccines against  
 PT microbial infection and cancer.  
 XX  
 XX Example 4; Fig 5c; 11pp; English.  
 PS  
 CC The invention relates to a novel immunogenic complex comprising a charged  
 CC organic carrier and a charged antigen which are electrostatically  
 CC associated. The complex induces a cytotoxic T lymphocyte (CTL) response.  
 CC The complex and/or vaccine can be used to treat a disease in a mammal,  
 CC where the complex/vaccine elicits, induces or otherwise facilitates an  
 CC immune response which inhibits, halts, delays or prevents the onset or  
 CC progression of the disease condition. In particular, the disease is a  
 CC condition resulting from a microbial infection or cancer. Microbial  
 CC infections which may be treated using the immunogenic complex include  
 CC human immunodeficiency virus (HIV), hepatitis B, hepatitis C,  
 CC tuberculosis or a parasitic condition, and cancers which may be treated  
 CC include melanoma, prostate cancer or breast cancer. The complexes and  
 CC vaccines simultaneously co-deliver antigen and adjuvant to the same  
 CC antigen presenting cell, which is often essential for induction of  
 CC appropriate immune responses. Sequences AAB22790-B22791 represent peptide  
 CC epitopes of the positively charged protein NY-ESO-1 used in an  
 CC exemplification of the invention  
 XX  
 SQ Sequence 9 AA;  
 Query Match 97.7%; Score 42; DB 3; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 SLLMWITQ 8  
 Db 1 SLLMWITQ 8  
 RESULT 7  
 AAY78470  
 ID AAY78470 standard; peptide; 9 AA.  
 XX  
 AC AAY78470;  
 XX  
 DT 10-MAY-2000 (first entry)  
 XX  
 DE NY-ESO-1 derived peptide #2.

XX Cancer; SSX family; SSX-1; SSX-2; SSX-3; SSX-4; SSX-5; NY-ESO-1;  
 KW HLA binding; human leukocyte antigen; cytolytic T cell; CTL; cytostatic;  
 KW melanoma; synovial sarcoma.  
 XX  
 OS Homo sapiens.  
 XX  
 FN WO200000824-A1.  
 XX  
 PD 06-JAN-2000.  
 XX  
 PF 25-JUN-1999; 99WO-US014493.  
 XX  
 PR 26-JUN-1998; 98US-00105839.  
 XX  
 PA (LUDW-) LUDWIG INST CANCER RES.  
 XX  
 PI Tureci O, Sahin U, Pfreundschuh M, Rammensee G, Stevanovic S;  
 PI Chen Y, Gure A, Old LJ;  
 XX  
 DR WPI; 2000-170933/15.  
 XX  
 PT Determining the possible presence of breast, endometrial, colorectal,  
 PT lung, bladder or head-neck cancer.  
 XX  
 PS Example 12; Page 21; 40pp; English.  
 XX  
 CC A method has been developed for determining the possible presence of a  
 CC cancer, which is not melanoma or synovial sarcoma. The method comprises  
 CC assaying a sample taken from the subject to determine the expression of  
 CC an SSX gene, and determining the expression as a determination of the  
 CC possible presence of cancer. Expression of SSX1 gene indicates possible  
 CC presence of breast, endometrial, colorectal, lung, bladder or head-neck  
 CC cancer. These cancers are also detected by SSX2 and SSX4 gene expression.  
 CC SSX2 gene expression additionally indicates possible presence of  
 CC lymphoma, renal cell cancer, glioma and prostate cancer. Expression of  
 CC SSX4 gene also indicates possible presence of ovarian or stomach cancer.  
 CC SSX5 gene expression indicates the same cancers as SSX1, except breast  
 CC cancer. Determining expression of SSX gene can be used to monitor  
 CC progress of melanoma or synovial sarcoma, which is not cancer. The SSX-  
 CC derived peptide complex stimulates proliferation of cytolytic T cells.  
 CC This is useful for treating cancer, especially melanoma. AAY78464 to  
 CC AAY78468 represent specifically claimed HLA binding peptides for use in  
 CC the method of the invention. AAZ88452 to AAZ88465 represent PCR primers  
 CC used in the isolation of SSX genes in the exemplification of the present  
 CC invention. AAY78469 to AAY78500, and AAY79684 to AAY79762 represent  
 CC peptides derived from SSX proteins or NY-ESO-1, which are used in the  
 CC exemplification of the present invention  
 XX  
 SQ Sequence 9 AA;  
 Query Match 97.7%; Score 42; DB 3; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 SLLMWITQ 8  
 Db 1 SLLMWITQ 8  
 RESULT 8  
 AAB02631  
 ID AAB02631 standard; peptide; 9 AA.  
 XX  
 AC AAB02631;  
 XX  
 DT 18-AUG-2000 (first entry)  
 XX  
 DE Tumour associated peptide antigen from NY-ESO-1 #2.  
 KW MAGE-A3; HLA class II; human leukocyte antigen; antibody; vaccine;  
 KW cancer; human; tumour; tumour associated gene product.  
 XX

OS Homo sapiens.  
XX WO2000020581-A1.  
XX 13-APR-2000.  
XX 15-SEP-1999; 99WO-US021230.  
XX 05-OCT-1998; 98US-00166448.  
XX (LUDW-) LUDWIG INST CANCER RES.  
XX (UYVR-) UNIV VRIJE BRUSSEL.  
XX Chaux P, Strobant V, Boon-Falleur T, Van Der Bruggen P;  
XX Schultz ES, Van Snick J, Lethe B, Thielemans K, Corthals J;  
XX Heirman C;  
XX WPI; 2000-317713/27.  
XX New MAGE-A3 class II binding peptides, useful to diagnose and treat  
XX tumors, are fragments of MAGE-A3 which bind to and are presented to T  
XX lymphocytes by human leukocyte antigen class II molecules.  
XX Disclosure; Page 33; 119pp; English.  
XX The present invention relates to MAGE-A3 (tumour associated gene product)  
XX human leukocyte antigen (HLA) class II-binding peptides (see AAB02566-  
XX B02595, and AAB02633-302637). These peptides are presented to T cells in  
XX the context of HLA class II molecules. The peptides stimulate the  
XX activity and proliferation of CD4+ T lymphocytes. The invention also  
XX includes nucleotide sequences encoding MAGE-3A peptides (see AAA37928 and  
XX AAA37938-A37940). The peptides and nucleotide sequences can be used to  
XX create antibodies against the MAGE-A3 peptides, the antibodies, peptides  
XX and nucleotide sequences can be used to create a vaccine. The peptides  
XX are used to diagnose or treat a disorder characterized by expression of  
XX MAGE-3, particularly cancer. The methods can also be used in the  
XX diagnosis of disorders associated with MAGE-3 expression. Included in the  
XX invention are other human tumour antigens (see AAB02598-B02637), and PCR  
XX primers used in the course of the invention (see AAA37929-A37937 and  
XX AAA37941-A37942)  
XX Sequence 9 AA;  
XX  
XX Query Match 97.7%; Score 42; DB 3; Length 9;  
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 1 SLLMWITQ 8  
XX | | | | | | | |  
XX Db 1 SLLMWITQ 8  
XX  
XX RESULT 9  
XX AAB08703  
XX ID AAB08703 standard; peptide; 9 AA.  
XX AC AAB08703;  
XX 02-JAN-2001 (first entry)  
XX Antigenic peptide from tumour rejection antigen NY-ESO-1.  
XX Epha3; HLA class II-binding peptide; human leukocyte antigen; antigen;  
XX CD4+ T lymphocyte; tumour associated gene; vaccine.  
XX Homo sapiens.  
XX OS  
XX WO2000050589-A1.  
XX 31-AUG-2000.  
XX 18-FEB-2000; 2000WO-US004326.  
XX

PR 22-FEB-1999; 99US-0121170P.  
XX 08-OCT-1999; 99US-0158566P.  
XX (LUDW-) LUDWIG INST CANCER RES.  
XX Chiari R, Coulie P, Boon-Falleur T;  
XX WPI; 2000-572089/53.  
XX Novel tyrosine kinase receptor, Epha3 human leukocyte antigen (HLA) class  
XX II binding peptide and nucleic acid encoding the receptor, useful for  
XX diagnosing and treating conditions characterized by expression of Epha3  
XX gene.  
XX Disclosure; Page 36; 107pp; English.  
XX AAB08668-B08704 represent antigenic peptides characteristic of tumours.  
XX The peptides may be combined in vaccines with a human Epha3 HLA (human  
XX leukocyte antigen) class II-binding peptide. Epha3 antigens, when  
XX presented by an antigen presenting cell having a HLA class II molecule,  
XX effectively induce activation and proliferation of CD4+ T lymphocytes.  
XX Epha3 is a tumour associated gene. Epha3 HLA binding peptides are used  
XX for selectively enriching a population of T lymphocytes. The peptides are  
XX also used for diagnosing a disorder characterized by Epha3 or Epha3 HLA  
XX binding peptide expression. The peptides are also used to treat a  
XX disorder characterized by Epha3 expression. The Epha3 binding peptides  
XX are useful in producing vaccines and antibody  
XX Sequence 9 AA;  
XX  
XX Query Match 97.7%; Score 42; DB 3; Length 9;  
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX QY 1 SLLMWITQ 8  
XX | | | | | | | |  
XX Db 1 SLLMWITQ 8  
XX  
XX RESULT 10  
XX AAE02120  
XX ID AAE02120 standard; peptide; 9 AA.  
XX AC AAE02120;  
XX 31-JUL-2001 (first entry)  
XX NY-ESO-1 human leukocyte antigen-A2-binding peptide #2.  
XX Human; cytostatic; immunogen; NY-ESO-1; human leukocyte antigen; HLA;  
XX CD8; cytotoxic T lymphocyte; cancer; carcinoma; melanoma; myeloma;  
XX brain tumour; sarcoma; vaccine; gene therapy.  
XX Homo sapiens.  
XX OS  
XX WO200129220-A2.  
XX 26-APR-2001.  
XX 19-OCT-2000; 2000WO-US028852.  
XX 19-OCT-1999; 99US-0160374P.  
XX 01-FEB-2000; 2000US-0179570P.  
XX (LUDW-) LUDWIG INST CANCER RES.  
XX Heidecker L, Van Den Eynde B, Boon-Falleur T, Brasseur F;  
XX WPI; 2001-328498/34.  
XX New antigenic peptides derived from MAGE-A12 polypeptides, useful for  
XX diagnosis and treatment of cancer, such as bladder, lung, breast, brain,  
XX prostate and renal carcinomas.

XX Disclosure; Page 21; 69pp; English.

XX The patent discloses antigenic peptides derived from MAGE-A12 protein and

XX presented by human leukocyte antigens (HLAs). These antigenic peptides

XX when presented by an antigen presenting cell having a HLA class I

XX molecule, effectively induce the activation and proliferation of CD8+

XX cytotoxic T lymphocytes (CTLs). MAGE-A12 is useful for treating a subject

XX having a disorder characterised by expression of MAGE-A12. The protein

XX microarray comprising MAGE-A12 is useful for diagnosing a disorder,

XX especially cancer, by determining the binding of an antibody, T

XX lymphocytes or a HLA molecule isolated from the subject suspected of

XX having the disorder characterised by the expression of MAGE-A12. MAGE-A12

XX is useful for treating cancers, including bladder carcinomas, melanomas,

XX esophageal, lung, head and neck, breast, colorectal carcinomas, and to

XX myelomas, brain tumours, sarcomas, prostate and renal carcinomas, and to

XX produce antibodies. MAGE-A12 antibodies are useful for diagnosing

XX disorders characterised by expression of MAGE-A12 immunogenic

XX polypeptide. These MAGE-A12 peptides are used as vaccines. They are also

XX used in gene therapy. The present sequence is an antigenic peptide

XX derived from NY-ESO-1. This peptide which is characteristic of tumours is

XX presented by HLA-A2 MHC (major histocompatibility complex) and is

XX recognised by CTLs

XX Sequence 9 AA;

XX

XX Query Match 97.7%; Score 42; DB 4; Length 9;

XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8

DB 1 SLLMWITQ 8

RESULT 11

AAAB69948

ID AAB69948 standard; peptide; 9 AA.

AC AAB69948;

XX

XX 27-APR-2001 (first entry)

XX

XX Human NY-ESO-1 CTL stimulating peptide #2.

XX

XX Human; NY-ESO-1; HLA; human leukocyte antigen; CTL; cytotoxic T cell;

XX HLA-A2; HLA-DR53; melanoma; adenocarcinoma; bladder carcinoma;

XX non-small cell lung carcinoma; tumour status determination.

XX

XX Homo sapiens.

XX

XX WO200107917-A1.

XX

XX 01-FEB-2001.

XX

XX 14-JUL-2000; 2000WO-US019220.

XX

XX 23-JUL-1999; 99US-00359503.

XX

XX (LUDW-) LUDWIG INST CANCER RES.

XX (SLOK) SLOAN KETTERING INST CANCER RES.

XX (CORR) CORNELL RES FOUND INC.

XX

XX Jager E, Stockert E, Old LJ, Knuth A, Chen Y, Scanlan M;

XX

XX WPI; 2001-182822/18.

XX

XX Method useful for determining the status (e.g. progression, regression or

XX stability of the disease) of a cancerous condition, involves determining

XX the levels of NY-ESO-1 specific antibodies in a sample taken from a

XX patient.

XX

XX Example 13; Page 24; 50pp; English.

XX The present sequence is given in a specification relating to a method for

XX determining the status of a cancerous condition in a patient with a

XX tumour that expresses NY-ESO-1. The method comprises assaying a sample

XX taken from the patient for antibodies that specifically bind to the NY-

XX ESO-1 and comparing the value obtained to a prior value obtained from

XX assay of a prior sample taken from the patient. Any difference between

XX the values is indicative of a change in status of the cancerous

XX condition. The method is useful for determining whether a cancerous

XX condition is progressing, regressing or remaining stable, in particular

XX in patients receiving treatment for a melanoma, adenocarcinoma, non-small

XX cell lung carcinoma or bladder carcinoma

XX Sequence 9 AA;

XX

XX Query Match 97.7%; Score 42; DB 4; Length 9;

XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;

XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8

DB 1 SLLMWITQ 8

RESULT 12

AAAG67166

ID AAG67166 standard; peptide; 9 AA.

AC AAG67166;

XX

XX 13-NOV-2001 (first entry)

XX

XX Cancer testis tumour antigen NY-ESO-1 derived CTL-stimulating peptide.

XX

XX Cancer testis tumour antigen; NY-ESO-1; LAGE-2; human leukocyte antigen;

XX HLA; HLA binding peptide; major histocompatibility complex; MHC; tumour;

XX cancer; testis tumour.

XX

XX Homo sapiens.

XX

XX WO200162917-A1.

XX

XX 30-AUG-2001.

XX

XX 22-JAN-2001; 2001WO-US002126.

XX

XX 22-FEB-2000; 2000US-00510635.

XX

XX (LUDW-) LUDWIG INST CANCER RES.

XX

XX Lethe B, Boon-Falleur T;

XX

XX WPI; 2001-550091/61.

XX

XX Genomic sequences of tumor associated antigen EY-ESO-1 (LAGE-2) useful

XX for diagnosing testicular tumors.

XX

XX Example 12; Page 24; 50pp; English.

XX

XX The present sequence represents a peptide which is derived from cancer

XX testis tumour antigen NY-ESO-1 (also called LAGE-2). The peptide

XX stimulates cytolytic T cell lines (CTLs). NY-ESO-1 is a molecule that is

XX processed to at least one human leukocyte antigen (HLA) binding peptide,

XX which binds to Class I and Class II major histocompatibility complex

XX (MHC). NY-ESO-1 is expressed in tumour mRNA and in testis, but not normal

XX colon, kidney, liver or brain tissue. The presence or level of expression

XX of NY-ESO-1 may be assayed for the diagnosis of cancer, especially testis

XX tumours

XX Sequence 9 AA;

XX

XX Query Match 97.7%; Score 42; DB 4; Length 9;

XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8  
 |||||

Db 1 SLLMWITQ 8

RESULT 13

AAU01537

ID AAU01537 standard; peptide; 9 AA.

XX AC AAU01537;

XX DT 18-JUL-2001 (first entry)

XX DE Cytolytic T cell line stimulator peptide #2.

XX KW NY-ESO-1; human; tumour rejection antigen precursor; SSX-2; MHC Class II;

XX KW major histocompatibility complex; helper T cell; HLA-DR; cancer;

XX KW human leukocyte antigen-determining region; disease progression;

XX KW disease regression; disease onset; body tissue; body fluid; enzyme label;

XX KW radioactive label; monoclonal antibody; cytolytic T cell line.

XX OS Homo sapiens.

XX PN WO200123560-A2.

XX PD 05-APR-2001.

XX PF 26-SEP-2000; 2000WO-US026411.

XX PR 29-SEP-1999; 99US-00408036.

XX PA (LUDW-) LUDWIG INST CANCER RES.

XX PI Tureci O, Sahin U, Pfreundschuh M;

XX PS WPI; 2001-266156/27.

XX PT Polypeptides binding to major histocompatibility complex class II human

XX PT leukocyte antigen-determining region molecule having amino acid sequence

XX PT found in tumor rejection antigen precursor used for stimulating

XX PT proliferation of helper T cells.

XX PS Example 12; Page 17; 62pp; English.

XX CC The sequence represents a human NY-ESO-1 tumour rejection antigen

XX CC precursor fragment which efficiently stimulates cytolytic T cell lines.

XX CC NY-ESO-1 and SSX-2 polypeptides, or fragments of, bind to major

XX CC histocompatibility complex (MHC) Class II molecules such as human

XX CC leukocyte antigen-determining region (HLA-DR) molecules and stimulate

XX CC proliferation of helper T cells. The peptides can be administered to an

XX CC HLA-DR positive subject in order to stimulate the helper T cells. An MHC

XX CC Class II HLA-DR-NY-ESO-1/SSX-2 complex expressed on the surface of a cell

XX CC or present in free form is useful for this stimulation. The nucleic acid

XX CC is useful for screening for a cancerous condition, which involves

XX CC contacting a subject sample to a cell line transfected with the

XX CC immunoreactive cell (helper T cell), where interaction is indicative of

XX CC cancer. In addition, a sample from a patient (for example, a body fluid

XX CC or tissue) can be monitored for the amount of the complex present in the

XX CC bloodstream. This is useful for determining regression, progression or

XX CC onset of a cancerous condition. The method involves contacting the sample

XX CC with a radioactive labelled or enzyme labelled monoclonal antibody which

XX CC specifically binds with the complex

XX SQ Sequence 9 AA;

Query Match 97.7%; Score 42; DB 4; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.4e+06;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8  
 |||||

Db 1 SLLMWITQ 8

RESULT 14

AAB31329

ID AAB31329 standard; peptide; 9 AA.

XX AC AAB31329;

XX DT 20-APR-2001 (first entry)

XX DE Exemplary antigen characteristic of tumours and derived from NY-ESO-1.

XX KW MAGE-A1; HLA; human leukocyte antigen; CD4+ T lymphocyte; cancer;

XX KW MAGE-A1 HLA class II-binding protein; vaccine.

XX OS Homo sapiens.

XX PN WO200078806-A1.

XX PD 28-DEC-2000.

XX PF 14-JUN-2000; 2000WO-US016287.

XX PR 18-JUN-1999; 99US-00336091.

XX PA (LUDW-) LUDWIG INST CANCER RES.

XX PI Van Snick J, Lethe B, Chaux P, Boon-Falleur T, Van Der Bruggen P;

XX PS WPI; 2001-102698/11.

XX DR Novel MAGE-A1 human leukocyte antigen class II peptides which bind to and

XX PT are presented to the class II molecules, useful for inducing immune

XX PT response and treating cancers characterized by expression of MAGE-A1.

XX PS Disclosure; Page 32; 78pp; English.

XX CC AAB31302-59 represent exemplary antigens which are characteristic of

XX CC tumours. They can be used to enhance the immune response of vaccines

XX CC comprising peptides derived from human MAGE-A1 HLA (human leukocyte

XX CC antigen) class II-binding protein. Peptides derived from the MAGE-A1 HLA

XX CC binding protein stimulate the activity and proliferation of CD4+ T

XX CC lymphocytes. The MAGE-A1 HLA binding protein is useful as a diagnostic

XX CC agent for diagnosing a disorder characterized by expression of MAGE-A1.

XX CC The protein is used for treating a disorder characterized by expression

XX CC of MAGE-A1 such as cancers e.g. melanoma, squamous cell carcinomas,

XX CC colorectal carcinomas, osteosarcomas, and lymphocytic leukemias. Peptides

XX CC derived from the MAGE-A1 HLA binding protein are useful in the production

XX CC of anti-tumour vaccines

XX SQ Sequence 9 AA;

Query Match 97.7%; Score 42; DB 4; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.4e+06;

Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8  
 |||||

Db 1 SLLMWITQ 8

RESULT 15

AAB85299

ID AAB85299 standard; peptide; 9 AA.

XX AC AAB85299;

XX DT 17-SEP-2001 (first entry)

XX DE HLA-A2 binding NY-ESO-1 peptide #2.

XX KW NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;

```

KW HLA-A2; T-cell sorter; tumor; immune tetramer.
OS Homo sapiens.
XX WO200136453-A2.
XX 25-MAY-2001.
XX 08-NOV-2000; 2000WO-US042010.
XX 15-NOV-1999; 99US-00440621.
XX 25-FEB-2000; 2000US-00514036.
XX 29-SEP-2000; 2000US-00676005.
XX (LUDW-) LUDWIG INST CANCER RES.
XX (UYOX-) UNIV OXFORD.
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
XX presents human leukocyte antigen-A2 molecule on its surface, binds to
XX human leukocyte antigen molecules and provokes lysis by cytolytic T
XX cells.
XX Example 1; Page 4; 38pp; English.
XX The invention provides NY-ESO-1 peptide derivatives which bind to human
XX leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells
XX (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an
XX amino acid having an uncharged polar side chain. The NY-ESO-1 peptide
XX derivatives are useful for determining if a cell presents an HLA-A2
XX molecule on its surface, by contacting a sample containing the cell with
XX the peptide or its derivative, and determining binding between them,
XX where the binding is indicative of HLA-A2 on the surface of the cell. The
XX NY-ESO-1 peptides and analogues are useful therapeutically, for
XX administration to a patient who is HLA-A2 positive and expresses NY-ESO-1
XX in connection with the pathology, as well as diagnostically, i.e. to
XX determine if HLA-A2 positive cells are present, or if relevant CTLs are
XX present. They are also useful for determining the presence of CTLs in a
XX sample. The peptides are useful as T-cell sorters, when incorporated into
XX immune tetramers. The present sequence represents a NY-ESO-1 peptide that
XX can bind to HLA-A2 molecule
XX Sequence 9 AA;
XX Query Match 97.7%; Score 42; DB 4; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 SLLMWITQ 8
XX |||||
XX 1 SLLMWITQ 8
XX
XX RESULT 16
XX AAB85315
XX ID AAB85315 standard; peptide; 9 AA.
XX AC AAB85315;
XX 17-SEP-2001 (first entry)
XX HLA-A2 binding NY-ESO-1 peptide analogue.
XX NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;
XX HLA-A2; T-cell sorter; tumor; immune tetramer.
XX Homo sapiens.
XX WO200136453-A2.
XX 25-MAY-2001.
XX 08-NOV-2000; 2000WO-US042010.
XX 15-NOV-1999; 99US-00440621.
XX 25-FEB-2000; 2000US-00514036.
XX 29-SEP-2000; 2000US-00676005.
XX (LUDW-) LUDWIG INST CANCER RES.
XX (UYOX-) UNIV OXFORD.
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
XX presents human leukocyte antigen-A2 molecule on its surface, binds to
XX human leukocyte antigen molecules and provokes lysis by cytolytic T
XX cells.
XX Example 1; Page 4; 38pp; English.
XX The invention provides NY-ESO-1 peptide derivatives which bind to human
XX leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells
XX (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an
XX amino acid having an uncharged polar side chain. The NY-ESO-1 peptide
XX derivatives are useful for determining if a cell presents an HLA-A2
XX molecule on its surface, by contacting a sample containing the cell with
XX the peptide or its derivative, and determining binding between them,
XX where the binding is indicative of HLA-A2 on the surface of the cell. The
XX NY-ESO-1 peptides and analogues are useful therapeutically, for
XX administration to a patient who is HLA-A2 positive and expresses NY-ESO-1
XX in connection with the pathology, as well as diagnostically, i.e. to
XX determine if HLA-A2 positive cells are present, or if relevant CTLs are
XX present. They are also useful for determining the presence of CTLs in a
XX sample. The peptides are useful as T-cell sorters, when incorporated into
XX immune tetramers. The present sequence represents a NY-ESO-1 peptide that
XX can bind to HLA-A2 molecule
XX Sequence 9 AA;
XX Query Match 97.7%; Score 42; DB 4; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 SLLMWITQ 8
XX |||||
XX 1 SLLMWITQ 8
XX
XX RESULT 17
XX AAB85304
XX ID AAB85304 standard; peptide; 9 AA.
XX AC AAB85304;
XX 17-SEP-2001 (first entry)
XX HLA-A2 binding NY-ESO-1 peptide analogue.
XX NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;
XX HLA-A2; T-cell sorter; tumor; immune tetramer.
XX Homo sapiens.
XX WO200136453-A2.
XX 25-MAY-2001.
XX 08-NOV-2000; 2000WO-US042010.
XX 15-NOV-1999; 99US-00440621.
XX 25-FEB-2000; 2000US-00514036.
XX (LUDW-) LUDWIG INST CANCER RES.
XX (UYOX-) UNIV OXFORD.
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
XX presents human leukocyte antigen-A2 molecule on its surface, binds to
XX human leukocyte antigen molecules and provokes lysis by cytolytic T
XX cells.
XX Claim 6; Page 16; 38pp; English.
XX The invention provides NY-ESO-1 peptide derivatives which bind to human
XX leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells
XX (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an
XX amino acid having an uncharged polar side chain. The NY-ESO-1 peptide
XX derivatives are useful for determining if a cell presents an HLA-A2
XX molecule on its surface, by contacting a sample containing the cell with
XX the peptide or its derivative, and determining binding between them,
XX where the binding is indicative of HLA-A2 on the surface of the cell. The
XX NY-ESO-1 peptides and analogues are useful therapeutically, for
XX administration to a patient who is HLA-A2 positive and expresses NY-ESO-1
XX in connection with the pathology, as well as diagnostically, i.e. to
XX determine if HLA-A2 positive cells are present, or if relevant CTLs are
XX present. They are also useful for determining the presence of CTLs in a
XX sample. The peptides are useful as T-cell sorters, when incorporated into
XX immune tetramers. The present sequence represents a NY-ESO-1 peptide
XX analogue that can bind to HLA-A2 molecule
XX Sequence 9 AA;
XX Query Match 97.7%; Score 42; DB 4; Length 9;
XX Best Local Similarity 100.0%; Pred. No. 1.4e+06;
XX Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 SLLMWITQ 8
XX |||||
XX 1 SLLMWITQ 8
XX
XX RESULT 17
XX AAB85304
XX ID AAB85304 standard; peptide; 9 AA.
XX AC AAB85304;
XX 17-SEP-2001 (first entry)
XX HLA-A2 binding NY-ESO-1 peptide analogue.
XX NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;
XX HLA-A2; T-cell sorter; tumor; immune tetramer.
XX Homo sapiens.
XX WO200136453-A2.
XX 25-MAY-2001.
XX 08-NOV-2000; 2000WO-US042010.
XX 15-NOV-1999; 99US-00440621.
XX 25-FEB-2000; 2000US-00514036.

```



```

PR 29-SEP-2000; 2000US-00676005.
XX (LUDW-) LUDWIG INST CANCER RES.
PA (UYOX-) UNIV OXFORD.
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
PT presents human leukocyte antigen-A2 molecule on its surface, binds to
PT human leukocyte antigen molecules and provokes lysis by cytolytic T
PT cells.
XX
XX Example 19; Page 16; 38pp; English.
XX
XX The invention provides NY-ESO-1 peptide derivatives which bind to human
CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells
CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an
CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide
CC derivatives are useful for determining if a cell presents an HLA-A2
CC molecule on its surface, by contacting a sample containing the cell with
CC the peptide or its derivative, and determining binding between them;
CC where the binding is indicative of HLA-A2 on the surface of the cell. The
CC NY-ESO-1 peptides and analogues are useful therapeutically, for
CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1
CC in connection with the pathology, as well as diagnostically, i.e. to
CC determine if HLA-A2 positive cells are present, or if relevant CTLs are
CC present. They are also useful for determining the presence of CTLs in a
CC sample. The peptides are useful as T-cell sorters, when incorporated into
CC immune tetramers. The present sequence represents a NY-ESO-1 peptide
CC analogue that can bind to HLA-A2 molecule
XX
SQ Sequence 9 AA;
Query Match 97.7%; Score 42; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 1 SLLMWITQ 8

RESULT 18
AAB85303
ID AAB85303 standard; peptide; 9 AA.
XX
AC AAB85303;
XX
DT 17-SEP-2001 (first entry)
XX
DE HLA-A2 binding NY-ESO-1 peptide.
XX
KW NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;
KW HLA-A2; T-cell sorter; tumor; immune tetramer.
XX
OS Homo sapiens.
XX
PN WO200136453-A2.
XX
PD 25-MAY-2001.
XX
PF 08-NOV-2000; 2000WO-US042010.
XX
PR 15-NOV-1999; 99US-00440621.
XX
PR 25-FEB-2000; 2000US-00514036.
XX
PR 29-SEP-2000; 2000US-00676005.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
PA (UYOX-) UNIV OXFORD.
XX
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
PT presents human leukocyte antigen-A2 molecule on its surface, binds to
PT human leukocyte antigen molecules and provokes lysis by cytolytic T
PT cells.
XX
XX Example 19; Page 16; 38pp; English.
XX
XX The invention provides NY-ESO-1 peptide derivatives which bind to human
CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells
CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an
CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide
CC derivatives are useful for determining if a cell presents an HLA-A2
CC molecule on its surface, by contacting a sample containing the cell with
CC the peptide or its derivative, and determining binding between them;
CC where the binding is indicative of HLA-A2 on the surface of the cell. The
CC NY-ESO-1 peptides and analogues are useful therapeutically, for
CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1
CC in connection with the pathology, as well as diagnostically, i.e. to
CC determine if HLA-A2 positive cells are present, or if relevant CTLs are
CC present. They are also useful for determining the presence of CTLs in a
CC sample. The peptides are useful as T-cell sorters, when incorporated into
CC immune tetramers. The present sequence represents a NY-ESO-1 peptide
CC analogue that can bind to HLA-A2 molecule
XX
SQ Sequence 9 AA;
Query Match 97.7%; Score 42; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 1 SLLMWITQ 8

RESULT 19
AAB85305
ID AAB85305 standard; peptide; 9 AA.
XX
AC AAB85305;
XX
DT 17-SEP-2001 (first entry)
XX
DE HLA-A2 binding NY-ESO-1 peptide analogue.
XX
KW NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;
KW HLA-A2; T-cell sorter; tumor; immune tetramer.
XX
OS Homo sapiens.
XX
PN WO200136453-A2.
XX
PD 25-MAY-2001.
XX
PF 08-NOV-2000; 2000WO-US042010.
XX
PR 15-NOV-1999; 99US-00440621.
XX
PR 25-FEB-2000; 2000US-00514036.
XX
PR 29-SEP-2000; 2000US-00676005.
XX
PA (LUDW-) LUDWIG INST CANCER RES.
PA (UYOX-) UNIV OXFORD.
XX
XX Valmori D, Cerottini J, Romero P, Cerundolo V;
XX WPI; 2001-451454/48.
XX
XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell
PT presents human leukocyte antigen-A2 molecule on its surface, binds to
PT human leukocyte antigen molecules and provokes lysis by cytolytic T
PT cells.

```

PT cells.  
 XX Example 19; Page 16; 38pp; English.  
 XX The invention provides NY-ESO-1 peptide derivatives which bind to human  
 CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells  
 CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an  
 CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide  
 CC derivatives are useful for determining if a cell presents an HLA-A2  
 CC molecule on its surface, by contacting a sample containing the cell with  
 CC the peptide or its derivative, and determining binding between them,  
 CC where the binding is indicative of HLA-A2 on the surface of the cell.  
 CC NY-ESO-1 peptides and analogues are useful therapeutically, for  
 CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1  
 CC in connection with the pathology, as well as diagnostically, i.e. to  
 CC determine if HLA-A2 positive cells are present, or if relevant CTLs are  
 CC present. They are also useful for determining the presence of CTLs in a  
 CC sample. The peptides are useful as T-cell sorters, when incorporated into  
 CC immune tetramers. The present sequence represents a NY-ESO-1 peptide  
 CC analogue that can bind to HLA-A2 molecule  
 XX Sequence 9 AA;  
 SQ

Query Match 97.7%; Score 42; DB 4; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 DB 1 SLLMWITQ 8  
 |||||

RESULT 20  
 AAB85308  
 ID AAB85308 standard; peptide; 9 AA.  
 AC AAB85308;  
 XX  
 DT 17-SEP-2001 (first entry)  
 XX HLA-A2 binding NY-ESO-1 peptide #12.  
 DE NY-ESO-1; human leukocyte antigen; HLA; lysis; cytolytic T cell; CTL;  
 KW HLA-A2; T-cell sorter; tumor; immune tetramer.  
 OS Homo sapiens.  
 OS Synthetic.  
 XX WO200136453-A2.  
 XX 25-MAY-2001.  
 XX 08-NOV-2000; 2000WO-US042010.  
 XX 15-NOV-1999; 99US-00440621.  
 XX 25-FEB-2000; 2000US-00514036.  
 XX 29-SEP-2000; 2000US-00676005.  
 XX (LUDW-) LUDWIG INST CANCER RES.  
 XX (UYOX-) UNIV OXFORD.  
 XX Valmori D, Cerottini J, Romero P, Cerundolo V;  
 XX WPI; 2001-451454/48.  
 XX Novel isolated NY-ESO-1 nonapeptide useful for determining if a cell  
 XX presents human leukocyte antigen-A2 molecule on its surface, binds to  
 XX human leukocyte antigen molecules and provokes lysis by cytolytic T  
 XX cells.  
 XX Example 14; Page 13; 38pp; English.  
 XX The invention provides NY-ESO-1 peptide derivatives which bind to human

CC leukocyte antigen (HLA) molecules and provokes lysis by cytolytic T cells  
 CC (CTLs). The NY-ESO-1 nonapeptide is of formula SLLMWITQX, where X is an  
 CC amino acid having an uncharged polar side chain. The NY-ESO-1 peptide  
 CC derivatives are useful for determining if a cell presents an HLA-A2  
 CC molecule on its surface, by contacting a sample containing the cell with  
 CC the peptide or its derivative, and determining binding between them,  
 CC where the binding is indicative of HLA-A2 on the surface of the cell. The  
 CC NY-ESO-1 peptides and analogues are useful therapeutically, for  
 CC administration to a patient who is HLA-A2 positive and expresses NY-ESO-1  
 CC in connection with the pathology, as well as diagnostically, i.e. to  
 CC determine if HLA-A2 positive cells are present, or if relevant CTLs are  
 CC present. They are also useful for determining the presence of CTLs in a  
 CC sample. The peptides are useful as T-cell sorters, when incorporated into  
 CC immune tetramers. The present sequence represents a NY-ESO-1 peptide that  
 CC was tested for its binding capacity to a HLA-A2 molecule  
 XX Sequence 9 AA;  
 SQ

Query Match 97.7%; Score 42; DB 4; Length 9;  
 Best Local Similarity 100.0%; Pred. No. 1.4e+06;  
 Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 DB 1 SLLMWITQ 8  
 |||||

RESULT 21  
 AAB82017  
 ID AAB82017 standard; peptide; 9 AA.  
 XX AAB82017;  
 XX 12-JUN-2001 (first entry)  
 XX HLA- binding peptide derived from NY-ESO-1.  
 DE Multiple myeloma; tumour rejection antigen precursor; MAGE; BAGE; GAGE;  
 KW LAGE; NY-ESO-1; PRAME; DAGE; human; HLA.  
 OS Homo sapiens.  
 XX US6210886-B1.  
 XX 03-APR-2001.  
 XX 30-OCT-1998; 98US-00183931.  
 XX 04-FEB-1998; 98US-00018422.  
 XX (LUDW-) LUDWIG INST CANCER RES.  
 XX Van Baren N, Brasseur F, Boon-Palleur T;  
 XX WPI; 2001-289628/30.  
 XX Detecting multiple myeloma in a patient, comprises contacting a nucleic  
 XX acid containing sample taken from bone marrow or blood with a  
 XX hybridization probe specific for a tumor rejection antigen precursor.  
 XX Example 3; Col 11; 16pp; English.  
 XX The present invention relates to a method for detecting multiple myeloma.  
 CC The method comprises contacting a nucleic acid containing a sample taken  
 CC from a bone marrow or blood of a patient, with a hybridisation probe  
 CC specific for a tumour rejection antigen precursor. Tumour rejection  
 CC antigen precursors used in the present invention are the MAGE family,  
 CC BAGE, GAGE, LAGE, NY-ESO-1 and PRAME (previously referred to as DAGE).  
 CC Expression of the tumour rejection antigen precursor indicates possible  
 CC multiple myeloma in the patient. The method can also be used for  
 CC monitoring the disease progress and course of therapeutic regime. The  
 CC present sequence is a peptide derived from a tumour rejection antigen  
 CC precursor, which was used in the method of the present invention

```
XX SQ Sequence 9 AA;
Query Match 97.7%; Score 42; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
DB 1 SLLMWITQ 8

RESULT 22
AAE06850
ID AAE06850 standard; peptide; 9 AA.
XX AC AAE06850;
XX DT 16-OCT-2001 (first entry)
XX DE Human NY-ESO-1 antigenic peptide #2.
XX KW MAGE antigenic peptide; Human leukocyte antigen; HLA-B35; HLA-B44;
XX KW tumour cell; immunostimulant; antigen presentation; cancer; melanoma;
XX KW CD8+ cytotoxic T lymphocyte; colorectal; prostate; gastric carcinoma;
XX KW myeloma; brain tumour; sarcoma; seminoma; ovarian tumour; cytostatic;
XX KW gene therapy; tumour rejection antigen; TRA; human; NY-ESO-1; MHC;
XX KW major histocompatibility complex.
XX OS Homo sapiens.
XX PF WO200153833-A1.
XX PN 26-JUL-2001;
XX PD 19-JAN-2001; 2001WO-US002008.
XX PR 20-JAN-2000; 2000US-0177242P.
XX PR 25-OCT-2000; 2000US-0243212P.
XX PA (LUDW-) LUDWIG INST CANCER RES.
XX PI Luiten R, Boon-Falleur T, Van Der Bruggen P, Stroobant V;
XX PI Demotte N, Schultz E;
XX DR WPI; 2001-488724/53.
XX PS Functional variants and isolated mimetics of a MAGE-A1 HLA-B35 or HLA-B44
XX PT binding peptide, or of a MAGE-A3 HLA-B35 binding peptide, used in
XX PT diagnosis and treatment of a disorder characterized by expression of MAGE
XX PT -A1 or -A3.
XX PS Disclosure; Page 28; 103pp; English.
XX CC The invention relates to functional variants and isolated mimetics of a
XX CC MAGE-A1 human leukocyte antigen (HLA)-B35 or HLA-B44 binding peptide, or
XX CC of a MAGE-A3 HLA-B35 binding peptide, identified by methods described in
XX CC the specification. MAGE genes encode tumour rejection antigens (TRAs)
XX CC presented to T lymphocytes by HLA-B35 and HLA-B44 molecules. The MAGE
XX CC antigenic peptide acts by binding to HLA molecules on tumour cells and
XX CC stimulating recognition of these cells and thus signalling them to the
XX CC immune system for destruction. The peptide when presented by HLA molecule
XX CC induces the activation and stimulation of CD8+ cytotoxic T lymphocytes.
XX CC The MAGE antigenic peptide is used to treat and diagnose disorders
XX CC characterised by expression of MAGE-A1 or -A3. Disorders include cancers
XX CC e.g. melanomas, oesophageal, lung, head and neck, breast, colorectal,
XX CC prostate, renal, bladder, hepatocellular, papillary thyroid and gastric
XX CC carcinomas, myelomas, brain tumours, sarcomas, seminomas, and ovarian
XX CC tumours. The present sequence is human NY-ESO-1 tumour associated
XX CC antigenic peptide presented by major histocompatibility complex (MHC) HLA
XX CC -A2. The antigenic peptide is used in combination with peptides of the
XX CC invention for inducing an immune response
```

```
SQ Sequence 9 AA;
Query Match 97.7%; Score 42; DB 4; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
DB 1 SLLMWITQ 8

RESULT 23
AAE26809
ID AAE26809 standard; peptide; 9 AA.
XX AC AAE26809;
XX DT 13-DEC-2002 (first entry)
XX DE Human HLA-A2.1 restricted NY-ESO-1 peptide epitope #2.
XX KW Human; cancer; breast cancer; ovarian cancer; melanoma; cell therapy;
XX KW epitope; human leukocyte antigen; HLA-A2.1.
XX OS Homo sapiens.
XX PN WO200265992-A2.
XX PD 29-AUG-2002.
XX PF 19-FEB-2002; 2002WO-US005748.
XX PR 20-FEB-2001; 2001US-0270252P.
XX PA (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PI Degraw J, Moriarty A, Leturcq DJ, Jackson MR, Peterson PA;
XX PI Heiskala M;
XX DR WPI; 2002-667033/71.
XX PT Treating a subject with cancer comprises combining the CD+8 cells, which
XX PT are stimulated with non-naturally occurring antigen-presenting cell line,
XX PT with adherent blood monocytes and inoculating the subject with CD8+
XX PT suspension.
XX PS Example 2; Page 94; 99pp; English.
XX CC The invention relates to a method of treating a subject with cancer. The
XX CC method involves combining the CD+8 cells, which are stimulated with non
XX CC naturally occurring antigen-presenting cell (mAPC) line, with adherent
XX CC blood monocytes and inoculating the subject with CD8+ suspension. The
XX CC method is useful for treating cancer e.g. ovarian cancer, breast cancer
XX CC and melanoma etc. It is also useful in cell therapy. The present sequence
XX CC is human leukocyte antigen A2 (HLA-A2).1 restricted peptide epitope used
XX CC to treat breast and ovarian cancer
XX SQ Sequence 9 AA;
Query Match 97.7%; Score 42; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
DB 1 SLLMWITQ 8

RESULT 24
AAE26808
ID AAE26808 standard; peptide; 9 AA.
XX AC AAE26808;
```

```

XX DT 13-DEC-2002 (first entry)
XX DE Human HLA-A2.1 restricted NY-ESO-1 peptide epitope #1.
XX KW Human; cancer; breast cancer; ovarian cancer; melanoma; cell therapy;
XX KW epitope; human leukocyte antigen; HLA-A2.1.
XX OS Homo sapiens.
XX XX WO200265992-A2.
XX PN 29-AUG-2002.
XX PD
XX XX 19-FEB-2002; 2002WO-US005748.
XX PF
XX XX 20-FEB-2001; 2001US-0270252P.
XX PR
XX XX (ORTH ) ORTHO-MCNEIL PHARM INC.
XX PA
XX PI Degraw J, Moriarty A, Leturcq DJ, Jackson MR, Peterson PA;
XX PI Heiskala M;
XX XX WPI; 2002-667033/71.
XX DR
XX XX Treating a subject with cancer comprises combining the CD-8 cells, which
XX PT are stimulated with non-naturally occurring antigen-presenting cell line,
XX PT with adherent blood monocytes and inoculating the subject with CD8+
XX PT suspension.
XX XX
XX PS Example 2; Page 94; 99pp; English.
XX CC The invention relates to a method of treating a subject with cancer. The
XX CC method involves combining the CD-8 cells, which are stimulated with non
XX CC naturally occurring antigen-presenting cell (mAPC) line, with adherent
XX CC blood monocytes and inoculating the subject with CD8+ suspension. The
XX CC method is useful for treating cancer e.g. ovarian cancer, breast cancer
XX CC and melanoma etc. It is also useful in cell therapy. The present sequence
XX CC is human leukocyte antigen A2 (HLA-A2).1 restricted peptide epitope used
XX CC to treat breast and ovarian cancer
XX XX
XX SQ Sequence 9 AA;

Query Match 97.7%; Score 42; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db |||||
1 SLLMWITQ 8

Search completed: August 22, 2004, 10:59:56
Job time : 123 secs

RESULT 25
AAO21430
ID AAO21430 standard; peptide; 9 AA.
XX AC
XX AC AAO21430;
XX DT 06-AUG-2002 (first entry)
XX DE HLA-A2 restricted peptide sequence.
XX KW Immunostimulant; human leukocyte antigen; HLA-Cw3; HLA-Cw6; cytolytic;
XX KW proliferation; T cell; HLA-CW3/HLA-CW6; HLA-A2.
XX XX
XX OS Homo sapiens.
XX XX WO200226778-A2.
XX PN
XX PD
XX PF 04-APR-2002.
XX PF 24-SEP-2001; 2001WO-US029920.
XX XX

```

```

PR 26-SEP-2000; 2000US-00670456.
XX XX (LUDW-) LUDWIG INST CANCER RES.
XX PA
XX PI Gnjatich S, Old LJ, Nagata Y, Jager E, Chen Y, Knuth A;
XX XX WPI; 2002-435193/46.
XX DR
XX XX Novel isolated human peptide that binds to human leukocyte antigen-Cw3 or
XX PT HLA-Cw6, useful for stimulating proliferation of cytolytic T cells.
XX PT
XX PS Example 3; Page 9; 21pp; English.
XX XX
XX CC The invention relates to an isolated peptide which binds to a human
XX CC leukocyte antigen (HLA)-Cw3 molecule or binds to a HLA-Cw6 molecule. The
XX CC isolated peptide provokes proliferation of T cells specific to a complex
XX CC of the isolated peptide and HLA-Cw3, or the isolated peptide and HLA-Cw6.
XX CC The isolated peptide is useful for stimulating proliferation of a
XX CC cytolytic T cell response, by contacting a T cell containing sample with
XX CC a cell which presents a complex of HLA-Cw3/HLA-Cw6 and the isolated
XX CC peptide of the invention on its surface. This sequence represents an HLA-
XX CC A2 restricted peptide sequence relating to the invention
XX XX
XX SQ Sequence 9 AA;

Query Match 97.7%; Score 42; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.4e+06;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db |||||
1 SLLMWITQ 8

Search completed: August 22, 2004, 10:59:56
Job time : 123 secs

```

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2004, 10:54:38 ; Search time 113 Seconds  
(without alignments)  
25.130 Million cell updates/sec

Title: US-10-706-475-10

Perfect score: 43

Sequence: 1 SLMLWITQX 9

Scoring table: BLOSUM62XX

Gapop 10.0 , Gapext 0.5

Searched: 1017041 segs, 315518202 residues

Total number of hits satisfying chosen parameters: 1017041

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 50 summaries

Database :

SPREMBL\_25:\*  
1: sp\_archaea:\*  
2: sp\_bacteria:\*  
3: sp\_fungi:\*  
4: sp\_human:\*  
5: sp\_invertebrate:\*  
6: sp\_mammal:\*  
7: sp\_mhc:\*  
8: sp\_organelle:\*  
9: sp\_phage:\*  
10: sp\_plant:\*  
11: sp\_rodent:\*  
12: sp\_virus:\*  
13: sp\_vertebrate:\*  
14: sp\_unclassified:\*  
15: sp\_rviro:\*  
16: sp\_bacteriap:\*  
17: sp\_archaeap:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	% Match	Query Length	DB ID	Description
1	42	97.7	180	4 Q9Y479	Q9Y479 homo sapien
2	36	83.7	198	16 Q8UCP4	Q8UCP4 agrobacteri
3	36	83.7	401	11 Q8COT0	Q8COT0 mus musculu
4	35	81.4	861	16 Q06944	Q06944 synechocyst
5	34	79.1	202	5 Q95PB6	Q95PB6 caenorhabdi
6	34	79.1	251	16 Q8KE76	Q8KE76 chlorobium
7	34	79.1	299	10 Q9ZVK1	Q9ZVK1 arabidopsis
8	34	79.1	530	4 Q9C0G1	Q9C0G1 homo sapien
9	34	79.1	620	17 Q96XC8	Q96XC8 sulfolobus
10	34	79.1	1137	5 Q9VXF4	Q9VXF4 drosophila
11	34	79.1	1137	5 Q8T9H7	Q8T9H7 drosophila
12	33	76.7	122	6 Q7YAI1	Q7YAI1 percus guir
13	33	76.7	227	16 Q7WQK1	Q7WQK1 bordetella
14	33	76.7	227	16 Q7WCJ5	Q7WCJ5 bordetella
15	33	76.7	227	16 Q7VZW4	Q7VZW4 bordetella
16	33	76.7	362	16 Q7VF34	Q7VF34 helicobacte

17	33	76.7	479	17 Q9H3K2	Q9H3K2 halobacteri
18	33	76.7	571	10 Q7XE56	Q7XE56 oryza sativ
19	33	76.7	683	16 Q82WC4	Q82WC4 nitrosomona
20	33	76.7	713	10 Q9FGS9	Q9FGS9 arabidopsis
21	33	76.7	728	10 Q8VY13	Q8VY13 arabidopsis
22	32	74.4	121	5 Q8IE17	Q8IE17 plasmodium
23	32	74.4	127	8 Q7YBD6	Q7YBD6 tapinella s
24	32	74.4	171	4 Q9Y2R7	Q9Y2R7 homo sapien
25	32	74.4	229	4 Q96FF6	Q96FF6 homo sapien
26	32	74.4	240	16 Q89YL2	Q89YL2 bacteroides
27	32	74.4	251	2 Q93GH0	Q93GH0 bacillus su
28	32	74.4	251	2 Q52853	Q52853 bacillus su
29	32	74.4	278	16 Q9JZQ7	Q9JZQ7 neisseria m
30	32	74.4	424	4 Q8IXA2	Q8IXA2 homo sapien
31	32	74.4	454	4 Q8N1C5	Q8N1C5 homo sapien
32	32	74.4	454	11 Q80J15	Q80J15 mus musculu
33	32	74.4	458	16 Q8FEC2	Q8FEC2 escherichia
34	32	74.4	721	10 Q9LTA0	Q9LTA0 arabidopsis
35	32	74.4	722	13 Q8UUU2	Q8UUU2 xenopus lae
36	32	74.4	724	11 Q70304	Q70304 mus musculu
37	32	74.4	724	11 Q8K3B3	Q8K3B3 mus musculu
38	32	74.4	738	10 Q8RWS6	Q8RWS6 arabidopsis
39	32	74.4	739	10 Q9LT99	Q9LT99 arabidopsis
40	32	74.4	753	10 Q7XUW3	Q7XUW3 oryza sativ
41	32	74.4	872	16 Q9YIU6	Q9YIU6 streptomyce
42	32	74.4	999	16 Q8YME7	Q8YME7 anabaena sp
43	32	74.4	1076	10 Q9SHX8	Q9SHX8 arabidopsis
44	31	72.1	101	10 Q9LKL7	Q9LKL7 vitis berlia
45	31	72.1	104	4 Q8TAY4	Q8TAY4 homo sapien
46	31	72.1	122	8 Q8HH81	Q8HH81 diglymma cl
47	31	72.1	124	16 Q82Q49	Q82Q49 streptomyce
48	31	72.1	130	8 Q8HH80	Q8HH80 diglymma cl
49	31	72.1	132	8 Q8HH79	Q8HH79 diglymma cl
50	31	72.1	134	16 Q8F6X7	Q8F6X7 leptospira

#### ALIGNMENTS

#### RESULT 1

Q9Y479	PRELIMINARY;	PRT;	180 AA.
ID Q9Y479			
AC Q9Y479;			
DT 01-NOV-1999 (TrEMBLrel. 12, Created)			
DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)			
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)			
DE LAGE-1S protein (Cancer/testis antigen 2).			
GN LAGE1.			
OS Homo sapiens (Human).			
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;			
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.			
OX NCBI_TaxID=9606;			
RN [1]__TaxID=9606;			
RP SEQUENCE FROM N.A.			
RC TISSUE=Melanoma;			
RX MEDLINE=99325550; PubMed=10399963;			
RA Aarnoudse C.A., Van den Doel P.B., Heemskerk B., Schrier P.I.;			
RT "Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an			
RL unexpected translation product of LAGE-1.";			
RN Int. J. Cancer 82:442-448(1999).			
RA Nelsen D.L.;			
RP SEQUENCE FROM N.A.			
RA Arachya S., Bardaro T., Galgoczy P., Yamagata T., Esposito T.,			
RA Patlan H., Ciccodicola A., Kenwick S., Platzer M., D'Urso M.,			
RT "Multiple pathogenic and benign genomic rearrangements occur at a 35-			
RL kb duplication involving the NEMO and the LAGE2 genes.";			
Hum. Mol. Genet. 0:0-0(2001).			
DR EMBL; AJ012834; CAA10194.1; -.			
DR EMBL; AF277315; AAL27015.1; -.			
SQ SEQUENCE 180 AA; 18236 MW; 9077FAF953543A25 CRC64;			

Query Match 97.7%; Score 42; DB 4; Length 180;

```

Best Local Similarity 100.0%; Pred. No. 3.9;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 157 SLLMWITQ 164

RESULT 2
Q8UCP4 PRELIMINARY; PRT; 198 AA.
AC Q8UCP4;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein Atu2439.
GN ATU2439 OR AGR C 4424.
OS Agrobacterium tumefaciens (strain C58 / ATCC 33970).
OC Bacteria; Proteobacteria; Alphaproteobacteria; Rhizobiales;
OC Rhizobiaceae; Rhizobium/Agrobacterium group; Agrobacterium.
OX NCBI_TaxID=176299;
RN SEQUENCE FROM N.A.
RX MEDLINE=21608550; PubMed=11743193;
RA Wood D.W., Setubal J.C., Kaul R., Monks D.E., Kitajima J.P.,
RA Okura V.K., Zhou Y., Chen L., Wood G.E., Almeida N.F. Jr., Woo L.,
RA Chen Y., Paulsen I.T., Eisen J.A., Karp P.D., Bovee D. Sr.,
RA Chapman P., Clendenning J., Deatherage G., Gillet W., Grant C.,
RA Kutyavin T., Levy R., Li M.-J., McClelland E., Palmieri A.,
RA Raymond C., Rouse G., Saenphimmachak C., Wu Z., Romero P., Gordon D.,
RA Zhang S., Yoo H., Tao Y., Biddle P., Jung M., Krespan W., Perry M.,
RA Gordon-Kamm B., Liao L., Kim S., Hendrick C., Zhao Z.-Y., Dolan M.,
RA Chumley P., Tinsley S.V., Tomb J.-F., Gordon M.P., Olson M.V.,
RA Nestor E.W.;
RA "The genome of the natural genetic engineer Agrobacterium tumefaciens
RT C58."
RL Science 294:2317-2323(2001).
RN SEQUENCE FROM N.A.
RX MEDLINE=21608551; PubMed=11743194;
RA Goodner B., Hinkle G., Gattung S., Miller N., Blanchard M.,
RA Qurollo B., Goldman B.S., Cao Y., Askenazi M., Halling C., Mullin L.,
RA Houtiel K., Gordon J., Vaudin M., Iartchouk O., Epp A., Liu F.,
RA Wollam C., Allinger M., Doughty D., Scott C., Lappas C., Markelz B.,
RA Flanagan C., Crowell C., Gurson J., Lomo C., Sear C., Strub G.,
RA Cielo C., Slater S.;
RA "Genome sequence of the plant pathogen and biotechnology agent
RT Agrobacterium tumefaciens C58."
RL Science 294:2323-2328(2001).
DR EMBL; AE009191; AAL43427.1; ALT_INIT.
DR EMBL; AE008157; AAX88176.1; -.
DR InterPro; IPR008325; UCP033924.
DR PIRSF; PIRSF033924; UCP033924.1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 198 AA; 21154 MW; FA40C6E548F0562F CRC64;

Query Match 83.7%; Score 36; DB 16; Length 198;
Best Local Similarity 85.7%; Pred. No. 52;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7
Db 25 SLLMWIT 31

RESULT 3
Q8C0T0 PRELIMINARY; PRT; 401 AA.
AC Q8C0T0;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical type-1 copper.

```

```

OS Mus musculus (Mouse).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
OX NCBI_TaxID=10090;
RN SEQUENCE FROM N.A.
RX STRAIN=C57BL/6J; TISSUE=Testis;
RX MEDLINE=22354683; PubMed=12466851;
RA The FANTOM Consortium,
RA "Analysis of the mouse transcriptome based on functional annotation of
RT 60,770 full-length cDNAs."
RL Nature 420:563-573(2002).
DR EMBL; AK029920; BAC26677.1; -.
DR GO; GO:0005507; F:copper ion binding; IEA.
DR GO; GO:0005489; F:electron transporter activity; IEA.
DR GO; GO:0006118; P:electron transport; IEA.
DR InterPro; IPR000923; BlueCu 1.
DR PROSITE; PS00196; COPPER_BLUE; 1.
KW Hypothetical protein.
SQ SEQUENCE 401 AA; 45562 MW; F34F237653D6FCF9 CRC64;

Query Match 83.7%; Score 36; DB 11; Length 401;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7
Db 316 SLLMWIT 322

RESULT 4
O06944 PRELIMINARY; PRT; 861 AA.
AC O06944; Q55995;
DT 01-JUL-1997 (TrEMBLrel. 04, Created)
DT 01-JUL-1997 (TrEMBLrel. 04, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Hypothetical protein sl10737.
GN SL10737.
OS Synchocystis sp. (strain PCC 6803).
OC Bacteria; Cyanobacteria; Chroococcales; Synchocystis.
OX NCBI_TaxID=1148;
RN SEQUENCE FROM N.A.
RX MEDLINE=96127529; PubMed=8590279;
RA Kaneko T., Tanaka A., Sato S., Kotani H., Sazuka T., Miyajima N.,
RA Suglura M., Tabata S.;
RA "Sequence analysis of the genome of the unicellular cyanobacterium
RT Synchocystis sp. strain PCC6803. I. Sequence features in the 1 Mb
RT region from map positions 64% to 92% of the genome."
RL DNA Res. 2:153-166(1995).
RN SEQUENCE FROM N.A.
RX MEDLINE=97061201; PubMed=8905231;
RA Kaneko T., Sato S., Kotani H., Tanaka A., Asamizu E., Nakamura Y.,
RA Miyajima N., Hiroseawa M., Suglura M., Sasamoto S., Kimura T.,
RA Hosouchi T., Matsuno A., Muraki A., Nakazaki N., Naruo K., Okumura S.,
RA Shimpō S., Takeuchi C., Wada T., Watanabe A., Yamada M.,
RA Tabata S.;
RA "Sequence analysis of the genome of the unicellular cyanobacterium
RT Synchocystis sp. strain PCC6803. II. Sequence determination of the
RT entire genome and assignment of potential protein-coding regions."
RL DNA Res. 3:109-136(1996).
DR EMBL; D64005; BAA10778.1; -.
DR PIR; S77086; S77086.
DR InterPro; IPR008941; TPR-like.
DR InterPro; IPR007016; Wzy C.
DR Pfam; PF04932; wzy C; 1.
KW Hypothetical protein; Complete proteome.
SQ SEQUENCE 861 AA; 96882 MW; A064B98C2D9B6C59 CRC64;

Query Match 81.4%; Score 35; DB 16; Length 861;

```

Best Local Similarity 75.0%; Pred. No. 3.1e+02;  
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
Db 157 SLLMWITQ 164

RESULT 5  
Q95YB6 PRELIMINARY; PRT; 202 AA.  
ID Q95YB6  
AC Q95YB6;  
DT 01-DEC-2001 (TrEMBLrel. 19, Created)  
DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Hypothetical protein.  
GN F28A10.8  
OS Caenorhabditis elegans.  
OC Eukaryota; Metazoa; Nematoda; Chromadorea; Rhabditida; Rhabditoidea;  
OC Rhabditidae; Pelodermidae; Caenorhabditis.  
OC NCBI\_TaxID=6239;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RX MEDLINE=99069613; PubMed=9851916;  
RA None;

RT "Genome sequence of the nematode C. elegans: a platform for  
RT investigating biology. The C. elegans Sequencing Consortium.";  
RL Science 282.2012-2018(1998).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Miller N., Wamsley P., Gibson A.;

RT "The sequence of C. elegans cosmid F28A10.";  
RL Submitted (MAR-1999) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RC STRAIN=Bristol N2;  
RA Waterston R.;

RT "Direct Submission.";  
RL Submitted (NOV-2001) to the EMBL/GenBank/DBJ databases.  
RL EMBL: AC006632; AAK85474.1;  
DR WormPep: F28A10.8; CE19413.  
DR InterPro: IPR005515; YOMI.  
DR Pfam: PF03782; VOMI; 1.  
KW Hypothetical protein.

SQ SEQUENCE 202 AA; 22172 MW; 129FDF141832D165 CRC64;  
Query Match 79.1%; Score 34; DB 5; Length 202;  
Best Local Similarity 85.7%; Pred. No. 1.2e+02;  
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
Db 10 SLLMWIT 16

RESULT 6  
Q8KE76 PRELIMINARY; PRT; 251 AA.  
ID Q8KE76  
AC Q8KE76;  
DT 01-OCT-2002 (TrEMBLrel. 22, Created)  
DT 01-OCT-2002 (TrEMBLrel. 22, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Hypothetical protein CT0814.  
GN CT0814.  
OS Chlorobium tepidum.  
OC Bacteria; Chlorobi; Chlorobia; Chlorobiales; Chlorobiaceae;  
OC Chlorobium.  
OC NCBI\_TaxID=1097;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=TL5 / ATCC 49652 / DSM 12025;

RX MEDLINE=22103585; PubMed=12093901;  
RA Eisen J.A., Nelson K.E., Paulsen I.T., Heidelberg J.F., Wu M.,  
RA Dodson R.J., Deboy R., Gwinn M.L., Nelson W.C., Haft D.H.,  
RA Hickey E.K., Peterson J.D., Durkin A.S., Kolonay J.L., Yang F.,  
RA Holt I., Umayam L.A., Mason T., Brenner M., Shea T.P., Parksey D.,  
RA Nierman W.C., Feldblyum T.V., Hansen C.L., Craven M.B., Radune D.,  
RA Vamathevan J., Khouri H., White O., Gruber T.M., Ketchum K.A.,  
RA Venter J.C., Tettelin H., Bryant D.A., Fraser C.M.;  
RT "The complete genome sequence of Chlorobium tepidum TL5, a  
RT photosynthetic, anaerobic, green-sulfur bacterium.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:9509-9514(2002).  
DR EMBL: AE012849; AAM72050.1; -.  
DR TIGR: CT0814; -.  
DR GO: GO:0016491; P:oxidoreductase activity; IEA.  
DR GO: GO:0006118; P:electron transport; IEA.  
DR InterPro: IPR000415; Nitroreductase.  
DR Pfam: PF00881; Nitroreductase; 1.  
KW Hypothetical protein; Complete proteome.  
SQ SEQUENCE 251 AA; 27932 MW; F7DA5ED4FCF7985 CRC64;

Query Match 79.1%; Score 34; DB 16; Length 251;  
Best Local Similarity 75.0%; Pred. No. 1.5e+02;  
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
Db 87 SLLMWITQ 94

## RESULT 7

Q92VK1 PRELIMINARY; PRT; 299 AA.  
ID Q92VK1  
AC Q92VK1;  
DT 01-MAY-1999 (TrEMBLrel. 10, Created)  
DT 01-MAY-1999 (TrEMBLrel. 10, Last sequence update)  
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
DE Putative endoxylolucan glycosyltransferase.  
GN AT2G14620.  
OS Arabidopsis thaliana (Mouse-ear cress).  
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;  
OC eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
OX NCBI\_TaxID=3702;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=cv. Columbia;  
RX MEDLINE=20083487; PubMed=10617197;  
RA Lin X., Kaul S., Rounsley S.D., Shea T.P., Benito M.-I., Town C.D.,  
RA Fujii C.Y., Mason T.M., Bowman C.L., Barnstead M.E., Feldblyum T.V.,  
RA Buell C.R., Ketchum K.A., Lee J.U., Rongming C.M., Koo H., Moffat K.S.,  
RA Cronin L.A., Shen M., Vanaken S.E., Umayam L., Tallon L.J., Gill J.E.,  
RA Adams M.D., Carrera A.J., Creasy T.H., Goodman H.M., Somerville C.R.,  
RA Copenhaver G.P., Preuss D., Nierman W.C., White O., Eisen J.A.,  
RA Salzberg S.L., Fraser C.M., Venter J.C.;  
RT "Sequence and analysis of chromosome 2 of the plant Arabidopsis  
RT thaliana",  
RL Nature 402:761-768(1999).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC STRAIN=cv. Columbia;  
RA Lin X.;  
RL Submitted (MAR-2000) to the EMBL/GenBank/DBJ databases.  
RN [3]  
RP SEQUENCE FROM N.A.  
RA Yamada K., Banh J., Chang C.H., Chang E., Dale J.M., Goldsmith A.D.,  
RA Lee J.M., Onodera C.S., Quach H.L., Tang C., Toriumi M., Wu H.C.,  
RA Yamamura Y., Yu G., Yu S., Bowser L., Carrinci P., Chen H., Cheuk R.,  
RA Hayashizaki Y., Ishida J., Jones T., Kamiya A., Karlin-Neumann G.,  
RA Kawai J., Kim C., Lam B., Lin J., Meyers M.C., Miranda M.,  
RA Narusaka M., Nguyen M., Palm C.J., Sakurai T., Satou M., Seki M.,  
RA Shinn P., Southwick A., Shinozaki K., Davis R.W., Ecker J.R.,  
RT "Full length cDNA of gene At2g14620 (GI:15225976).";

RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.

RN [4]  
 RP SEQUENCE FROM N.A.  
 RA Yamada K., Banh J., Chan M.M., Chang C.H., Chang E., Dale J.M.,  
 RA Deng J.M., Goldsmith A.D., Lee J.M., Onodera C.S., Quach H.L.,  
 RA Tang C., Toriumi M., Wu H.C., Yamamura Y., Yu G., Bowser L.,  
 RA Carninci P., Chen H., Cheuk R., Hayashizaki Y., Ishida J., Jones T.,  
 RA Kaniya A., Karlin-Neumann G., Kawai J., Kim C., Lam B., Lin J.,  
 RA Meyers M.C., Miranda M., Narusaka M., Nguyen M., Palm C.J.,  
 RA Sakurai T., Satou M., Seki M., Shimizu P., Southwick A., Shinozaki K.,  
 RA Davis R.W., Ecker J.R., Theologis A.;  
 RT "Arabidopsis Open Reading Frame (ORF) Clones."  
 RL Submitted (APR-2002) to the EMBL/GenBank/DBJ databases.  
 DR EMBL: AAC05398; AAC69380.1; -;  
 DR EMBL: AY070415; AAL49911.1; -;  
 DR EMBL: AY065966; AAM20246.1; -;  
 DR PIR: D84519; D84519.  
 DR HSP; P23904; IAJK.  
 DR GO: GO:0004553; F:hydrolase activity, hydrolyzing O-glycosyl . . . ; IEA.  
 DR GO: GO:0016740; F:transferase activity; IEA.  
 DR GO: GO:0005970; F:carbohydrate metabolism; IEA.  
 DR InterPro: IPR008985; ConA-like lec.gl.  
 DR InterPro: IPR000757; Glyco\_hydro\_16.  
 DR Pfam: PF00722; Glyco\_hydro\_16; 1.  
 KW Transferase.  
 SQ SEQUENCE 299 AA; 34687 MW; C8A688EFB7E910A5 CRC64;

Query Match 79.1%; Score 34; DB 10; Length 299;  
 Best Local Similarity 62.5%; Pred. No. 1.8e+02;  
 Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8

Db 21 SLLMWISQ 28

RESULT 8

ID Q9C0G1 PRELIMINARY; PRT; 530 AA.  
 AC Q9C0G1;  
 DT 01-JUN-2001 (TrEMBLrel. 17, Created)  
 DT 01-JUN-2001 (TrEMBLrel. 17, Last sequence update)  
 DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)  
 DE Hypothetical protein KIAA1702 (Fragment).  
 GN KIAA1702.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=21082932; PubMed=11214970;  
 RA Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;  
 RT "Prediction of the coding sequences of unidentified human genes. XIX.  
 The complete sequences of 100 new cDNA clones from brain which code  
 for large proteins in vitro."  
 RL DNA Res. 7:347-355(2000).  
 DR EMBL: AB051489; BA821793.1; -;  
 DR GO: GO:0005351; F:sugar porter activity; IEA.  
 DR GO: GO:0009401; P:phosphoenolpyruvate-dependent sugar phospho. . . ; IEA.  
 DR InterPro: IPR002114; HPR\_SerP\_S.  
 DR PROSITE: PS00589; PTS\_HPR\_SER; 1.  
 KW Hypothetical protein.  
 FT NON\_TPR 1  
 SQ SEQUENCE 530 AA; 60257 MW; 47638AA273036481 CRC64;

Query Match 79.1%; Score 34; DB 4; Length 530;  
 Best Local Similarity 85.7%; Pred. No. 3e+02;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LLMWITQ 8

Db 27 LFMWITQ 33

RESULT 9  
 Q96XC8 PRELIMINARY; PRT; 620 AA.  
 ID Q96XC8;  
 AC Q96XC8;  
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
 DT 01-JUN-2003 (TrEMBLrel. 24, Last annotation update)  
 DE Hypothetical protein SF2587.  
 GN SF2587.  
 OS Sulfolobus tokodaii.  
 OC Archaea; Crenarchaeota; Thermoprotei; Sulfolobales; Sulfolobaceae;  
 OC Sulfolobus.  
 OX NCBI\_TaxID=111955;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=JCM 10545 / 7;  
 RX MEDLINE=21456156; PubMed=11572479;  
 RA Kawarabayashi Y., Hino Y., Horikawa H., Jin-no K., Takahashi M.,  
 RA Sekine M., Baba S.-I., Ankai A., Kosugi H., Hosoyama A., Fukui S.,  
 RA Nagai Y., Nishijima K., Otsuka R., Nakazawa H., Takamiya M., Kato Y.,  
 RA Yoshizawa T., Tanaka T., Kudoh Y., Yamazaki J., Kushida N., Oguchi A.,  
 RA Aoki K.-I., Masuda S., Yanagii M., Nishimura M., Yamagishi A.,  
 RA Oshima T., Kikuchi H.;  
 RT "Complete genome sequence of an aerobic thermoacidophilic  
 Crenarchaeon, Sulfolobus tokodaii strain 7."  
 RL DNA Res. 8:123-140(2001).  
 DR EMBL: AP000990; BAB67700.1; -;  
 KW Hypothetical protein; Complete proteome.  
 SQ SEQUENCE 620 AA; 68673 MW; FE398E1860560918 CRC64;

Query Match 79.1%; Score 34; DB 17; Length 620;

Best Local Similarity 85.7%; Pred. No. 3.5e+02;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWIT 7

Db 328 SLLMWIT 334

RESULT 10

ID Q9VXF4 PRELIMINARY; PRT; 1137 AA.  
 AC Q9VXF4;  
 DT 01-MAY-2000 (TrEMBLrel. 13, Created)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last sequence update)  
 DT 01-MAY-2000 (TrEMBLrel. 13, Last annotation update)  
 DE CG9902 protein.  
 GN CG9902.  
 OS Drosophila melanogaster (Fruit fly).  
 OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
 OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
 OC Ephydroidea; Drosophilidae; Drosophila.  
 OX NCBI\_TaxID=7227;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC STRAIN=Berkley;  
 RX MEDLINE=20196006; PubMed=10731132;  
 RA Adams M.D., Celisner S.E., Holt R.A., Evans C.A., Gocayne J.D.,  
 RA Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A., Galie R.F.,  
 RA George R.A., Lewis S.E., Richards S., Ashburner M., Henderson S.N.,  
 RA Sutton G.G., Wortman J.R., Yandell M.D., Zhang Q., Chen L.X.,  
 RA Brandon R.C., Rogers Y.-H.C., Blazek R.G., Champe M., Pfeiffer B.D.,  
 RA Wan K.H., Doyle C., Baxter E.G., Helt G., Nelson C.R., Miklos G.L.G.,  
 RA Abril J.F., Aghayani A., An H.-J., Andrews-Pfannkoch C., Baldwin D.,  
 RA Ballew R.M., Basu A., Baxendale J., Bayraktaroglu L., Beasley E.M.,  
 RA Beeson K.Y., Bens P.V., Bereman B.P., Bhandari D., Bolshakov S.,  
 RA Borkova D., Botchan M.R., Bouck J., Brokstein P., Brotter P.,  
 RA Burtis K.C., Busam D.A., Butler H., Cadieu E., Center A., Chandra I.,  
 RA Cherry J.M., Cawley S., Dahlke C., Davenport L.B., Davies P.,  
 RA de Pablos B., Delcher A., Deng Z., Mays A.D., Dew I., Dietz S.M.,  
 RA Dodson K., Doup L.E., Downes M., Dugan-Rocha S., Dunkov B.C., Dunn P.,



```
RA Durbin K.J., Evangelista C.C., Ferraz C., Ferreira S., Fleischmann W.,
RA Fosler C., Gabriellian A.E., Garg N.S., Gelbart W.M., Glasser K.,
RA Glodek A., Gong F., Gorrell J.H., Gu Z., Guan P., Harris M.,
RA Harris N.L., Harvey D., Heiman T.J., Hernandez J.R., Houck J.,
RA Hostin D., Houson K.A., Howland T.J., Wei M.-H., Ibegwam C.,
RA Jalali M., Kalush F., Karpen G.H., Ke Z., Kemison J.A., Ketchum K.A.,
RA Kimmel B.E., Kodira C.D., Kraft C., Kravitz S., Kulp D., Lai Z.,
RA Lasko P., Lei Y., Levitsky A.A., Li J., Li Z., Liang Y., Lin X.,
RA Liu X., Mattei B., McIntosh T.C., McLeod M.P., McPherson D.,
RA Merkulov G., Milshina N.V., Mobarry C., Morris J., Moshrefi A.,
RA Mount S.M., Moy M., Murphy B., Murphy L., Muzny D.M., Nelson D.L.,
RA Nelson D.R., Nelson K.A., Nixon K., Nuskern D.R., Pacieb J.M.,
RA Palazolo M., Pittman G.S., Pan S., Saunders R.D.C., Scheeler F., Shen H.,
RA Reinert K., Remington K., Simpson M., Skupski M.P., Smith T.,
RA Shue B.C., Siden-Kiamos I., Stappleton M., Strong R., Sun E.,
RA Spier E., Spradling A.C., Stappleton M., Strong R., Sun E.,
RA Swirskas R., Tector C., Turner R., Venter E., Wang A.H., Wang X.,
RA Wang Z.-Y., Wasarman D.A., Weinstein G.M., Weissenbach J.,
RA Williams S.M., Woodage T., Worley K.C., Wu D., Yang S., Yao Q.A.,
RA Ye J., Yeh R.-P., Zaveri J.S., Zhan M.C., Zhang G., Zhao X., Zheng L.,
RA Zheng X.H., Zhong F.N., Zhong W., Zhou X., Zhu S., Zhu X., Smith H.O.,
RA Gibbs R.A., Myers E.W., Rubin G.M., Venter J.C.;
RT "The genome sequence of Drosophila melanogaster."
RL Science 287:2185-2195(2000).
DR EMBL: AE003502; AAF48620.1; -.
DR FlyBase: FBgn0030757; CG9902.
SQ SEQUENCE 1137 AA; 129332 MW; 4DE52C0D7E792B21 CRC64;

Query Match 79.1%; Score 34; DB 5; Length 1137;
Best Local Similarity 75.0%; Pred. No. 6e-02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 88 SLLMWFSQ 95

RESULT 11
Q8T9H7 PRELIMINARY; PRT; 1137 AA.
AC Q8T9H7;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE GM14421p.
GN CG9902.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
CX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA Stappleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Farfan D., Frise B., George R.,
RA Gonzalez M., Guarin H., Li P., Liao G., Miranda A., Mungall C.J.,
RA Nunoo J., Pacieb J., Paragas V., Park S., Phouanavong S., Wan K.,
RA Yu C., Lewis S.E., Rubin G.M., Celniker S.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY069289; AAL39434.1; -.
DR FlyBase: FBgn0030757; CG9902.
SQ SEQUENCE 1137 AA; 129366 MW; F16FPA33647D3B6 CRC64;

Query Match 79.1%; Score 34; DB 5; Length 1137;
Best Local Similarity 75.0%; Pred. No. 6e-02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 88 SLLMWFSQ 95

RESULT 12
Q8T9H7 PRELIMINARY; PRT; 1137 AA.
AC Q8T9H7;
DT 01-JUN-2002 (TrEMBLrel. 21, Created)
DT 01-JUN-2002 (TrEMBLrel. 21, Last sequence update)
DT 01-OCT-2002 (TrEMBLrel. 22, Last annotation update)
DE GM14421p.
GN CG9902.
OS Drosophila melanogaster (Fruit fly).
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;
OC Ephydroidea; Drosophilidae; Drosophila.
CX NCBI_TaxID=7227;
RN [1]
RP SEQUENCE FROM N.A.
RA Stappleton M., Brokstein P., Hong L., Agbayani A., Carlson J.,
RA Champe M., Chavez C., Dorsett V., Farfan D., Frise B., George R.,
RA Gonzalez M., Guarin H., Li P., Liao G., Miranda A., Mungall C.J.,
RA Nunoo J., Pacieb J., Paragas V., Park S., Phouanavong S., Wan K.,
RA Yu C., Lewis S.E., Rubin G.M., Celniker S.;
RL Submitted (DEC-2001) to the EMBL/GenBank/DBJ databases.
DR EMBL: AY069289; AAL39434.1; -.
DR FlyBase: FBgn0030757; CG9902.
SQ SEQUENCE 1137 AA; 129366 MW; F16FPA33647D3B6 CRC64;

Query Match 79.1%; Score 34; DB 5; Length 1137;
Best Local Similarity 75.0%; Pred. No. 6e-02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
Db 88 SLLMWFSQ 95

RESULT 13
Q7WQK1 PRELIMINARY; PRT; 227 AA.
AC Q7WQK1;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Glutamate/aspartate transport system permease protein.
GN GLTK OR B80331.
OS Bordetella bronchiseptica (Alcaligenes bronchisepticus).
OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;
OC Alcaligenaceae; Bordetella.
CX NCBI_TaxID=518;
RN [1]
RP SEQUENCE FROM N.A.
RA STRAIN=RB50 / ATCC BAA-588;
RA MEDLINE=22827954; PubMed=12910271;
RA Parkhill J., Sebahia M., Preston A., Murphy L.D., Thomson N.,
RA Harris D.E., Holden M.T.G., Churcher C.M., Bentley S.D., Mungall K.L.,
RA Cerdeno-Tarraga A.M., Temple L., James K., Harris B., Quail M.A.,
RA Achtman M., Ackin R., Baker S., Basham D., Bason N., Cherevach I.,
RA Chillingworth T., Collins M., Cronin A., Davis P., Doggett J.,
RA Felwell T., Goble A., Hamlin N., Hauser H., Holroyd S., Jagels K.,
RA Leather S., Moule S., Norberczak H., O'Neill S., Ormond D., Price C.,
RA Rabinowitsch E., Rutter S., Sanders M., Saunders D., Seeger K.,
RA Sharp S., Simmonds M., Skelton J., Squares R., Squares S., Stevens K.,
RA Unwin L., Whitehead S., Barrell B.G., Maskell D.J.;
RT "Comparative analysis of the genome sequences of Bordetella pertussis,
RT Bordetella parapertussis and Bordetella bronchiseptica."
RL Nat. Genet. 35:32-40(2003).
DR EMBL: BX640437; CAE30829.1; -.
KW Complete proteome.
SQ SEQUENCE 227 AA; 24798 MW; 4A5A84A73EEFB1E7 CRC64;
```

```

Query Match      76.7%; Score 33; DB 16; Length 227;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LLMWITQ 8
Db 83 LLOWITQ 89

RESULT 14
Q7WVCJ5 PRELIMINARY; PRT; 227 AA.
AC Q7WVCJ5;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Glutamate/aspartate transport system permease protein.
GN GLTK OR BP0328.
OS Bordetella parapertussis.
OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;
OC Alcaligenaceae; Bordetella.
OX NCBI_TaxID=519;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=12822 / ATCC BAA-597;
RX MEDLINE=22827954; PubMed=12910271;
RA Parkhill J., Sebahia M., Preston A., Murphy L.D., Thomson N.,
RA Harris D.E., Hoiden M.T.G., Churcher C.M., Bentley S.D., Mungall K.L.,
RA Cerdeno-Tarraga A.M., Temple L., James K., Harris B., Quail M.A.,
RA Achtman M., Atkin R., Baker S., Basham D., Bason N., Cherevach I.,
RA Chillingworth T., Collins M., Cronin A., Davis P., Doggett J.,
RA Feltwell T., Goble A., Hamlin N., Hauser H., Holroyd S., Jagels K.,
RA Leather S., Moule S., Norberczak H., O'Neill S., Ormond D., Price C.,
RA Rabinowitsch E., Rutter S., Sanders M., Saunders S., Stevens K.,
RA Sharp S., Simmonds M., Skelton J., Squares R., Squares S., Stevens K.,
RA Unwin L., Whitehead S., Barrell B.G., Maskell D.J.;
RT "Comparative analysis of the genome sequences of Bordetella pertussis,
RT Bordetella parapertussis and Bordetella bronchiseptica.";
PL Nat. Genet. 35:32-40(2003).
DR EMBL; BX640424; CAE35912.1; -.
KW Complete proteome.
SQ SEQUENCE 227 AA; 24814 MW; AF0FC4A9B0B08D3CA CRC64;

Query Match      76.7%; Score 33; DB 16; Length 227;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 LLMWITQ 8
Db 83 LLOWITQ 89

RESULT 15
Q7VZW4 PRELIMINARY; PRT; 227 AA.
AC Q7VZW4;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Glutamate/aspartate transport system permease protein.
GN GLTK OR BP0767.
OS Bordetella pertussis.
OC Bacteria; Proteobacteria; Betaproteobacteria; Burkholderiales;
OC Alcaligenaceae; Bordetella.
OX NCBI_TaxID=520;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=Tohama I / ATCC BAA-599 / NCTC 13251;
RX MEDLINE=22827954; PubMed=12910271;
RA Parkhill J., Sebahia M., Preston A., Murphy L.D., Thomson N.,
RA Harris D.E., Hoiden M.T.G., Churcher C.M., Bentley S.D., Mungall K.L.,
RA Cerdeno-Tarraga A.M., Temple L., James K., Harris B., Quail M.A.,

```

```

RA Achtman M., Atkin R., Baker S., Basham D., Bason N., Cherevach I.,
RA Chillingworth T., Collins M., Cronin A., Davis P., Doggett J.,
RA Feltwell T., Goble A., Hamlin N., Hauser H., Holroyd S., Jagels K.,
RA Leather S., Moule S., Norberczak H., O'Neill S., Ormond D., Price C.,
RA Rabinowitsch E., Rutter S., Sanders M., Saunders D., Seeger K.,
RA Sharp S., Simmonds M., Skelton J., Squares R., Squares S., Stevens K.,
RA Unwin L., Whitehead S., Barrell B.G., Maskell D.J.;
RT "Comparative analysis of the genome sequences of Bordetella pertussis,
RT Bordetella parapertussis and Bordetella bronchiseptica.";
PL Nat. Genet. 35:32-40(2003).
DR EMBL; BX640413; CAE41073.1; -.
KW Complete proteome.
SQ SEQUENCE 227 AA; 24798 MW; 4A5A84A73EEFB1E7 CRC64;

```

```

Query Match      76.7%; Score 33; DB 16; Length 227;
Best Local Similarity 85.7%; Pred. No. 2.1e+02;
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 2 LLMWITQ 8
Db 83 LLOWITQ 89

```

```

RESULT 16
Q7VVF34 PRELIMINARY; PRT; 362 AA.
AC Q7VVF34;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Integrase/recombinase XerD.
GN XERD OR HH1845.
OS Helicobacter hepaticus.
OC Bacteria; Proteobacteria; Epsilonproteobacteria; Campylobacteriales;
OC Helicobacteraceae; Helicobacter.
OX NCBI_TaxID=32025;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=ATCC 51449 / 3B1;
RX MEDLINE=22709201; PubMed=12810954;
RA Suerbaum S., Josenhans C., Sterzenbach T., Drescher B., Brandt P.,
RA Bell M., Droge M., Fartmann B., Fischer H.-P., Ge Z., Hoerster A.,
RA Holland R., Klein K., Koenig J., Macko L., Mendz G.L., Nyakatura G.,
RA Schauer D.B., Shen Z., Weber J., Frosch M., Fox J.G.;
RT "The complete genome sequence of the carcinogenic bacterium
RT Helicobacter hepaticus.";
PL Proc. Natl. Acad. Sci. U.S.A. 100:7901-7906(2003).
DR EMBL; AE017149; AAP78442.1; -.
KW Complete proteome.
SQ SEQUENCE 362 AA; 41280 MW; 581A08F96F841C0D CRC64;

```

```

Query Match      76.7%; Score 33; DB 16; Length 362;
Best Local Similarity 75.0%; Pred. No. 3.2e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

Qy 1 SLLMWITQ 8
Db 14 SLLFWITR 21

```

```

RESULT 17
Q9HSK2 PRELIMINARY; PRT; 479 AA.
AC Q9HSK2;
DT 01-MAR-2001 (TrEMBLrel. 16, Created)
DT 01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Vng0189c.
GN VNG0189C.
OS Halobacterium sp. (strain NRC-1 / ATCC 700922 / JCM 11081).
OC Archaea; Euryarchaeota; Halobacteriales; Halobacteriaceae;
OC Halobacteriaceae; Halobacterium.
OX NCBI_TaxID=64091;

```

```

RN  [1]
RP  SEQUENCE FROM N.A.
RX  MEDLINE=20504483; PubMed=11016950;
RA  Ng W.V., Kennedy S.P., Mahairas G.G., Berquist B., Pan M.,
RA  Shukla H.D., Lasky S.R., Baig N.S., Thorsson V., Shrogha J.,
RA  Swartzell S., Weir D., Hall J., Dahl T.A., Welti R., Goo Y.A.,
RA  Leithausser B., Keller K., Cruz R., Danson M.J., Hough D.W.,
RA  Maddocks D.G., Jablonski P.E., Krebs M.P., Angevine C.M., Dale H.,
RA  Isenbarger T.A., Beck R.F., Pohlischer M., Spudich J.L., Jung K.-H.,
RA  Alam M., Freitas T., Hou S., Daniels C.J., Dennis P.P., Omer A.D.,
RA  Ehardt H., Lowe T.M., Liang P., Riley M., Hood L., DasSarma S.;
RT  "Genome sequence of Halobacterium species NRC-1.";
RL  Proc. Natl. Acad. Sci. U.S.A. 97:12176-12181(2000).
DR  EMBL; AE004984; AAC18802.1; -.
DR  F01; F84179; F84179.
DR  GO; GO:0003824; F:catalytic activity; IEA.
DR  InterPro; IPR006674; HD.
DR  InterPro; IPR003607; Met_phosphohydro.
DR  Pfam; PF01966; HD; 1.
DR  SMART; SM00471; HDC; 1.
DR  Complete proteome.
RW  SEQUENCE 479 AA; 53083 MW; 9081FC3F14BE8C1B CRC64;

Query Match 76.7%; Score 33; DB 17; Length 479;
Best Local Similarity 62.5%; Pred. No. 4.2e+02;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY  1 SLLMWITQ 8
Db  263 ALYMWITQ 270

RESULT 18
Q7XE56 PRELIMINARY; PRT; 571 AA.
AC  Q7XE56;
DT  01-OCT-2003 (TrEMBLrel. 25, Created)
DT  01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT  01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE  Hypothetical protein.
GN  OSJNB004011.1.
OS  Oryza sativa (japonica cultivar-group).
OC  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC  Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
OC  Ehrhartoideae; Oryzoae; Oryza.
OX  NCBI_TaxID=39947;
[1]
RN  SEQUENCE FROM N.A.
RP  STRAIN=cv. Nipponbare;
RC  The Rice Chromosome 10 Sequencing Consortium;
RA  "In-depth view of structure, activity, and evolution of rice
RT  chromosome 10.";
RL  Science 300:1566-1569(2003).
[2]
RN  SEQUENCE FROM N.A.
RP  STRAIN=cv. Nipponbare;
RC  Buell C.R., Wing R.A., McCombie W.R., Messing J., Yuan Q.;
RL  Submitted (May-2003) to the EMBL/GenBank/DBJ databases.
DR  EMBL; AE017098; AAP53934.1; -.
RW  Hypothetical protein.
RW  SEQUENCE 571 AA; 63008 MW; 401866DAAC2A8F5F CRC64;

Query Match 76.7%; Score 33; DB 10; Length 571;
Best Local Similarity 75.0%; Pred. No. 4.9e+02;
Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY  1 SLLMWITQ 8
Db  403 TLLTWITQ 410

RESULT 19
Q82WC4 PRELIMINARY; PRT; 683 AA.
AC  Q82WC4;
DT  01-JUN-2003 (TrEMBLrel. 24, Created)
DT  01-JUN-2003 (TrEMBLrel. 24, Last sequence update)
DT  01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE  Cytochrome c-type biogenesis protein (CcmF).
GN  CCMF OR NE0788.
OS  Nitrosomonas europaea.
OC  Bacteria; Proteobacteria; Betaproteobacteria; Nitrosomonadales;
OC  Nitrosomonadaceae; Nitrosomonas.
OX  NCBI_TaxID=915;
[1]
RN  SEQUENCE FROM N.A. / IFO 14298;
RC  STRAIN=ATCC 19718 / IFO 14298;
RX  MEDLINE=22586410; PubMed=12700255;
RA  Chain P., Lamerdin J.E., Larimer F.W., Regala W., Lao V., Land M.,
RA  Hauser L., Hooper A.B., Klotz M.G., Norton J., Sayavedra-Soto L.A.,
RA  Arciero D.M., Hommes N.G., Whittaker M.M., Arp D.J.;
RT  "Complete genome sequence of the ammonia-oxidizing bacterium and
RT  obligate chemolithoautotroph Nitrosomonas europaea.";
RL  J. Bacteriol. 185:2759-2773(2003).
DR  EMBL; BX321858; CAD84679.1; -.
DR  GO; GO:0016020; C:membrane; IEA.
DR  GO; GO:0015232; P:heme transporter activity; IEA.
DR  GO; GO:0017004; P:cytochrome biogenesis; IEA.
DR  GO; GO:0008535; P:cytochrome c oxidase biogenesis; IEA.
DR  GO; GO:0015886; P:heme transport; IEA.
DR  InterPro; IPR002541; Cyt_c_asm.
DR  InterPro; IPR003568; Cyt_c_biol.
DR  InterPro; IPR003567; Cyt_c_biol.
DR  Pfam; PF01578; Cyt_c_asm; 1.
DR  PRINTS; PR01410; CCBIOGENESIS.
DR  TIGRFAMs; TIGR00353; nrfe; 1.
DR  Complete proteome.
RW  SEQUENCE 683 AA; 74061 MW; 6A0624E452D77FC9 CRC64;

Query Match 76.7%; Score 33; DB 16; Length 683;
Best Local Similarity 71.4%; Pred. No. 5.8e+02;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY  1 SLLMWIT 7
Db  95 SLLMWIT 101

RESULT 20
Q9FGS9 PRELIMINARY; PRT; 713 AA.
AC  Q9FGS9;
DT  01-MAR-2001 (TrEMBLrel. 16, Created)
DT  01-MAR-2001 (TrEMBLrel. 16, Last sequence update)
DT  01-JUN-2003 (TrEMBLrel. 24, Last annotation update)
DE  FRO1 and FRO2-like protein.
OS  Arabidopsis thaliana (Mouse-ear cress).
OC  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC  Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC  eusoids II; Brassicales; Brassicaceae; Arabidopsids.
OX  NCBI_TaxID=3702;
[1]
RN  SEQUENCE FROM N.A.
RP  STRAIN=Columbia;
RC  MEDLINE=20181125; PubMed=10718197;
RX  Sato S., Nakamura Y., Kaneko T., Katoh T., Asamizu E., Kotani H.,
RA  Tabata S.;
RT  "Structural analysis of Arabidopsis thaliana chromosome 5. X. Sequence
RT  features of the regions of 3,076,755 bp covered by sixty P1 and TAC
RT  clones.";
RL  DNA Res. 7:31-63(2000).
DR  EMBL; AB024031; BAB09387.1; -.
DR  GO; GO:0016020; C:membrane; IEA.
DR  GO; GO:0016491; F:oxidoreductase activity; IEA.
DR  GO; GO:0005215; F:transporter activity; IEA.
DR  GO; GO:0006118; P:electron transport; IEA.

```

```

QY      2 LLWWIT 7
DB      248 LLWWIT 253

RESULT 22
Q8IEI7
ID Q8IEI7 PRELIMINARY; PRT; 121 AA.
AC Q8IEI7;
DT 01-MAR-2003 (TrEMBLrel. 23, Created)
DT 01-MAR-2003 (TrEMBLrel. 23, Last sequence update)
DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)
DE Hypothetical protein.
GN MAL13P1.62.
OS Plasmodium falciparum (isolate 3D7).
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
CX NCBI_TaxID=36329;
RN [1]
RP SEQUENCE FROM N.A.
RA Harris B., Lennard N., Clark L., Line A., Barron A., Corton C.,
RA Berriman M., Pain A., Hall N., Atkin R., Chillingworth C., Doggett J.,
RA Ormond D., Sanders M., Hayes R., Hall S., Quail M., Barrell B.,
RL Submitted (SEP-2002) to the EMBL/GenBank/DBJ databases.
DR EMBL; AL844509; CAD52270.1; -.
RW Hypothetical protein.
SQ SEQUENCE 121 AA; 15146 MW; C99C76BE87B2F5D6 CRC64;

Query Match 74.4%; Score 32; DB 5; Length 121;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 SLLMWI 6
DB      17 SLLMWI 22

RESULT 23
Q7YBD6
ID Q7YBD6 PRELIMINARY; PRT; 127 AA.
AC QYBD6;
DT 01-OCT-2003 (TrEMBLrel. 25, Created)
DT 01-OCT-2003 (TrEMBLrel. 25, Last sequence update)
DT 01-OCT-2003 (TrEMBLrel. 25, Last annotation update)
DE Cytochrome oxidase subunit I (Fragment).
GN COI.
OS Tapinella sp. KPJ-2003.
OC Mitochondrion.
OC Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;
OC Neoptera; Paraneoptera; Psocoptera; Troctomorpha; Pachytroctidae;
OC Tapinella.
CX NCBI_TaxID=239299;
RN [1]
RP SEQUENCE FROM N.A.
RA Johnson K.P., Mockford E.L.;
RT "Molecular systematics of Psocomorpha (Psocoptera).";
RL Syst. Entomol. 28:409-416(2003).
DR EMBL; AY275295; AAP97113.1; -.
KW Mitochondrion.
FT NON_TER 1
FT NON_TER 127 127
SQ SEQUENCE 127 AA; 13949 MW; 9EF19D85424BF551 CRC64;

Query Match 74.4%; Score 32; DB 8; Length 127;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 SLLMWI 6
DB      96 SLLMWI 101

RESULT 24

```

Q9Y2R7 PRELIMINARY; PRT; 171 AA.  
 AC Q9Y2R7;  
 DT 01-NOV-1999 (TrEMBLrel. 12, Created)  
 DT 01-NOV-1999 (TrEMBLrel. 12, Last sequence update)  
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)  
 DE HSPC013 (Apoptosis related protein APR-3).  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=2049367; PubMed=11042152;  
 RA Zhang Q.H., Ye X., Wu X.Y., Ren S.X., Zhao M., Zhao C.J., Fu G.,  
 RA Shen Y., Fan H.Y., Lu G., Zhong M., Xu X.R., Han Z.G., Zhang J.W.,  
 RA Tao J., Huang Q.H., Zhou J., Hu Q.X., Gu J., Chen S.J., Chen Z.,  
 RT "Cloning and functional analysis of cDNAs with open reading frames for  
 RT 300 previously undefined genes expressed in CD34+ hematopoietic  
 RT stem/progenitor cells.";  
 RL Genome Res. 10:1546-1560(2000).  
 RN [2]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RA Strausberg R.;  
 RL Submitted (JUL-2002) to the EMBL/GenBank/DBJ databases.  
 DR ENBL; AF077037; AAD2770.1; -.  
 DR ENBL; BC035850; AAH35850.1; -.  
 DR InterPro; IPR006209; EGF-like.  
 DR InterPro; IPR006210; IEGF.  
 DR SMART; SM00181; EGF; 1.  
 DR PROSITE; PS00022; EGF 1; 1.  
 DR PROSITE; PS01186; EGF\_2; 1.  
 KW EGF-like domain.  
 SQ SEQUENCE 171 AA; 18597 MW; 91A42CD2B2CB0883 CRC64;

Search completed: August 22, 2004, 11:02:24  
 Job time : 114 secs

Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 SLLMWITQ 8  
 Db 215 SILLWATQ 222

Query Match 74.4%; Score 32; DB 4; Length 171;  
 Best Local Similarity 62.5%; Pred. No. 2.5e+02;  
 Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 Db 157 SILLWATQ 164

RESULT 25  
 Q96FF6 PRELIMINARY; PRT; 229 AA.  
 AC Q96FF6;  
 DT 01-DEC-2001 (TrEMBLrel. 19, Created)  
 DT 01-DEC-2001 (TrEMBLrel. 19, Last sequence update)  
 DT 01-MAR-2003 (TrEMBLrel. 23, Last annotation update)  
 DE Hypothetical protein.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RC TISSUE=Brain;  
 RA Strausberg R.;  
 RL Submitted (JUL-2001) to the EMBL/GenBank/DBJ databases.  
 DR ENBL; BC011006; AAH1006.1; -.  
 DR InterPro; IPR006209; EGF-like.  
 DR InterPro; IPR006210; IEGF.  
 DR SMART; SM00181; EGF; 1.  
 DR PROSITE; PS00022; EGF 1; 1.  
 DR PROSITE; PS01186; EGF\_2; 1.  
 KW Hypothetical protein; EGF-like domain.  
 SQ SEQUENCE 229 AA; 24688 MW; F2C63F934A47ED33 CRC64;

Query Match 74.4%; Score 32; DB 4; Length 229;  
 Best Local Similarity 62.5%; Pred. No. 3.2e+02;

THIS PAGE BLANK (UPSIDE)

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2004, 10:47:33 ; Search time 23 Seconds  
(without alignments)  
20.375 Million cell updates/sec

Title: US-10-706-475-10

Perfect score: 43

Sequence: 1 SLLMWITQX 9

Scoring table: BLOSUM62XX

Gapop 10.0 , Gapext 0.5

Searched: 141681 seqs, 52070155 residues

Total number of hits satisfying chosen parameters: 141681

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%  
Listing first 50 summaries

Database : SwissProt\_42.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	42	97.7	180	1 CTG1_HUMAN	P78358 homo sapien
2	34	79.1	122	1 YN10_YEAST	Q03880 saccharomyc
3	34	79.1	299	1 XT10_ARATH	Q92VX1 arabidopsis
4	32	74.4	145	1 YD54_METJA	O58749 methanococ
5	32	74.4	724	1 P85A_BOVIN	P23727 bos taurus
6	32	74.4	724	1 P85A_HUMAN	P27986 homo sapien
7	32	74.4	724	1 P85A_MOUSE	P26450 mus musculu
8	32	74.4	724	1 P85A_RAT	Q63787 rattus norv
9	32	74.4	2331	1 RRPL_MABVM	P31352 marburg vir
10	32	74.4	2331	1 RRPL_MABVP	P35262 marburg vir
11	31	72.1	213	1 NUKM_SOLTU	O43844 solanum tub
12	31	72.1	356	1 CKR8_MACMU	O97685 macaca mula
13	31	72.1	437	1 PFTB_BOVIN	P49355 bos taurus
14	31	72.1	437	1 PFTB_HUMAN	P49356 homo sapien
15	31	72.1	437	1 PFTB_RAT	Q02293 rattus norv
16	31	72.1	6885	1 SNE2_HUMAN	Q8WXH0 homo sapien
17	31	72.1	8797	1 SNE1_HUMAN	Q8NF91 homo sapien
18	30	69.8	83	1 VES1_HPV16	P06927 human papil
19	30	69.8	121	1 KV40_HUMAN	P06312 homo sapien
20	30	69.8	133	1 KV4B_HUMAN	P06313 homo sapien
21	30	69.8	134	1 KV4C_HUMAN	P06314 homo sapien
22	30	69.8	351	1 HRPX_PLALO	P04929 plasmodium
23	30	69.8	406	1 HOCF_HAENI	P44621 haemophilus
24	30	69.8	675	1 RGS9_MOUSE	O54828 mus musculu
25	30	69.8	676	1 KALM_CHICK	P33005 gallus gall
26	30	69.8	702	1 HPFA_RHURU	O88460 rhodospiril
27	30	69.8	706	1 HPFA_BRAVA	Q98K83 bradyrhizob
28	30	69.8	806	1 R1R1_HSV7J	P50641 human herpe
29	30	69.8	2179	1 POLG_EC23W	O73556 e genome po
30	30	69.8	2180	1 POLG_EC22H	Q65578 e genome po
31	30	69.8	2188	1 POLG_EC23C	Q3Y4D8 e genome po
32	29	67.4	68	1 NP31_MOUSE	Q07475 mus musculu
33	29	67.4	98	1 NULM_POLOR	Q55916 polypteru

34 29 67.4 117 1 V117\_ASPL5  
35 29 67.4 184 1 21KD\_ZYMMO  
36 29 67.4 207 1 TIM1\_CANFA  
37 29 67.4 234 1 SNG4\_HUMAN  
38 29 67.4 240 1 ICAN\_FORPU  
39 29 67.4 284 1 XT13\_ARATH  
40 29 67.4 305 1 NULM\_APILI  
41 29 67.4 326 1 NU37\_MOUSE  
42 29 67.4 326 1 O4AG\_HUMAN  
43 29 67.4 328 1 O8S4\_CANAL  
44 29 67.4 402 1 YVCB\_EACSU  
45 29 67.4 463 1 DALD\_YERPE  
46 29 67.4 464 1 C1SY\_PIG  
47 29 67.4 464 1 C1SY\_PIG  
48 29 67.4 466 1 C1SY\_HUMAN  
49 29 67.4 492 1 NU4M\_CHOCR  
50 29 67.4 523 1 NU4M\_PROWI

#### ALIGNMENTS

##### RESULT 1

CTG1\_HUMAN  
ID CTG1\_HUMAN STANDARD; PRT; 180 AA.  
AC P78358;  
DT 15-DEC-1998 (Rel. 37, Created)  
DT 15-DEC-1998 (Rel. 37, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Cancer/testis antigen 1 (Autoimmunogenic cancer/testis antigen NY-ESO-1).  
GN CTAG1 OR CTAG.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=97203161; PubMed=9050879;  
RA Chen Y.-T., Scanlan M.J., Sahlin U., Tuereci O., Gure A.O., Tsang S., Williamson B., Stockert E., Pfundschnuh M., Old L.J.;  
RT "A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening."  
RL Proc. Natl. Acad. Sci. U.S.A. 94:1914-1918(1997).  
RN [2]  
RP SEQUENCE FROM N.A.  
RX TISSUE=Melanoma;  
RC MEDLINE=98289662; PubMed=9626360;  
RA Lethe B., Lucas S., Michaux L., de Smet C., Godelaine D., Serrano A., de Plaen E., Boon T.;  
RT "LAG-1, a new gene with tumor specificity."  
RL Int. J. Cancer 76:903-908(1998).  
RN [3]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=98430682; PubMed=9759882;  
RA Wang R.-F., Johnston S.L., Zeng G., Topalian S.L., Schwartzentruber D.J., Rosenberg S.A.;  
RT "A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames."  
RL J. Immunol. 161:3596-3606(1998).  
CC -!- TISSUE SPECIFICITY: Expressed in testis and ovary and in a wide variety of cancers. Detected in uterine myometrium.  
CC -!- SIMILARITY: Belongs to the CTAG family.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).  
CC -----  
CC EMBL; U87459; AAB49693.1; --

```

DR EMBL; AJ003149; CAA05908.1; -
DR EMBL; AF038567; AAD05202.1; -
DR Genew; HGNC:2491; CTAG1.
DR MIM; 300156; -.
KW Transmembrane; Antigen.
FT DOMAIN 156 172
FT TRANSMEM 156 172
SQ SEQUENCE 180 AA; 17992 MW; B122C5C2C8B51569 CRC64;
      GLY-RICH.
      POTENTIAL.
Query Match 97.7%; Score 42; DB 1; Length 180;
Best Local Similarity 100.0%; Pred. No. 0.69;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8
DB 157 SLLMWITQ 164

RESULT 2
YK10_YEAST STANDARD; PRT; 122 AA.
AC Q03880;
DT 01-NOV-1997 (Rel. 35, Last sequence update)
DT 10-OCT-2003 (Rel. 42, Last annotation update)
DE Hypothetical 14.0 kDa protein in RPL15B-GCR3 intergenic region.
GN YK123W OR YK8564.05.
OS Saccharomyces cerevisiae (Baker's yeast).
OC Eukaryota; Fungi; Ascomycota; Saccharomycotina; Saccharomycetes;
OC Saccharomycetales; Saccharomycetaceae; Saccharomycetes.
OX NCBI_TaxID=4932;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=S288C / AB972;
RX MEDLINE=97313268; PubMed=9169872;
RA Bowman S., Churcher C.M., Badcock K., Brown D., Chillingworth T.,
RA Connor R., Dedman K., Devlin K., Gentles S., Hamlin N., Hunt S.,
RA Jagsels K., Lye G., Moule S., Odell C., Pearson D., Rajandream M.A.,
RA Rice P., Skelton J., Walsh S., Whitehead S., Bartell B.G.;
RT "The nucleotide sequence of Saccharomyces cerevisiae chromosome
RT XIII."
RL Nature 387:90-93(1997).
CC -!- SIMILARITY: TO S.POMBE SPBP23A10.02.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (see http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; Z49273; CAA89272.1; -
DR PIR; S54492; S54492
DR GenOnline; 142792; -.
DR SGD; S0004730; PRR1.
KW Hypothetical protein; Transmembrane.
FT TRANSMEM 21 41
FT TRANSMEM 47 67
FT TRANSMEM 47 67
SQ SEQUENCE 122 AA; 13962 MW; 5CAA6929D55F2C40 CRC64;
      POTENTIAL.
Query Match 79.1%; Score 34; DB 1; Length 122;
Best Local Similarity 85.7%; Pred. No. 13;
Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7
DB 56 SLLMWIT 62

RESULT 3
XT10_ARATH STANDARD; PRT; 299 AA.
ID XT10_ARATH

```

```

AC Q9ZVK1;
DT 15-MAR-2004 (Rel. 43, Created)
DT 15-MAR-2004 (Rel. 43, Last sequence update)
DT 15-MAR-2004 (Rel. 43, Last annotation update)
DE Probable xyloglucan endotransglucosylase/hydrolase protein 10
DE precursor (EC 2.4.1.207) (At-XTH10) (XTH-10).
GN XTH10 OR XTR14 OR AIZG14620 OR T6B13.14.
OS Arabidopsis thaliana (Mouse-ear cress).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids;
OC eurosids II; Brassicales; Brassicaceae; Arabidopsids.
OX NCBI_TaxID=3702;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=20083487; PubMed=10617197;
RA Lin X., Kaul S., Rounsley S.D., Shea T.P., Benito M.-I., Town C.D.,
RA Fujii C.Y., Mason T.M., Bowman C.L., Barnstead M.B., Feldblum T.V.,
RA Buell C.R., Ketchum K.A., Lee J.J., Ronning C.M., Koo H.L.,
RA Moffat K.S., Cronin L.A., Shen M., Pai G., Van Aken S., Umayam L.,
RA Tallon L.J., Gill J.E., Adams M.B., Carrera A.J., Creasy T.H.,
RA Goodman H.M., Somerville C.R., Coppenhaver G.P., Preuss D.,
RA Nierman W.C., White O., Eisen J.A., Salzberg S.L., Fraser C.M.,
RA Venter J.C.;
RT "Sequence and analysis of chromosome 2 of the plant Arabidopsis
RT thaliana."
RL Nature 402:761-768(1999).
RN [2]
RP SEQUENCE FROM N.A.
RC STRAIN=cv. Columbia;
RX MEDLINE=22954850; PubMed=14593172;
RA Yamada K., Lim J., Dale J.M., Chen H., Shinn P., Palm C.J.,
RA Southwick A.M., Wu H.C., Kim C.J., Nguyen M., Pham P.K., Cheuk R.F.,
RA Karlin-Newmann G., Liu S.X., Lam B., Sakano H., Wu T., Yu G.,
RA Miranda M., Quach H.L., Tripp M., Chang C.H., Lee J.M., Toriumi M.J.,
RA Chan M.W., Tang C.C., Onodera C.S., Deng J.M., Akiyama K., Ansari Y.,
RA Akawa T., Banh J., Banno F., Bowser L., Brooks S.Y., Carninci P.,
RA Chao Q., Choy N., Enju A., Goldsmith A.D., Gurjal M., Hansen N.F.,
RA Hayashizaki Y., Johnson-Hopson C., Hsuan V.W., Iida K., Karnes M.,
RA Khan S., Koesema E., Ishida J., Jiang P.X., Jones T., Kawai J.,
RA Kamiya A., Meyers C., Nakajima M., Narusaka M., Seki M., Sakurai T.,
RA Satou M., Tamare R., Vaysberg M., Wallender E.K., Wong C., Yamamura Y.,
RA Yuan S., Shinozaki K., Davis R.W., Ineologis A., Ecker J.R.;
RT "Empirical analysis of transcriptional activity in the Arabidopsis
RT genome."
RL Science 302:842-846(2003).
RN [3]
RP Nomenclature.
RX MEDLINE=2402747; PubMed=12514239;
RA Rose J.K.C., Braam J., Fry S.C., Nishitani K.;
RT "The XTH family of enzymes involved in xyloglucan
RT endotransglucosylation and endohydrolysis: current perspectives and a
RT new unifying nomenclature."
RL Plant Cell Physiol. 43:1421-1435(2002).
CC -!- FUNCTION: Catalyzes xyloglucan endohydrolysis (XEH) and/or
CC endotransglucosylation (XET). Cleaves and religates xyloglucan
CC polymers, an essential constituent of the primary cell wall, and
CC thereby participates in cell wall construction of growing tissues
CC (By similarity).
CC -!- CATALYTIC ACTIVITY: Breaks a beta-(1->4) bond in the backbone of a
CC xyloglucan and transfers the xyloglucanyl segment on to O-4 of the
CC non-reducing terminal glucose residue of an acceptor, which can be
CC a xyloglucan or an oligosaccharide of xyloglucan.
CC -!- SUBCELLULAR LOCATION: Apoplast (Probable).
CC -!- PTM: Contains at least one intrachain disulfide bond essential for
CC its enzymatic activity (By similarity).
CC -!- SIMILARITY: Belongs to family 16 of glycosyl hydrolases. XTH
CC group 1 subfamily.
CC -!- DATABASE: NAME=XTH-World;
CC WWW="http://www.plantbio.cornell.edu/XTH".
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

```



CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC -----  
CC EMBL; AC005398; AAC69380.1; -;  
CC DR EMBL; AV070415; AAL4991.1; -;  
CC DR EMBL; AY065966; AAM20246.1; -;  
CC DR PIR; D84519; D84519.  
CC DR HSP; P23904; IAKK.

CC InterPro; IPR008985; ConA like lec\_gl.  
CC InterPro; IPR000757; Glyco\_hydro\_16.  
CC Pfam; PF00722; Glyco\_hydro\_16; 1.  
CC PROSITE; PS01034; GLYCOSYL\_HYDROL\_F16; FALSE NEG.

CC Hydrolase; Transferase; Glycosidase; Cell wall; Apoplast; Signal;  
CC Multigene family.  
CC FT SIGNAL 1 29 POTENTIAL.  
CC FT CHAIN 30 299 PROBABLE XYLOGLUCAN  
CC FT ENDOTRANSGLUCOSYLASE/HYDROLASE PROTEIN  
CC FT 10.

CC ACT SITE 111 111 NUCLEOPHILE (BY SIMILARITY).  
CC FT ACT\_SITE 115 115 PROTON DONOR (BY SIMILARITY).  
CC FT CARBOHYD 51 51 N-LINKED (GLCNAC. . .) (POTENTIAL).  
CC FT CARBOHYD 238 238 N-LINKED (GLCNAC. . .) (POTENTIAL).  
CC SQ SEQUENCE 299 AA; 34687 MW; C8A688EFB7E910A5 CRC64;

Query Match 79.1%; Score 34; DB 1; Length 299;  
Best Local Similarity 62.5%; Pred. No. 31;  
Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
| | | | |  
DB 21 SLLMWVSQ 28

RESULT 4  
ID YD54 METUA STANDARD; PRT; 145 AA.  
Q58749;  
AC Q58749;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 16-OCT-2001 (Rel. 40, Last annotation update)  
DE Hypothetical protein M1354.

GN M1354.  
OS Methanococcus jannaschii.  
OC Archaea; Euryarchaeota; Methanococci; Methanococcales;  
OC Methanocaldococcaceae; Methanocaldococcus.  
OX NCBI\_TaxID=2190;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC STRAIN=JAL-1 / DSM 2661 / ATCC 43067;  
RX MEDLINE=96337999; PubMed=8688087;

RA Bult C.J., White O., Olsen G.J., Zhou L., Fleischmann R.D.,  
RA Sutton G.G., Blake J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D.,  
RA Kerlavage A.R., Dougherty B.A., Tomb J.-F., Adams M.D., Reich C.I.,  
RA Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Glodek A.,  
RA Scott J.L., Geoghagen N.S.M., Weidman J.F., Fuhrmann J.L., Nguyen D.,  
RA Uterback T.R., Kelley J.M., Peterson J.D., Sadow P.W., Hanna M.C.,  
RA Cotton M.D., Roberts K.M., Hurst M.A., Kaine B.P., Borodovsky M.,  
RA Klenk H.-P., Fraser C.M., Smith H.O., Woese C.R., Venter J.C.;  
RA "Complete genome sequence of the methanogenic archaeon, Methanococcus  
RT jannaschii";  
RL Science 273:1058-1073(1996).

CC -1- SUBCELLULAR LOCATION: Integral membrane protein (Potential).  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

CC EMBL; U67575; AAB99366.1; -;  
CC PIR; A64469; A64469.  
CC TIGR; M1354; -;  
CC KW Hypothetical protein; Transmembrane; Complete proteome.  
CC FT TRANSMEM 3 23 POTENTIAL.  
CC FT TRANSMEM 83 103 POTENTIAL.  
CC FT TRANSMEM 105 125 POTENTIAL.  
CC SQ SEQUENCE 145 AA; 16713 MW; 15EFEE71C5262B37 CRC64;

Query Match 74.4%; Score 32; DB 1; Length 145;  
Best Local Similarity 71.4%; Pred. No. 35;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
| | | | |  
DB 106 SLLWVIT 112

RESULT 5  
ID P85A BOVIN STANDARD; PRT; 724 AA.  
AC P23727;  
DT 01-NOV-1991 (Rel. 20, Created)  
DT 01-NOV-1991 (Rel. 20, Last sequence update)  
DT 10-OCT-2003 (Rel. 42, Last annotation update)

DE Phosphatidylinositol 3-kinase regulatory alpha subunit (PI3-kinase  
DE p85-alpha subunit) (ptdins-3-kinase p85-alpha) (PI3K).  
GN PIK3R1.  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
OC Bovidae; Bovinae; Bos.  
OX NCBI\_TaxID=9913;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=91191567; PubMed=1707345;  
RA Otsu M., Hiles I.D., Goot I., Fry M.J., Ruiz-Larrea F., Panayotou G.,  
RA Thompson A., Dhand R., Hsuan J., Totty N., Smith A.D., Morgan S.J.,  
RA Courtneidge S.A., Parker P.J., Waterfield M.D.;  
RA "Characterization of two 85 kd proteins that associate with receptor  
RT tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase";  
RL Cell 65:91-104(1991).

RN [2]  
RP CIRCULAR DICHOISM AND FLUORESCENCE SPECTROSCOPY.  
RX MEDLINE=93049176; PubMed=1330335;  
RA Panayotou G., Bax B., Gout I., Federwisch M., Wrzobowski B., Dhand R.,  
RA Fry M.J., Blundell T.L., Wollmer A., Waterfield M.D.;  
RA "Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2  
RT domain with a PDGF receptor phosphorylation site: structural features  
RT and analysis of conformational changes";  
RL EMBO J. 11:4261-4272(1992).

RN [3]  
RP STRUCTURE BY NMR OF 1-84.  
RX MEDLINE=93272320; PubMed=7684655;  
RA Booker G.W., Gout I., Downing A.K., Driscoll P.C., Boyd J.,  
RA Waterfield M.D., Campbell I.D.;  
RA "Solution structure and ligand-binding site of the SH3 domain of the  
RT p85 alpha subunit of phosphatidylinositol 3-kinase";  
RL Cell 73:813-822(1993).

RN [4]  
RP STRUCTURE BY NMR OF 314-431.  
RX MEDLINE=92357146; PubMed=1323062;  
RA Booker G.W., Breeze A.L., Downing A.K., Panayotou G., Gout I.,  
RA Waterfield M.D., Campbell I.D.;  
RA "Structure of an SH2 domain of the p85 alpha subunit of  
RT phosphatidylinositol-3-OH kinase";  
RL Nature 358:684-687(1992).

RN [5]  
RP STRUCTURE BY NMR OF 321-434.  
RX MEDLINE=97110350; PubMed=8952511;  
RA Guenther U.L., Liu Y., Sanford D., Bachovchin W.W., Schaffhausen B.;  
RA "NMR analysis of interactions of a phosphatidylinositol 3'-kinase SH2  
RT

RT domain with phosphotyrosine peptides reveals interdependence of major  
 RT binding sites.";  
 RL Biochemistry 35:15570-15581(1996).  
 RN [6]  
 RP STRUCTURE BY NMR OF 614-724.  
 RX MEDLINE=98173872; PubMed=9512716;  
 RA Siegal G., Davis B., Kristsensen S.M., Sankar A., Linacre J.,  
 RA Stein R.C., Panayotou G., Waterfield M.D., Driscoll P.C.;  
 RT "Solution structure of the C-terminal SH2 domain of the p85 alpha  
 RT regulatory subunit of phosphoinositide 3-kinase.";  
 RL J. Mol. Biol. 276:461-478(1998).  
 CC  
 CC -|- FUNCTION: BINDS TO ACTIVATED (PHOSPHORYLATED) PROTEIN-TYROSINE  
 CC KINASES, THROUGH ITS SH2 DOMAIN, AND ACTS AS AN ADAPTER, MEDIATING  
 CC THE ASSOCIATION OF THE PILO CATALYTIC UNIT TO THE PLASMA MEMBRANE.  
 CC NECESSARY FOR THE INSULIN-STIMULATED INCREASE IN GLUCOSE UPTAKE  
 CC AND GLYCOGEN SYNTHESIS IN INSULIN-SENSITIVE TISSUES.  
 CC -|- SUBUNIT: HETERODIMER OF A P110 (CATALYTIC) AND A P85 (REGULATORY)  
 CC SUBUNITS.  
 CC -|- SIMILARITY: Belongs to the PI3K p85 subunit family.  
 CC -|- SIMILARITY: Contains 1 Rho-GAP domain.  
 CC -|- SIMILARITY: Contains 2 SH2 domains.  
 CC -|- SIMILARITY: Contains 1 SH3 domain.  
 CC  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC  
 CC -----  
 CC EMBL; M61745; AAA79511.1; -;  
 CC PIR; A38749; A38749.  
 CC PDB; 2PNA; 31-JAN-94.  
 CC PDB; 2PNB; 31-JAN-94.  
 CC PDB; 2PNI; 31-OCT-93.  
 CC PDB; 1PNJ; 31-OCT-93.  
 CC PDB; 1BFI; 25-FEB-98.  
 CC PDB; 1BFJ; 25-FEB-98.  
 CC PDB; 1QAD; 26-SEP-01.  
 CC InterPro; IPR001720; PI3kinase\_P85.  
 CC InterPro; IPR008936; RhoGAP.  
 CC InterPro; IPR000198; RhoGAP.  
 CC InterPro; IPR000980; SH2.  
 CC Pfam; PF00620; RhoGAP; 1.  
 CC Pfam; PF00017; SH2; 2.  
 CC Pfam; PF00018; SH3; 1.  
 CC PRINTS; PR00678; PI3KINASEP85.  
 CC PRINTS; PR00401; SH2DOMAIN.  
 CC ProDom; PD000093; SH2; 2.  
 CC SMART; SM00324; RhoGAP; 1.  
 CC SMART; SM00252; SH2; 2.  
 CC SMART; SM00326; SH3; 1.  
 CC PROSITE; PS50238; RHO-GAP; 1.  
 CC PROSITE; PS50001; SH2; 2.  
 CC PROSITE; PS50002; SH3; 1.  
 CC SH3 domain; SH2 domain; Repeat; 3D-structure.  
 CC DOMAIN 3 79  
 CC SH3.  
 CC FT DOMAIN 113 301  
 CC FT DOMAIN 333 428  
 CC FT DOMAIN 624 718  
 CC FT STRAND 7 10  
 CC FT STRAND 14 14  
 CC FT TURN 19 20  
 CC FT STRAND 21 21  
 CC FT STRAND 24 24  
 CC FT TURN 26 27  
 CC FT STRAND 29 31  
 CC FT STRAND 37 39  
 CC FT HELIX 40 41  
 CC FT TURN 50 52  
 CC FT TURN 55 60  
 CC FT STRAND

FT TURN 61 64  
 FT STRAND 65 70  
 FT STRAND 74 78  
 FT TURN 81 82  
 FT HELIX 340 347  
 FT TURN 348 348  
 FT STRAND 354 359  
 FT STRAND 368 373  
 FT STRAND 378 382  
 FT STRAND 384 384  
 FT STRAND 391 391  
 FT STRAND 401 409  
 FT HELIX 413 413  
 FT TURN 418 419  
 FT STRAND 422 422  
 FT STRAND 427 427  
 FT HELIX 617 619  
 FT STRAND 621 624  
 FT STRAND 625 625  
 FT TURN 627 628  
 FT HELIX 631 638  
 FT TURN 639 640  
 FT TURN 643 644  
 FT STRAND 645 650  
 FT STRAND 657 662  
 FT STRAND 667 672  
 FT STRAND 675 675  
 FT TURN 676 677  
 FT STRAND 678 678  
 FT STRAND 682 683  
 FT TURN 684 685  
 FT STRAND 686 687  
 FT HELIX 691 700  
 FT TURN 703 703  
 FT STRAND 704 704  
 FT TURN 705 705  
 FT HELIX 706 708  
 FT TURN 709 709  
 FT STRAND 710 710  
 FT STRAND 716 717  
 FT TURN 718 719  
 SQ SEQUENCE 724 AA; 83497 MW; EBDP6E754BBP7321 CRC64;  
 Query Match 74.4%; Score 32; DB 1; Length 724;  
 Best Local Similarity 83.3%; Pred.No. 1.7e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 3 LMLWITQ 8  
 DB 581 LMLWITQ 586  
 RESULT 6  
 P85A\_HUMAN STANDARD; PRT; 724 AA.  
 AC P27986;  
 DT 01-AUG-1992 (Rel. 23, Created)  
 DT 01-AUG-1992 (Rel. 23, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE Phosphatidylinositol 3-kinase regulatory alpha subunit (PI3-kinase  
 DE p85-alpha subunit) (Ptdins-3-kinase p85-alpha) (PI3K).  
 GN PIK3R1 OR GRE1.  
 OS Homo sapiens (Human).  
 OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 OX NCBI\_TaxID=9606;  
 RN [1]  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=91191565; PubMed=1849461;  
 RA Skolnik E.Y., Margolis B., Mohammadi M., Lowenstein E., Fischer R.,  
 RA Drepps A., Ullrich A., Schlessinger J.;  
 RT "Cloning of PI3 kinase-associated p85 utilizing a novel method for  
 RT expression/cloning of target proteins for receptor tyrosine

RT kinases.";  
RL Cell 65:83-90(1991).  
RN [2]  
RX X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-85.  
RA MEDLINE=96196433; PubMed=8648629;  
RL Liang J., Chen J.K., Schreiber S.L., Clardy J.;  
RT "Crystal structure of PI3K SH3 domain at 2.0-A resolution.";  
RL J. Mol. Biol. 257:632-643(1996).  
RN [3]  
RX X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 324-434.  
RA MEDLINE=96195449; PubMed=859763;  
RL Nolte R.T., Eck M.J., Schlessinger J., Shoelson S.E., Harrison S.C.;  
RT "Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain  
and its phosphopeptide complexes.";  
RL Nat. Struct. Biol. 3:364-373(1996).  
RN [4]  
RX X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 115-298.  
RA MEDLINE=97121392; PubMed=8962058;  
RL Musacchio A., Cantley L.C., Harrison S.C.;  
RT "Crystal structure of the breakpoint cluster region-homology domain  
from phosphoinositide 3-kinase p85 alpha subunit.";  
RL Proc. Natl. Acad. Sci. U.S.A. 93:14373-14378(1996).  
RN [5]  
RX X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 617-724 IN COMPLEX WITH  
PDGFRB.  
RA MEDLINE=91450159; PubMed=11567151;  
RL Paupit R.A., Dennis C.A., Derbyshire D.J., Breeze A.L., Weston S.A.,  
Rowse S., Murshudov G.N.;  
RT "NMR trial models: experiences with the colicin immunity protein Im7  
and the p85alpha C-terminal SH2-peptide complex.";  
RL Acta Crystallogr. D 57:1397-1404(2001).  
RN [6]  
RX STRUCTURE BY NMR OF 1-79.  
RA MEDLINE=93208889; PubMed=7681364;  
RL Koyama S., Yu H., Dalgarno D.C., Shin T.B., Zydowsky L.D.,  
Schreiber S.L.;  
RT "Structure of the PI3K SH3 domain and analysis of the SH3 family.";  
RL Cell 72:945-952(1993).  
RN [7]  
RX STRUCTURE BY NMR OF 91-104.  
RA MEDLINE=97121261; PubMed=8961927;  
RL Ranzoni D.A., Pugh D.J., Siligardi G., Das P., Morton C.J., Rossi C.,  
Waterfield M.D., Campbell I.D., Ladbury J.E.;  
RT "Structural and thermodynamic characterization of the interaction of  
the SH3 domain from Fyn with the proline-rich binding site on the p85  
subunit of PI3-kinase.";  
RL Biochemistry 35:15646-15653(1996).  
RN [8]  
RX STRUCTURE BY NMR OF 617-724.  
RA MEDLINE=96312955; PubMed=8670861;  
RL Breeze A.L., Kara B.V., Barratt D.G., Anderson M., Smith J.C.,  
Luke R.W., Best J.R., Carlidge S.A.;  
RT "Structure of a specific peptide complex of the carboxy-terminal SH2  
domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.";  
RL EMBO J. 15:3579-3589(1996).  
RN [9]  
RX VARIANT ILE-326.  
RA MEDLINE=97184306; PubMed=9032108;  
RL Hansen T., Andersen C.B., Echalow S.M., Urhammer S.A., Clausen J.O.,  
Vestergaard H., Owens D., Hansen L., Pedersen O.;  
RT "Identification of a common amino acid polymorphism in the p85alpha  
regulatory subunit of phosphatidylinositol 3-kinase: effects on  
glucose disappearance constant, glucose effectiveness, and the  
insulin sensitivity index.";  
RL Diabetes 46:494-501(1997).  
RN [10]  
RX VARIANT SEVERE INSULIN RESISTANCE GLN-409, AND VARIANT ILE-326.  
RA MEDLINE=20230645; PubMed=10768093;  
RL Baynes K.C.R., Beeson C.A., Panayotou G., Stein R., Soos M.,  
Hansen T., Simpson H., O'Rahilly S., Shepherd P.R., Whitehead J.P.;  
RT "Natural variants of human p85 alpha phosphoinositide 3-kinase in  
severe insulin resistance: a novel variant with impaired  
insulin-stimulated lipid kinase activity.";

Diabetologia 43:321-331(2000).  
-!- FUNCTION: Binds to activated (phosphorylated) protein-Tyr kinases,  
through its SH2 domain, and acts as an adapter, mediating the  
association of the p110 catalytic unit to the plasma membrane.  
Necessary for the insulin-stimulated increase in glucose uptake  
and glycogen synthesis in insulin-sensitive tissues.  
-!- SUBUNIT: Heterodimer of a p110 (catalytic) and a p85 (regulatory)  
subunits. Interacts with phosphorylated TOM1L1 (By similarity).  
-!- DISEASE: Defects in PIK3R1 are a cause of severe insulin  
resistance.  
-!- SIMILARITY: Belongs to the PI3K p85 subunit family.  
-!- SIMILARITY: Contains 1 Rho-GAP domain.  
-!- SIMILARITY: Contains 2 SH2 domains.  
-!- SIMILARITY: Contains 1 SH3 domain.  
-!- DATABASE: NAME=PI3K; NOTE=PI3K 1:6-12(2000);  
WWW="http://www.ncbi.nlm.nih.gov/prov/guide/1773542685\_g.htm".  
-----  
This SWISS-PROT entry is copyright. It is produced through a collaboration  
between the Swiss Institute of Bioinformatics and the EMBL outstation -  
the European Bioinformatics Institute. There are no restrictions on its  
use by non-profit institutions as long as its content is in no way  
modified and this statement is not removed. Usage by and for commercial  
entities requires a license agreement (See <http://www.ebi.ac.uk/submit/>  
or send an email to [license@ebi.ac.uk](mailto:license@ebi.ac.uk)).

EMBL; M61906; -; NOT ANNOTATED\_CDS.  
PIR; A38748; A38748.  
PDB; 1PKS; 31-MAY-94.  
PDB; 1PKT; 31-MAY-94.  
PDB; 1PHT; 07-DEC-95.  
PDB; 1PBW; 12-MAR-97.  
PDB; 1PIC; 17-SEP-97.  
PDB; 1AON; 25-FEB-98.  
PDB; 1A2G; 25-FEB-98.  
PDB; 1H9O; 27-NOV-01.  
Genew; HGNC:8979; PIK3R1.  
MIM; 171833; -.  
GO; GO:0016303; P:phosphatidylinositol 3-kinase activity; NAS.  
GO; GO:0005545; P:phosphatidylinositol binding; NAS.  
GO; GO:0007242; P:intracellular signaling cascade; NAS.  
InterPro; IPR001720; PI3kinase\_p85.  
InterPro; IPR008936; RhoGAP.  
InterPro; IPR000198; RhoGAP.  
InterPro; IPR000980; SH2.  
InterPro; IPR001452; SH3.  
Pfam; PF00620; RhoGAP; 1.  
Pfam; PF00017; SH2; 2.  
Pfam; PF00018; SH3; 1.  
PRINTS; PR00678; PI3KINASEP85.  
PRINTS; PR00401; SH2DOMAIN.  
ProDom; PD000093; SH2; 2.  
SMART; SM00324; RhoGAP; 1.  
SMART; SM00252; SH2; 2.  
SMART; SM00326; SH3; 1.  
PROSITE; PS50238; RHOAP; 1.  
PROSITE; PS50001; SH2; 2.  
PROSITE; PS50002; SH3; 1.  
SH3 domain; SH2 domain; Repeat; 3D-structure; Polymorphism;  
Disease mutation.  
DOMAIN 3 79  
FT DOMAIN 113 301  
FT DOMAIN 333 428  
FT DOMAIN 624 718  
FT VARIANT 326 326  
FT VARIANT 409 409  
FT STRAND 4 10  
FT STRAND 14 14  
FT TURN 19 20  
FT STRAND 21 21



RN [1]  
 RP SEQUENCE FROM N.A. (ISOFORMS P85-ALPHA AND P55-ALPHA).  
 RC STRAIN=Wistar; TISSUE=Brain;  
 RX MEDLINE=96214979; PubMed=8621382;  
 RA Inukai K., Anai M., van Breda E., Hosaka T., Katagiri H., Funaki M.,  
 RA Fukushima Y., Ogihara T., Yazaki Y., Kikuchi M., Oka Y., Asano T.;  
 RT "A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase  
 RT structurally similar to p55PIK is generated by alternative splicing  
 RT of the p85alpha gene.";  
 RL J. Biol. Chem. 271:5317-5320(1996).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORM P50-ALPHA).  
 RC TISSUE=Liver;  
 RX MEDLINE=97218222; PubMed=9065454;  
 RA Inukai K., Funaki M., Ogihara T., Katagiri H., Kanda A., Anai M.,  
 RA Fukushima Y., Hosaka T., Suzuki M., Shin B., Takata K., Yazaki Y.,  
 RA Kikuchi M., Oka Y., Asano T.;  
 RT "p85alpha gene generates three isoforms of regulatory subunit for  
 RT phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and  
 RT p85alpha, with different PI 3-kinase activity elevating responses to  
 RT insulin.";  
 RL J. Biol. Chem. 272:7873-7882(1997).  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORM P50-ALPHA).  
 RC TISSUE=Liver;  
 RX MEDLINE=97079666; PubMed=8921377;  
 RA Fruman D.A., Cantley L.C., Carpenter C.L.;  
 RT "Structural organization and alternative splicing of the murine  
 RT phosphoinositide 3-kinase p85 alpha gene.";  
 RL Genomics 37:113-121(1996).  
 CC -!- FUNCTION: Binds to activated (phosphorylated) protein-Tyr kinases,  
 CC through its SH2 domain, and acts as an adapter, mediating the  
 CC association of the PI10 catalytic unit to the plasma membrane.  
 CC Necessary for the insulin-stimulated increase in glucose uptake  
 CC and glycogen synthesis in insulin-sensitive tissues.  
 CC -!- SUBUNIT: Heterodimer of a PI10 (catalytic) and a P85 (regulatory)  
 CC subunits. Interacts with phosphorylated TOM1L1 (by similarity).  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=3;  
 CC Name=p85-alpha;  
 CC IsoId=Q63787-1; Sequence=Displayed;  
 CC Name=p55-alpha;  
 CC IsoId=Q63787-2; Sequence=VSP\_004709, VSP\_004710;  
 CC Name=p50-alpha;  
 CC IsoId=Q63787-3; Sequence=VSP\_004711, VSP\_004712;  
 CC -!- TISSUE SPECIFICITY: The p85-alpha isoform is widely expressed.  
 CC Expression of the p55-alpha isoform is highest in brain and  
 CC skeletal muscle. The p50-alpha isoform is abundant in liver with  
 CC lower levels in brain and muscle.  
 CC -!- SIMILARITY: Belongs to the PI3K p85 subunit family.  
 CC -!- SIMILARITY: Contains 1 Rho-GAP domain.  
 CC -!- SIMILARITY: Contains 2 SH2 domains.  
 CC -!- SIMILARITY: Contains 1 SH3 domain.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
 CC -----  
 DR EMBL; D64045; BAA18932.1; -;  
 DR EMBL; D64048; BAA18933.1; -;  
 DR EMBL; U50412; AAC52846.1; -;  
 DR EMBL; D78486; BAA24426.1; -;  
 DR PDB; 1FU5; 21-FEB-01.  
 DR PDB; 1FU6; 21-FEB-01.  
 DR InterPro; IPR001720; P13kinase\_P85.  
 DR InterPro; IPR008936; Rho GAP.  
 DR InterPro; IPR000198; RhoGAP.  
 DR InterPro; IPR000980; SH2.  
 DR InterPro; IPR001452; SH3.

DR Pfam; PF00620; RhoGAP; 1.  
 DR Pfam; PF00017; SH2; 2.  
 DR Pfam; PF00018; SH3; 1.  
 DR PRINTS; PR00678; PI3KINASP85.  
 DR PRINTS; PR00401; SH2DOMAIN.  
 DR PRODOM; PR000093; SH2; 2.  
 DR SMART; SM00324; RhoGAP; 1.  
 DR SMART; SM00252; SH2; 2.  
 DR SMART; SM00326; SH3; 1.  
 DR PROSITE; PS0238; RHO GAP; 1.  
 DR PROSITE; PS50001; SH2; 2.  
 DR PROSITE; PS50002; SH3; 1.  
 KW SH3 domain; SH2 domain; Repeat; Alternative splicing; 3D-structure.  
 FT DOMAIN 3 79  
 FT DOMAIN 113 301  
 FT DOMAIN 333 428  
 FT DOMAIN 624 718  
 FT VARSPLIC 1 270  
 FT VARSPLIC 271 304  
 FT FT  
 FT FT  
 FT VARSPLIC 1 300  
 FT VARSPLIC 301 306  
 FT ROPAPA -> MHNLOQT (in isoform p50-alpha).  
 FT /FTid=VSP\_004712.  
 SQ SEQUENCE 724 AA; 83531 MW; 95C65CF612873B84 CRC64;  
 Query Match 74.4%; Score 32; DB 1; Length 724;  
 Best Local Similarity 83.3%; Pred. No. 1.7e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
 QY 3 LMWITQ 8  
 Db 581 LMWLQ 586  
 -----  
 RESULT 9  
 REPL\_MABVM STANDARD; PRT; 2331 AA.  
 ID RRPL\_MABVM  
 AC P31352;  
 DT 01-JUL-1993 (Rel. 26, Created)  
 DT 01-FEB-1996 (Rel. 33, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE RNA-directed RNA polymerase (EC 2.7.7.48) (Large structural protein)  
 DE (L protein).  
 GN L.  
 OS Marburg virus (strain Musoke).  
 OC Viruses; ssRNA negative-strand viruses; Mononegavirales; Filoviridae;  
 OC Marburg-like viruses.  
 OX NCBI\_TaxID=33727;  
 RN [1]\_TaxID=33727;  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=92188528; PubMed=1546452;  
 RA Muehlberger E., Sanchez A., Randolph A., Will C., Kiley M.P.,  
 RA Klenk H.D., Feldmann H.;  
 RT "The nucleotide sequence of the L gene of Marburg virus, a filovirus:  
 RT homologies with paramyxoviruses and rhabdoviruses.";  
 RL Virology 187:534-547(1992).  
 RN [2]  
 RP REVISIONS.  
 RA Feldmann H.;  
 RA Submitted (SEP-1994) to the EMBL/GenBank/DBJ databases.  
 CC -!- FUNCTION: THIS PROTEIN IS PROBABLY A COMPONENT OF THE ACTIVE  
 CC POLYMERASE. IT MAY FUNCTION IN RNA SYNTHESIS, CAPPING, AS WELL AS  
 CC METHYLATION OF CAPS, AND POLY(A) SYNTHESIS.  
 CC -!- CATALYTIC ACTIVITY: N nucleoside triphosphate = N diphosphate +  
 CC {RNA} (N).  
 CC -!- SIMILARITY: PRIMARILY WITH THE N-TERMINAL HALF OF THE L PROTEINS  
 CC OF RHABDOVIRUSES AND PARAMYXOVIRUSES.  
 CC -----  
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; M92834; AAA46562.1; ALT\_SEQ.  
 DR EMBL; Z12132; CAA78120.1; -.  
 DR PIR; A42450; RRIWMV.  
 DR InterPro; IPR007098; RNA\_pol\_monon.  
 DR InterPro; IPR001016; Viral\_RNA\_pol\_L.  
 DR Pfam; PF00946; Paramyx\_RNA\_pol\_1.  
 KW Transferase; RNA-directed RNA polymerase.  
 SQ SEQUENCE 2331 AA; 267090 MW; 1D54C60DA1BED3CF CRC64;

Query Match 74.4%; Score 32; DB 1; Length 2331;  
 Best Local Similarity 62.5%; Pred. No. 5.4e+02;  
 Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 ||:|:|  
 DB 1249 SLLMWITQ 1256

RESULT 10  
 ID\_RRLP\_MABVP STANDARD; PRT; 2331 AA.  
 AC P35262;  
 DT 01-FEB-1994 (Rel. 28, Created)  
 DT 01-FEB-1994 (Rel. 28, Last sequence update)  
 DT 28-FEB-2003 (Rel. 41, Last annotation update)  
 DE RNA-directed RNA polymerase (EC 2.7.7.48) (Large structural protein)  
 DE (L protein).  
 GN L.

OS Marburg virus (strain Popp).  
 OC Viruses; ssRNA negative-strand viruses; Mononegavirales; Filoviridae;  
 OC Marburg-like viruses.  
 OC NCBI\_TaxID=33728;  
 RN (1)  
 RP SEQUENCE FROM N.A.  
 RX MEDLINE=96028047; PubMed=7487490;  
 RA Bukreyev A.A., Volchkov V.E., Blinov V.M., Dryga S.A., Netesov S.V.;

RT "The complete nucleotide sequence of the Popp (1967) strain of Marburg  
 virus: a comparison with the Musoke (1980) strain.";  
 RL Arch. Virol. 140:1589-1600(1995).  
 CC -!- FUNCTION: THIS PROTEIN IS PROBABLY A COMPONENT OF THE ACTIVE  
 POLYMERASE. IT MAY FUNCTION IN RNA SYNTHESIS, CAPPING, AS WELL AS  
 METHYLATION OF CAPS, AND POLY(A) SYNTHESIS.  
 CC -!- CATALYTIC ACTIVITY: N nucleoside triphosphate = N diphosphate +  
 {RNA}(N).  
 CC -!- SIMILARITY: PRIMARILY WITH THE N-TERMINAL HALF OF THE L PROTEINS  
 OF RHABDOVIRUSES AND PARAMYXOVIRUSES.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; X68494; CAA48508.1; -.  
 DR EMBL; Z29337; CAA82542.1; -.  
 DR PIR; S44054; S44054.  
 DR InterPro; IPR007098; RNA\_pol\_monon.  
 DR InterPro; IPR001016; Viral\_RNA\_pol\_L.  
 DR Pfam; PF00946; Paramyx\_RNA\_pol\_1.  
 KW Transferase; RNA-directed RNA polymerase.  
 SQ SEQUENCE 2331 AA; 266635 MW; 7ED1D61D0EEF9B8B CRC64;

Query Match 74.4%; Score 32; DB 1; Length 2331;  
 Best Local Similarity 62.5%; Pred. No. 5.4e+02;

Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;  
 QY 1 SLLMWITQ 8  
 ||:|:|  
 DB 1249 SLLMWITQ 1256

RESULT 11  
 ID\_NUKM\_SOLITU STANDARD; PRT; 213 AA.  
 AC Q43844;  
 DT 01-NOV-1997 (Rel. 35, Created)  
 DT 01-NOV-1997 (Rel. 35, Last sequence update)  
 DT 10-OCT-2003 (Rel. 42, Last annotation update)  
 DE NADH-ubiquinone oxidoreductase 20 kDa subunit, mitochondrial precursor  
 DE (EC 1.6.5.3) (EC 1.6.99.3) (Complex I-20KD) (CI-20KD).  
 OS Solanum tuberosum (Potato).  
 OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 OC Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; asterids;  
 OC Lamiales; Solanales; Solanaceae; Solanum.  
 OC NCBI\_TaxID=41113;  
 RN (1)

RP SEQUENCE FROM N.A.  
 RC STRAIN=cv. Desiree; TIGSUB=Leaf;  
 RX MEDLINE=97071689; PubMed=8914535;  
 RA Heiser V., Grohmann L., Brennicke A.;

RT "The plant mitochondrial 22 kDa (PSST) subunit of respiratory chain  
 complex I is encoded by a nuclear gene with enhanced transcript  
 RT levels in flowers.";  
 RL Plant Mol. Biol. 31:1195-1204(1996).  
 CC -!- CATALYTIC ACTIVITY: NADH + ubiquinone = NAD(+) + ubiquinol.  
 CC -!- CATALYTIC ACTIVITY: NADH + acceptor = NAD(+) + reduced acceptor.  
 CC -!- COFACTOR: Binds 1 4Fe-4S cluster (Potential).  
 CC -!- SUBUNIT: Complex I is composed of about 40 different subunits.  
 CC -!- SIMILARITY: Belongs to the complex I 20 kDa subunit family.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
 CC the European Bioinformatics Institute. There are no restrictions on its  
 CC use by non-profit institutions as long as its content is in no way  
 CC modified and this statement is not removed. Usage by and for commercial  
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
 CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
 CC -----

DR EMBL; X96671; CAA65451.1; -.  
 DR PIR; T07603; T07603.  
 DR InterPro; IPR006138; Cmplxl\_20kDa.  
 DR InterPro; IPR006137; Oxidored\_q6.  
 DR Pfam; PF01058; oxidored\_q6\_1.  
 DR PROSITE; PS01150; COMPLEX1\_20K; 1.  
 KW Oxidoreductase; NAD; Ubiquinone; Mitochondrion; Transit peptide;  
 KW Iron-sulfur; 4Fe-4S.  
 FT TRANSIT 1 31 MITOCHONDRION (POTENTIAL).  
 FT CHAIN 32 213 NADH-UBIQUINONE OXIDOREDUCTASE 20 kDa  
 FT SUBUNIT.  
 FT METAL 88 88 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 89 89 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 153 153 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 FT METAL 183 183 IRON-SULFUR (4FE-4S) (POTENTIAL).  
 SQ SEQUENCE 213 AA; 23396 MW; 8047FAB323418FCB CRC64;

Query Match 72.1%; Score 31; DB 1; Length 213;  
 Best Local Similarity 85.7%; Pred. No. 77;  
 Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 LLMWITQ 8  
 ||:|:|  
 DB 207 LLMWITQ 213

RESULT 12  
 ID\_CKR8\_MACMU STANDARD; PRT; 356 AA.  
 KW CKR8\_MACMU

AC O97665;  
DT 16-OCT-2001 (Rel. 40, Created)  
DT 16-OCT-2001 (Rel. 40, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE C-C chemokine receptor type 8 (C-C CKR-8) (CC-CKR-8) (CCR-8).  
GN CCR8.  
OS Macaca mulatta (Rhesus macaque).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Cercopithecoidea;  
OC Cercopithecoidea; Macaca.  
OX NCBI\_TaxID=9544;  
RN [1]\_\_  
RP SEQUENCE FROM N.A.  
RC TISSUE=Spleen;  
RX MEDLINE=21354176; PubMed=11451684;  
RA Margulies B.J., Hauer D.A., Clements J.E.;  
RT "Identification and comparison of eleven rhesus macaque chemokine  
receptors.";  
RL AIDS Res. Hum. Retroviruses 17:981-986(2001).  
CC -1- FUNCTION: Receptor for the chemokines SCV1/1-309, SCV44/MIP-1-  
beta and SCV1/1TAC. May regulate monocyte chemotaxis and thymic  
cell line apoptosis (By similarity).  
CC -1- SUBCELLULAR LOCATION: Integral membrane protein.  
CC -1- SIMILARITY: Belongs to family 1 of G-protein coupled receptors.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; AF100205; AAC72403.1; -  
DR InterPro; IPR004068; CC\_8\_receptor.  
DR InterPro; IPR000276; GPCR\_Rhodopsn.  
DR Pfam; PF00001; 7tm.1; 1.  
DR PRINTS; PR01530; CHEMOKINER8.  
DR PRINTS; PR00237; GPCRHHODOPS.  
DR PROSITE; PS00237; G\_PROTEIN\_RECIP\_F1\_1; 1.  
DR PROSITE; PS00262; G\_PROTEIN\_RECIP\_F1\_2; 1.  
KW G-protein coupled receptor; transmembrane; Glycoprotein.  
FT DOMAIN 1 35  
FT TRANSMEM 36 63  
FT DOMAIN 64 73  
FT TRANSMEM 74 93  
FT DOMAIN 94 107  
FT TRANSMEM 108 129  
FT DOMAIN 130 146  
FT TRANSMEM 147 172  
FT DOMAIN 173 203  
FT TRANSMEM 204 223  
FT DOMAIN 224 239  
FT TRANSMEM 240 264  
FT DOMAIN 265 281  
FT TRANSMEM 282 305  
FT DOMAIN 306 356  
FT DISULFID 106 184  
SQ SEQUENCE 356 AA; 41210 MW; 1979628DBE44845B CRC64;  
Query Match 72.1%; Score 31; DB 1; Length 356;  
Best Local Similarity 71.4%; Pred. No. 1.3e+02;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
QY 1 SLLMWIT 7  
Db 155 SLLVWLT 161  
RESULT 13  
ID\_PFTB\_BOVIN STANDARD; PRT; 437 AA.  
AC P49355; Q9TS25;

DT 01-FEB-1996 (Rel. 33, Created)  
DT 01-FEB-1996 (Rel. 33, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Protein farnesyltransferase beta subunit (EC 2.5.1.58) (CAAX  
beta) (FTase-beta).  
GN FNTB.  
OS Bos taurus (Bovine).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
OC Bovidae; Bovinae; Bos.  
OX NCBI\_TaxID=9913;  
RN [1]\_\_  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RX MEDLINE=93266431; PubMed=8494894;  
RA Omer C.A., Kral A.M., Diehl R.E., Prendergast G.C., Powers S.,  
Allen C.M., Gibbs J.B., Kohl N.E.;  
RT "Characterization of recombinant human farnesyl-protein transferase:  
cloning, expression, farnesyl diphosphate binding, and functional  
homology with yeast prenyl-protein transferases.";  
RL Biochemistry 32:5167-5176(1993).  
CC -1- FUNCTION: Catalyzes the transfer of a farnesyl moiety from  
farnesyl pyrophosphate to a cysteine at the fourth position from  
the C-terminus of several proteins. The beta subunit is  
responsible for peptide-binding.  
CC -1- CATALYTIC ACTIVITY: Farnesyl diphosphate + protein-cysteine = S-  
farnesyl protein + diphosphate.  
CC -1- COFACTOR: Binds 1 zinc ion per subunit (By similarity).  
CC -1- SUBUNIT: Heterodimer of an alpha and a beta subunit.  
CC -1- SIMILARITY: Belongs to the protein prenyltransferase beta subunit  
family.  
CC -1- SIMILARITY: Contains 5 PFTB repeats.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announcement/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; L00633; AAA30524.1; -  
DR HSP; Q02293; 1FT2.  
DR InterPro; IPR001330; Prenyltrans.  
DR InterPro; IPR008930; Terp\_cyc\_toroid.  
DR Pfam; PF00432; Prenyltrans; 5.  
KW Transferase; Prenyltransferase; Repeat; Zinc.  
FT REPEAT 123 164  
FT REPEAT 174 215  
FT REPEAT 222 263  
FT REPEAT 270 312  
FT REPEAT 332 374  
FT REPEAT 297 297  
FT METAL 299 299  
FT METAL 362 362  
FT METAL 362 362  
SQ SEQUENCE 437 AA; 48767 MW; CE09DFA86AC6AB64 CRC64;  
Query Match 72.1%; Score 31; DB 1; Length 437;  
Best Local Similarity 71.4%; Pred. No. 1.6e+02;  
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1 SLLMWIT 7  
Db 272 SLLQWVT 278  
RESULT 14  
ID\_PFTB\_HUMAN STANDARD; PRT; 437 AA.  
AC P49356;  
DT 01-FEB-1996 (Rel. 33, Created)  
DT 01-FEB-1996 (Rel. 33, Last sequence update)

DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Protein farnesyltransferase beta subunit (EC 2.5.1.58) (CAAX  
DE farnesyltransferase beta subunit) (RAS proteins prenyltransferase  
DE beta) (Fase-beta).  
GN FNTB.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RX MEDLINE=9326431; PubMed=8494894;  
RA Omer C.A., Kral A.M., Diehl R.E., Prendergast G.C., Powers S.,  
RA Allen C.M., Gibbs J.B., Kohl N.E.;  
RT "Characterization of recombinant human farnesyl-protein transferase:  
RT cloning, expression, farnesyl diphosphate binding, and functional  
RT homology with yeast prenyl-protein transferases.";  
RL Biochemistry 32:5167-5176(1993).  
RN [2]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Placenta;  
RX MEDLINE=22389257; PubMed=12477932;  
RA Straube R.D., Feingold E.A., Grouse L.H., Derge J.G.,  
RA Klausner R.D., Collins F.S., Wagner L., Stenmen C.M., Schuler G.D.,  
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,  
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,  
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,  
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,  
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
RA Rodriguez A.C., Grimwood J., Myers R.M.,  
RA Butterfield V.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,  
RA Schnerch A., Schein J.B., Jones S.J.M., Marra M.A.;  
RT "Generation and initial analysis of more than 15,000 full-length  
RT human and mouse cDNA sequences.";  
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
RN [3]  
RP SEQUENCE OF 51-437 FROM N.A.  
RC TISSUE=Retina;  
RX MEDLINE=94102736; PubMed=8276393;  
RA Andres D.A., Milatovich A., Oczelik T., Wenzlau J.M., Brown M.S.,  
RA Goldstein J.L., Francke U.;  
RT "cDNA cloning of the two subunits of human CAAX farnesyltransferase  
RT and chromosomal mapping of FNTA and FNTB loci and related  
RT sequences.";  
RL Genomics 18:105-112(1993).  
CC -!- FUNCTION: Catalyzes the transfer of a farnesyl moiety from  
CC farnesyl pyrophosphate to a cysteine at the fourth position from  
CC the C-terminus of several proteins. The beta subunit is  
CC responsible for peptide-binding.  
CC -!- CATALYTIC ACTIVITY: Farnesyl diphosphate + protein-cysteine = S-  
CC farnesyl protein + diphosphate.  
CC -!- COFACTOR: Binds 1 zinc ion per subunit (By similarity).  
CC -!- SUBUNIT: Heterodimer of an alpha and a beta subunit.  
CC -!- SIMILARITY: Belongs to the protein prenyltransferase beta subunit  
CC family.  
CC -!- SIMILARITY: Contains 5 PFTB repeats.  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>)  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch))

DR EMBL; L00635; AAA35854.1; -.  
DR EMBL; BC020232; AAH20232.1; -.  
DR EMBL; L10414; AAA86286.1; -.  
DR EIR; B49274; B49274.  
DR HSP; Q02293; IFT2.  
DR Genew; HGNC:3785; FNTB.  
DR MIM; 134636; -.  
DR GO; GO:0004660; P:protein farnesyltransferase activity; TAS.  
DR GO; GO:0006503; P:C-terminal protein farnesylation; TAS.  
DR InterPro; IPR001330; Prenyltrans.  
DR InterPro; IPR008930; Terp\_cyc\_toroid.  
DR Pfam; PF00432; Prenyltrans; 5.  
KW Transferase; Prenyltransferase; Repeat; Zinc.  
FT REPEAT 123 164 PFTB 1.  
FT REPEAT 174 215 PFTB 2.  
FT REPEAT 222 263 PFTB 3.  
FT REPEAT 270 312 PFTB 4.  
FT REPEAT 332 374 PFTB 5.  
FT METAL 297 297 ZINC (BY SIMILARITY).  
FT METAL 299 299 ZINC (BY SIMILARITY).  
FT METAL 362 362 ZINC (BY SIMILARITY).  
FT CONFLICT 283 283 R -> L (IN REF. 3).  
SQ SEQUENCE 437 AA; 48773 MW; 838E571846146709 CRC64;  
  
Query Match 72.1%; Score 31; DB 1; Length 437;  
Best Local Similarity 71.4%; Pred. No. 1.6e+02;  
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1 SLLMWIT 7  
DB 272 SLLQVNT 278  
|||||  
  
RESULT 15  
ID PFTB RAT STANDARD; PRT; 437 AA.  
AC Q02293;  
DT 01-APR-1993 (Rel. 25, Created)  
DT 01-APR-1993 (Rel. 25, Last sequence update)  
DT 15-MAR-2004 (Rel. 43, Last annotation update)  
DE Protein farnesyltransferase beta subunit (EC 2.5.1.58) (CAAX  
DE farnesyltransferase beta subunit) (RAS proteins prenyltransferase  
DE beta) (Fase-beta).  
GN FNTB.  
OS Rattus norvegicus (Rat).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
OX NCBI\_TaxID=10116;  
RN [1]  
RP SEQUENCE FROM N.A., AND PARTIAL SEQUENCE.  
RC TISSUE=Brain;  
RX MEDLINE=91309145; PubMed=1855253;  
RA Chen W.-J., Andres D.A., Goldstein J.L., Russell D.W., Brown M.S.;  
RT "cDNA cloning and expression of the peptide-binding beta subunit of  
RT rat p21ras farnesyltransferase, the counterpart of yeast DPRI/RAH1.";  
RL Cell 66:327-334(1991).  
RN [2]  
RP X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS).  
RX MEDLINE=97218306; PubMed=9065406;  
RA Park H.-W., Boduluri S.R., Moomaw J.F., Casey P.J., Beese L.S.;  
RT "Crystal structure of protein farnesyltransferase at 2.25-A  
RT resolution.";  
RL Science 275:1800-1804(1997).  
RN [3]  
RP X-RAY CRYSTALLOGRAPHY (3.4 ANGSTROMS).  
RX MEDLINE=98322062; PubMed=9657673;  
RA Long S.B., Casey P.J., Beese L.S.;  
RT "Cocrystal structure of protein farnesyltransferase complexed with a  
RT farnesyl diphosphate substrate.";  
RL Biochemistry 37:9612-9618(1998).  
CC -!- FUNCTION: Catalyzes the transfer of a farnesyl moiety from  
CC farnesyl pyrophosphate to a cysteine at the fourth position from  
CC the C-terminus of several proteins. The beta subunit is



FT	TURN	195	196
FT	STRAND	199	199
FT	HELIX	201	214
FT	TURN	215	215
FT	TURN	219	224
FT	HELIX	225	230
FT	TURN	231	232
FT	TURN	233	233
FT	STRAND	233	233
FT	TURN	235	236
FT	STRAND	239	239
FT	TURN	243	244
FT	HELIX	249	261
FT	TURN	262	263
FT	HELIX	265	267
FT	TURN	270	278
FT	TURN	279	280
FT	STRAND	281	281
FT	TURN	283	285
FT	STRAND	288	289
FT	TURN	292	293
FT	STRAND	296	296
FT	TURN	298	299
FT	HELIX	300	303
FT	TURN	304	306
FT	HELIX	307	317
FT	TURN	318	319
FT	TURN	321	322
FT	HELIX	332	342
FT	STRAND	344	344
FT	TURN	346	347
FT	STRAND	350	350
FT	STRAND	353	353
FT	TURN	354	355
FT	STRAND	356	356
FT	HELIX	360	374
FT	STRAND	375	378
FT	TURN	379	380
FT	STRAND	381	384
FT	HELIX	390	392
FT	TURN	399	401
FT	HELIX	405	415
FT	TURN	416	417
FT	HELIX	424	426
FT	TURN	427	427
FT	HELIX	434	437
SQ	SEQUENCE	437 AA; 48673 MW; 41A9D6D79CD319A8 CRC64;	
Query Match 72.1%; Score 31; DB 1; Length 437;			
Best Local Similarity 71.4%; Pred. No. 1.6e+02;			
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;			
Qy	1 SLLMWIT 7		
Dd	272 SLIQWVT 278		
RESULT 16			
ID	SNE2 HUMAN STANDARD; PRT; 6885 AA.		
AC	Q8NWXH0; Q8NF49; QSTER7; Q8WWW3; Q8WWW4; Q8WWW5; Q8WXH1;		
AC	Q9NU50; Q9UF04; Q9Y2L4; Q9Y4R1;		
DT	10-OCT-2003 (Rel. 42, Created)		
DT	10-OCT-2003 (Rel. 42, Last sequence update)		
DT	10-OCT-2003 (Rel. 42, Last annotation update)		
DE	Nesprin 2 (Nuclear envelope spectrin repeat protein 2) (Synpe-2)		
DE	(Synaptic nuclear envelope protein 2) (Nucleus and actin connecting element protein) (NUANCE protein).		
GN	SYNE2 OR NUA OR KIAA1011.		
OS	Homo sapiens (Human).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;		
CC	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.		
OX	NCBI_taxid=9606;		
RN	[1]		

RP SEQUENCE FROM N.A. (ISOFORMS 1 AND 9), FUNCTION, CHARACTERIZATION, AND  
 RP INTERACTION WITH F-ACTIN.  
 RX MEDLINE=22113122; PubMed=12118075;  
 RA Zhen Y.-Y., Libotte T., Munck M., Noegel A.A., Korenbaum E.;  
 RT "NUANCE, a giant protein connecting the nucleus and actin  
 cytoskeleton";  
 RL J. Cell Sci. 115:3207-3222(2002).  
 RN [2]  
 RP SEQUENCE FROM N.A. (ISOFORMS 4; 5 AND 7).  
 RX MEDLINE=21652858; PubMed=11792814;  
 RA Zhang Q., Skepper J.N., Yang F., Davies J.D., Hegyi L., Roberts R.G.,  
 RA Weissberg P.L., Ellis J.A., Shanahan C.M.;  
 RT "Nesprins: a novel family of spectrin-repeat-containing proteins that  
 RT localize to the nuclear membrane in multiple tissues";  
 RL J. Cell Sci. 114:4485-4498(2001).  
 RN [3]  
 RP SEQUENCE FROM N.A. (ISOFORM 1).  
 RX MEDLINE=22296983; PubMed=12408964;  
 RA Zhang Q., Ragnauth C., Greener M.J., Shanahan C.M., Roberts R.G.;  
 RT "The nesprins are giant actin-binding proteins, orthologous to  
 RT Drosophila melanogaster muscle protein MSP-300";  
 RL Genomics 80:473-481(2002).  
 RN [4]  
 RP SEQUENCE FROM N.A. (ISOFORM 6).  
 RX MEDLINE=12508121;  
 RA Heilig R., Eckenberg R., Petit J.-L., Fonknechten N., Da Silva C.,  
 RA Catalico L., Levy M., Barbe V., De Berardinis V., Ureca-Vidal A.,  
 RA Pelletier E., Vico V., Anchoard V., Rowen L., Madan A., Qin S.,  
 RA Sun H., Du H., Pepin K., Artiguenave F., Robert C., Cruaud C.,  
 RA Bruels T., Jaillon O., Friedlander L., Samson G., Brottier P.,  
 RA Cure S., Segures B., Aniere F., Samain S., Crespeau H., Abbasi N.,  
 RA Alach N., Boeuf D., Dickhoff R., Dors M., Dubois I., Friedman C.,  
 RA Guayvenoux M., James R., Madan A., Mairey-Estrada B., Mangenot S.,  
 RA Martins N., Menard M., Orlas S., Ratcliffe A., Shaffer T., Trask B.,  
 RA Vacherie B., Bellemere C., Beiser C., Besnard-Gonnet M.,  
 RA Bartol-Mavel D., Boutard M., Brez-Silla S., Combette S.,  
 RA Dufosse-Laurent V., Ferron C., Lechaplais C., Louesse C., Muselet D.,  
 RA Magdelenat G., Pateau E., Petit E., Sirvain-Trukiewicz P., Trybou A.,  
 RA Vega-Czarny N., Bataille E., Bluet E., Bordelais I., Dubois M.,  
 RA Dumont C., Guerin T., Hafray S., Hammadi R., Wuanga J., Fellouin V.,  
 RA Robert D., Wunderle E., Gauguier G., Roy A., Sainte-Marthe L.,  
 RA Verdier J., Verdier-Discala C., Hillier L.W., Fulton L., McPherson J.,  
 RA Matsuda F., Wilson R., Scarpelli C., Gyapay G., Wincker P., Saurin W.,  
 RA Quetier F., Waterston R., Hood L., Weissbach J.;  
 RT "The DNA sequence and analysis of human chromosome 14";  
 RL Nature 421:601-607(2003).  
 RN [6]  
 RP SEQUENCE FROM N.A. (ISOFORM 8).  
 RX MEDLINE=22388257; PubMed=12477932;  
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,  
 RA Brownstein M.J., Udén T.B., Toshiyuki S., Carninci P., Prange C.,  
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,  
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,  
 RA Richards S., Worley K.C., Hale S.C., Garcia A.M., Gay L.J., Hulyk S.W.,  
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
 RA Rahy J., Helton E., Ketterman M., Madan A., Rodrigues S., Sanchez A.,  
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,  
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,  
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smalios D.E.,  
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;  
 RT "Generation and initial analysis of more than 15,000 full-length human  
 and mouse cDNA sequences";  
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).  
 RN [7]  
 RP SEQUENCE FROM N.A. (ISOFORM 3), AND SEQUENCE OF 1-956 AND 5133-6885  
 FROM N.A.  
 RX MEDLINE=99246063; PubMed=10231032;  
 RA Nagase T., Ishikawa K.-I., Suyama M., Kikuno R., Hirose M.,  
 RA Miyajima N., Tanaka A., Kotani H., Nomura N., Ohara O.;  
 RT "Prediction of the coding sequences of unidentified human genes. XIII.  
 RT The complete sequences of 100 new cDNA clones from brain which code  
 for large proteins in vitro";  
 RL DNA Res. 6:63-70(1999).  
 RN [9]  
 RP REVISIONS.  
 RX MEDLINE=22158633; PubMed=12168954;  
 RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;  
 RT "Construction of expression-ready cDNA clones for KIAA genes: manual  
 curation of 330 KIAA cDNA clones";  
 RL DNA Res. 9:99-106(2002).  
 RN [10]  
 RP SEQUENCE OF 5754-6885 FROM N.A.  
 RX MEDLINE=21154911; PubMed=11230166;  
 RA Wiemann S., Weil B., Wellenreuther R., Gassenhuber J., Glassl S.,  
 RA Ansorge W., Blocher M., Bloeker H., Bauersachs S., Blum H.,  
 RA Lauber J., Duesterhoeft A., Beyer A., Koehler K., Strack N.,  
 RA Mewes H.-W., Othenwaelder B., Obermaier B., Tampe J., Heubner D.,  
 RA Wambut R., Korn B., Klein M., Cusack A.;  
 RT "Towards a catalog of human genes and proteins: sequencing and  
 RT analysis of 500 novel complete protein coding human cDNAs";  
 RL Genome Res. 11:422-435(2001).  
 CC -!- FUNCTION: Involved in the maintenance of nuclear organization and  
 CC structural integrity. Probable anchoring protein which tethers the  
 CC nucleus to the cytoskeleton. Connects nuclei to the cytoskeleton  
 CC by interacting with the nuclear envelope and with F-actin in the  
 CC cytoplasm.  
 CC -!- SUBUNIT: Interacts with F-actin via its N-terminal domain.  
 CC -!- SUBCELLULAR LOCATION: Type IV membrane protein (potential). The  
 CC largest part of the protein is cytoplasmic, while its C-terminal  
 CC part is associated with the nuclear envelope, most probably the  
 CC outer nuclear membrane. Remains associated with the nuclear  
 CC envelope during its breakdown in mitotic cells.  
 CC -!- ALTERNATIVE PRODUCTS:  
 CC Event=Alternative splicing; Named isoforms=9;  
 CC Name=1;  
 CC IsoId=Q8WXH0-1; Sequence=Displayed;  
 CC Name=2;  
 CC IsoId=Q8WXH0-2; Sequence=VSP\_007164, VSP\_007166;  
 CC Note=Q8WXH0-2: experimental confirmation available;  
 CC Name=3;  
 CC IsoId=Q8WXH0-3; Sequence=VSP\_007155;  
 CC Note=Produced by exon skipping that results in a frameshift. No  
 CC experimental confirmation available;  
 CC Name=4; Synonyms=Beta;  
 CC IsoId=Q8WXH0-4; Sequence=VSP\_007156;  
 CC Name=5; Synonyms=Alpha;  
 CC IsoId=Q8WXH0-5; Sequence=VSP\_007157, VSP\_007164, VSP\_007165;  
 CC Name=6;

CC IsoId=Q8WXH0-6; Sequence=VSP\_007158, VSP\_007165, VSP\_007166;  
CC Note=No experimental confirmation available;  
CC Name=7; Synonyms=Gamma;  
CC IsoId=Q8WXH0-7; Sequence=VSP\_007154, VSP\_007163;  
CC Name=8;  
CC IsoId=Q8WXH0-8; Sequence=VSP\_007161, VSP\_007162;  
CC Note=No experimental confirmation available;  
CC Name=9; Synonyms=NUANCE-N-33;  
CC IsoId=Q8WXH0-9; Sequence=VSP\_007159, VSP\_007160;  
CC TISSUE SPECIFICITY: Widely expressed, with higher level in kidney,  
CC adult and fetal liver, stomach and placenta. Weakly expressed in  
CC skeletal muscle and brain. Isoform 5 is highly expressed in  
CC pancreas, skeletal muscle and heart.  
CC -1- DOMAIN: The Karsicht domain mediates the nuclear envelope  
CC targeting.  
CC -1- SIMILARITY: Belongs to the nesprin family.  
CC -1- SIMILARITY: Contains 1 actin-binding domain.  
CC -1- SIMILARITY: Contains 2 calponin-homology (CH) domains.  
CC -1- SIMILARITY: Contains 1 Karsicht domain.  
CC -1- SIMILARITY: Contains 13 leucine-rich (LRR) repeats.  
CC -1- SIMILARITY: Contains 9 spectrin repeats.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@sib-sib.ch](mailto:license@sib-sib.ch)).  
CC -----  
CC EMBL; AF435010; AAL33547.1; -  
CC EMBL; AF435011; AAL33548.1; -  
CC EMBL; AY061757; AAL33800.1; -  
CC EMBL; AY061758; AAL33801.1; -  
CC EMBL; AY061759; AAL33802.1; -  
CC EMBL; AF495911; AAN60443.1; -  
CC EMBL; AL117404; CAB55905.1; -  
CC EMBL; AL162832; -; NOT\_ANNOTATED\_CDS.  
CC EMBL; AL355094; -; NOT\_ANNOTATED\_CDS.  
CC -----  
CC Query Match 72.13; Score 31; DB 1; Length 6885;  
CC Best Local Similarity 50.08; Pred. No. 2.3e+03;  
CC Matches 4; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
CC  
CC QY 1 SLIMWITQ 8  
CC Db 6256 SILVWLTE 6263  
CC  
CC RESULT 17  
CC SNE1 HUMAN  
CC ID SNE1 HUMAN STANDARD; PRT; 8797 AA.  
CC AC Q8NF91; Q84890; Q8NF97; Q8TCPI; Q8WNR6; Q8WNR7; Q8WXP6; Q96N17;  
CC AC Q9COA7; Q9H525; Q9H526; Q9NS36; Q9NU50; Q9UJ06; Q9UJ07; Q9ULF6;  
CC DT 10-OCT-2003 (Rel. 42, Created)  
CC DT 10-OCT-2003 (Rel. 42, Last sequence update)  
CC DT 10-OCT-2003 (Rel. 42, Last annotation update)  
CC DE Nesprin 1 (Nuclear envelope spectrin repeat protein 1) (synaptic  
CC DE nuclear envelope protein 1) (Syn-1) (Myocyte nuclear envelope protein  
CC DE 1) (Wyne-1) (enaptin).  
CC GN SYNE1 OR MYNE1 OR KIAA0796 OR KIAA1756 OR KIAA1262.  
CC OS Homo sapiens (Human).  
CC OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
CC OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
CC OX NCBI\_TaxID=9606;  
CC RN [1]  
CC RP SEQUENCE FROM N.A. (ISOFORMS 2 AND 3), CHARACTERIZATION, AND  
CC RP MUTAGENESIS OF 8758-LEU-CYS-8763.  
CC RC TISSUE=Heart, Placenta, Skeletal muscle, Spleen, and Testis;  
CC RX MEDLINE=21652858; PubMed=11792814;  
CC RA Zhang Q., Skepper J.N., Yang F., Davies J.D., Hegyi L., Roberts R.G.,  
CC RA Weissberg P.L., Ellis J.A., Shanahan C.M.;  
CC RT "Nesprins: a novel family of spectrin-repeat-containing proteins that

RT localize to the nuclear membrane in multiple tissues.";  
RL J. Cell Sci. 114:4485-4498(2001).  
RN [2]  
RN SEQUENCE FROM N.A. (ISOFORM 1), AND SUBCELLULAR LOCATION.  
RC TISSUE=Heart, Spleen, and Testis;  
RX MEDLINE=22296983; PubMed=12408964;  
RA Zhang Q., Ragnauth C., Greener M.J., Shanahan C.M., Roberts R.G.;  
RA "The nesprins are giant actin-binding proteins, orthologous to  
RT Drosophila melanogaster muscle protein MSP-300.";  
RL Genomics 80:473-481(2002).  
RN [3]  
RN SEQUENCE FROM N.A. (ISOFORM 4), AND VARIANT GLY-8323.  
RA Braune S., Abraham S., Padmakumar V., Tunggal B., Noegel A.A.,  
RA Korenbaum E.;  
RT "The longest isoform of enaptin/Syne-1, a nuclear envelope associated  
RT protein, binds actin cytoskeleton via the alpha-actinin-like actin-  
RT binding domain.";  
RL Submitted (AUG-2002) to the EMBL/GenBank/DBSJ databases.  
RN [4]  
RN SEQUENCE FROM N.A. (ISOFORMS 8 AND 9).  
RA Zhang Q., Shanahan C.M.;  
RL Submitted (NOV-2002) to the EMBL/GenBank/DBSJ databases.  
RN [5]  
RN SEQUENCE FROM N.A.  
RA Almeida J., Clark S., Griffiths C., Lloyd D., Parker A., Smith M.,  
RA Tracey A., Williams S.;  
RL Submitted (NOV-2000) to the EMBL/GenBank/DBSJ databases.  
RN [6]  
RN SEQUENCE OF 1-856 FROM N.A.  
RC TISSUE=Kidney;  
RA Gough L., Fan J., Lisa G., Chu S., Winnick S., Beck K.A.;  
RT "Golgi localization of syne-1.";  
RL Submitted (NOV-2002) to the EMBL/GenBank/DBSJ databases.  
RN [7]  
RN SEQUENCE OF 28-778 AND 2901-3476 FROM N.A.  
RC TISSUE=Adrenal gland, and Teratocarcinoma;  
RA Ninomiya K., Wagatsuma M., Kanda K., Kondo H., Yokoi T., Kodaira H.,  
RA Furuya T., Takahashi M., Kikkawa E., Omura Y., Abe K., Kamiyama K.,  
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Sugiyama T., Irie R.,  
RA Otsuki T., Sato H., Wakamatsu A., Ishii S., Yamamoto J., Isono Y.,  
RA Kawai-rho Y., Saito K., Nishikawa T., Kimura K., Yamashita H.,  
RA Matsuo K., Nakamura Y., Sekine M., Kikuchi H., Murakawa K.,  
RA Kaneshori K., Takahashi-Fujii A., Oshima A., Sugiyama A., Kawakami B.,  
RA Takemoto M., Ota T., Suzuki Y., Sugano S., Nagahari K., Masuho Y.,  
RA Nagai K., Isogai T.;  
RT "NED0 human cDNA sequencing project.";  
RL Submitted (JUL-2002) to the EMBL/GenBank/DBSJ databases.  
RN [8]  
RN SEQUENCE OF 443-8797 FROM N.A. (ISOFORM 5).  
RC TISSUE=Brain;  
RX MEDLINE=21082932; PubMed=11214970;  
RA Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;  
RT "Prediction of the coding sequences of unidentified human genes. XIX.  
RT The complete sequences of 100 new cDNA clones from brain which code  
RT for large proteins in vitro.";  
RL DNA Res. 7:347-355(2000).  
RN [9]  
RN SEQUENCE OF 743-8797 FROM N.A. (ISOFORM 6).  
RC TISSUE=Brain;  
RA Ansgore W., Winkler U., Mewes H.-W., Weil B., Wiemann S.;  
RL Submitted (MAR-2002) to the EMBL/GenBank/DBSJ databases.  
RN [10]  
RN SEQUENCE OF 4219-8797 FROM N.A. (ISOFORM 7).  
RC TISSUE=Brain;  
RX MEDLINE=20039619; PubMed=10574462;  
RA Nagase T., Ishikawa K.-I., Kikuno R., Hirose M., Nomura N.,  
RA Ohara O.;  
RT "Prediction of the coding sequences of unidentified human genes. XV.  
RT The complete sequences of 100 new cDNA clones from brain which code  
RT for large proteins in vitro.";  
RL DNA Res. 6:337-345(1999).  
RN [11]  
RN SEQUENCE OF 6922-8797 FROM N.A.



CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

DR EMBL: K02718; AAA46938.1; ALT\_SEQ.  
DR PIR: A30016; WSWLHS.  
DR InterPro: IPR004270; Papilloma\_E5.  
DR Pfam: PF03025; Papilloma\_E5; 1.  
KW Early protein.  
SQ SEQUENCE 83 AA; 9401 MW; 442C0ABF0D77C0CF CRC64;

Query Match 69.8%; Score 30; DB 1; Length 83;  
Best Local Similarity 83.3%; Pred. No. 46;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
Qy 2 LLMWIT 7  
Db 47 LLLWIT 52

RESULT 19  
KV40 HUMAN  
ID KV40 HUMAN STANDARD; PRT; 121 AA.  
AC P06312;  
DT 01-JAN-1988 (Rel. 06, Created)  
DT 01-JAN-1988 (Rel. 06, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Ig kappa chain V-IV region precursor (Fragment).  
GN IGKV4-1.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=86041853; PubMed=2997712;  
RA Klobbeck H.G.; Bornkamm G.W.; Combriato R.; Pohlenz H.D.;  
Zachau H.G.;  
RT "Subgroup IV of human immunoglobulin K light chains is encoded by a  
RT single germline gene."  
RL Nucleic Acids Res. 13:6515-6529(1985).  
CC -!- MISCELLANEOUS: THERE IS ONLY ONE IG KAPPA V-IV GENE.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

EMBL: Z00023; CAA77318.1; --  
PIR: A01902; K4HU.  
DR HSSP; P80362; 1WTL.  
DR Genew; HGNC:5834; IGKV4-1.  
DR GO; GO:0005576; C:extracellular; NAS.  
DR GO; GO:0003823; F:antigen binding; NAS.  
DR GO; GO:0006955; P:immune response; NAS.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003596; IG\_V.  
DR Pfam; PF00047; Ig; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 1.  
KW Immunoglobulin V region; Signal.  
FT SIGNAL 1 20 IG KAPPA CHAIN V-IV REGION.  
FT CHAIN 21 >121 FRAMEWORK-1.  
FT DOMAIN 21 43 COMPLEMENTARITY-DETERMINING-1.  
FT DOMAIN 44 60 FRAMEWORK-2.  
FT DOMAIN 61 75 COMPLEMENTARITY-DETERMINING-2.  
FT DOMAIN 76 82 FRAMEWORK-3.  
FT DOMAIN 83 114 COMPLEMENTARITY-DETERMINING-3.  
FT DOMAIN 115 121 BY SIMILARITY.  
FT DISULFID 43 114

FT NON\_TER 121 121  
SQ SEQUENCE 121 AA; 13380 MW; 9586AD4188D33974 CRC64;  
Query Match 69.8%; Score 30; DB 1; Length 121;  
Best Local Similarity 71.4%; Pred. No. 67;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 SLLMWIT 7  
Db 10 SLLLWIS 16

RESULT 20  
KV4B HUMAN  
ID KV4B HUMAN STANDARD; PRT; 133 AA.  
AC P06313;  
DT 01-JAN-1988 (Rel. 06, Created)  
DT 01-JAN-1988 (Rel. 06, Last sequence update)  
DT 15-JUL-1999 (Rel. 38, Last annotation update)  
DE Ig kappa chain V-IV region JI precursor.  
OS Homo sapiens (Human).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
OX NCBI\_TaxID=9606;  
RN [1]  
RP SEQUENCE FROM N.A.  
RX MEDLINE=86041853; PubMed=2997712;  
RA Klobbeck H.G.; Bornkamm G.W.; Combriato R.; Pohlenz H.D.;  
Zachau H.G.;  
RT "Subgroup IV of human immunoglobulin K light chains is encoded by a  
RT single germline gene."  
RL Nucleic Acids Res. 13:6515-6529(1985).  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).

EMBL: Z00022; CAA77317.1; --  
PIR: A01904; K4HU1.  
DR HSSP; P80362; 1WTL.  
DR GO; GO:0005576; C:extracellular; NAS.  
DR GO; GO:0003823; F:antigen binding; NAS.  
DR GO; GO:0006955; P:immune response; NAS.  
DR InterPro; IPR007110; IG-like.  
DR InterPro; IPR003596; IG\_V.  
DR Pfam; PF00047; Ig; 1.  
DR SMART; SM00406; IGV; 1.  
DR PROSITE; PS0835; IG LIKE; 1.  
KW Immunoglobulin V region; Signal.  
FT SIGNAL 1 20 IG KAPPA CHAIN V-IV REGION JI.  
FT CHAIN 21 133 FRAMEWORK-1.  
FT DOMAIN 21 43 COMPLEMENTARITY-DETERMINING-1.  
FT DOMAIN 44 60 FRAMEWORK-2.  
FT DOMAIN 61 75 COMPLEMENTARITY-DETERMINING-2.  
FT DOMAIN 76 82 FRAMEWORK-3.  
FT DOMAIN 83 114 COMPLEMENTARITY-DETERMINING-3.  
FT DOMAIN 115 122 FRAMEWORK-4.  
FT DOMAIN 123 132 BY SIMILARITY.  
FT DISULFID 43 114  
FT NON\_TER 133 133  
SQ SEQUENCE 133 AA; 14632 MW; 5FB3953066744AF4 CRC64;  
Query Match 69.8%; Score 30; DB 1; Length 133;  
Best Local Similarity 71.4%; Pred. No. 73;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;  
Qy 1 SLLMWIT 7  
Db 10 SLLLWIS 16

```
RESULT 21
KV4C_HUMAN
ID KV4C_HUMAN STANDARD; PRT; 134 AA.
AC P06314;
DT 01-JAN-1988 (Rel. 06, Created)
DT 01-APR-1988 (Rel. 07, Last sequence update)
DE IG kappa chain V-IV region B17 precursor.
OS Homo sapiens (Human)
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OX NCBI_TaxID=9606;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=86041854; PubMed=2997713;
RA Marsh P., Mills F., Gould H.;
RT "Detection of a unique human V kappa IV germline gene by a cloned
RT cDNA probe.";
RL Nucleic Acids Res. 13:6531-6544(1985).
RP REVISION TO 76.
RA Marsh P.;
RL Submitted (OCT-1986) to the EMBL/GenBank/DBJ databases.
CC
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR HSSP; P80362; 1WTL.
DR GO; GO:0005576; C:extracellular; NAS.
DR GO; GO:0003823; F:antigen binding; NAS.
DR GO; GO:0006955; P:immune response; NAS.
DR InterPro; IPR007110; IG-like.
DR InterPro; IPR003596; IG_V.
DR Pfam; PF00047; IG; 1.
DR SMART; SM00406; IGV; 1.
DR PROSITE; PS50835; IG LIKE; 1.
KW Immunoglobulin V region; Signal.
FT SIGNAL 1 20
FT CHAIN 21 134 IG KAPPA CHAIN V-IV REGION B17.
FT DOMAIN 21 43 FRAMEWORK-1.
FT DOMAIN 44 60 COMPLEMENTARITY-DETERMINING-1.
FT DOMAIN 61 75 FRAMEWORK-2.
FT DOMAIN 76 82 COMPLEMENTARITY-DETERMINING-2.
FT DOMAIN 83 114 FRAMEWORK-3.
FT DOMAIN 115 121 COMPLEMENTARITY-DETERMINING-3.
FT DOMAIN 122 133 FRAMEWORK-4.
FT DISULFID 43 114 BY SIMILARITY.
FT NON TER 134 134
SQ SEQUENCE 134 AA; 14966 MW; 6413A22FD0738832 CRC64;

Query Match 69.8%; Score 30; DB 1; Length 134;
Best Local Similarity 71.4%; Pred. No. 74;
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1 SLLMWIT 7
Db 10 SLLMWIS 16

RESULT 22
HRPX_PLALO
ID HRPX_PLALO STANDARD; PRT; 351 AA.
AC P04929;
DT 13-AUG-1987 (Rel. 05, Created)
DT 13-AUG-1987 (Rel. 05, Last sequence update)
```

```
DT 15-JUL-1999 (Rel. 38, Last annotation update)
DE Histidine-rich glycoprotein precursor.
OS Plasmodium lophurae.
OC Eukaryota; Alveolata; Apicomplexa; Haemosporida; Plasmodium.
OX NCBI_TaxID=5853;
RN [1]
RP SEQUENCE FROM N.A.
RX MEDLINE=85061618; PubMed=6095114;
RA Ravetch J.V., Feder R., Pavlovic A., Blobel G.;
RT "Primary structure and genomic organization of the histidine-rich
RT protein of the malaria parasite Plasmodium lophurae.";
RL Nature 312:1616-1620(1984).
CC -!- MISCELLANEOUS: In the intraerythrocytic stages of development of
CC P. lophurae in ducks, there is a synthesis of a major protein that
CC accumulates to comprise at least 50% of the cellular mass: the
CC histidine rich protein.
CC -----
CC This SWISS-PROT entry is copyright. It is produced through a collaboration
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC the European Bioinformatics Institute. There are no restrictions on its
CC use by non-profit institutions as long as its content is in no way
CC modified and this statement is not removed. Usage by and for commercial
CC entities requires a license agreement (See http://www.isb-sib.ch/announce/
CC or send an email to license@isb-sib.ch).
CC -----
DR EMBL; X01469; CAA25698.1; -.
DR PIR; A22692; KGZQHL.
KW Malaria; Repeat; Glycoprotein; Signal.
FT SIGNAL 1 23
FT PROPEP 24 47
FT CHAIN 48 351 HISTIDINE-RICH GLYCOPROTEIN.
FT CARBOHYD 40 40 N-LINKED (GLCNAC... ) (PROBABLE).
FT DOMAIN 59 90 2 X 16 AA TANDEM REPEATS.
FT REPEAT 59 74 16-1.
FT REPEAT 75 90 16-2.
FT REPEAT 91 123 2 X 17 AA TANDEM REPEATS.
FT DOMAIN 101 107 17-1.
FT REPEAT 108 123 17-2.
FT DOMAIN 124 153 2 X 15 AA TANDEM REPEATS.
FT REPEAT 124 138 15-1.
FT REPEAT 139 153 15-2.
FT DOMAIN 173 351 18 X 10 AA TANDEM REPEATS.
SQ SEQUENCE 351 AA; 44032 MW; D19A48D47D890453 CRC64;

Query Match 69.8%; Score 30; DB 1; Length 351;
Best Local Similarity 62.5%; Pred. No. 1.9e+02;
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8
Db 12 SFLVWISQ 19

RESULT 23
HOFC_HAEIN
ID HOFC_HAEIN STANDARD; PRT; 406 AA.
AC P44621;
DT 01-NOV-1995 (Rel. 32, Created)
DT 01-NOV-1995 (Rel. 32, Last sequence update)
DT 28-FEB-2003 (Rel. 41, Last annotation update)
DE Protein transport protein hoFc homolog.
GN HOFC OR HOFC OR HIO297.
OS Haemophilus influenzae.
OC Bacteria; Proteobacteria; Gammaproteobacteria; Pasteurellales;
OC Pasteurellaceae; Haemophilus.
OX NCBI_TaxID=727;
RN [1]
RP SEQUENCE FROM N.A.
RC STRAIN=RD / KW20 / ATCC 51907;
RX MEDLINE=95350630; PubMed=7542800;
RA Fleischnann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
RA Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA McKenney K., Sutton G., Fitzhugh W., Fields C.A., Gocayne J.D.,
```

RA Scott J.D., Shirley R., Liu L.-I., Glodok A., Kelley J.M.,  
RA Weidman J.F., Phillips C.A., Spriggs T., Hedblom E., Cotton M.D.,  
RA Uterback T.R., Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C.,  
RA Fine L.D., Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M.,  
RA Gnehm C.L., McDonald L.A., Small K.V., Fraser C.M., Smith H.O.,  
RA Venter J.C.;  
RA "Whole-genome random sequencing and assembly of Haemophilus influenzae  
RT Rd.";  
RL Science 269:496-512(1995).  
CC -!- SUBCELLULAR LOCATION: Integral membrane protein. Inner membrane  
CC (Probable).  
CC -!- SIMILARITY: BELONGS TO THE PULF/OUTF/EXEF/XPSF/XPCS FAMILY.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; U32715; AAC21961.1; --  
CC DR PIR; D64060; D64060.  
CC DR TIGR; H10297; --  
CC DR InterPro; IPR003004; Bac\_GSPF.  
CC DR InterPro; IPR001992; Bact\_secr\_systII.  
CC DR Pfam; PF00482; GSP11\_F\_1; secr\_systII.  
CC DR PRINTS; PR00812; BCTERIALGSPF.  
CC DR PROSITE; PS00874; 12SP\_F; 1.  
CC KW Transpos; Transmembrane; Inner membrane; Complete proteome.  
CC TRANSMEM 167 187 POTENTIAL.  
CC FT TRANSMEM 214 234 POTENTIAL.  
CC FT TRANSMEM 379 399 POTENTIAL.  
CC SQ SEQUENCE 406 AA; 46290 MW; 429D83B7C10F8F82 CRC64;

Query Match 59.8%; Score 30; DB 1; Length 406;  
Best Local Similarity 50.8%; Pred. No. 2.2e+02;  
Matches 4; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
| | | | |  
Db 312 SLLQWSQ 319

RESULT 24

RG99 MOUSE  
ID RG99\_MOUSE STANDARD; PRT; 675 AA.  
AC O54828; Q9Z0S0;  
DT 13-DEC-1998 (Rel. 37, Created)  
DT 30-MAY-2000 (Rel. 39, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Regulator of G-protein signaling 9 (RG99).  
GN RG99.  
OS Mus musculus (Mouse).  
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
OX NCBI\_TaxID=10090;  
RN [1]  
RP SEQUENCE FROM N.A. (ISOFORM 1).  
RX MEDLINE=98119533; PubMed=9459445;  
RA He W., Cowan C.W., Wensel T.G.;  
RT "RG99, a GTPase accelerator for phototransduction.";  
RL Neuron 20:95-102(1998).  
RN [2]  
RP SEQUENCE FROM N.A. (ISOFORM 2).  
RC STRAIN=C57BL/6; TISSUE=Forebrain;  
RX MEDLINE=99165807; PubMed=10066255;  
RA Rahman Z., Gold S.J., Potenza M.N., Cowan C.W., Ni Y.G., He W.,  
RA Wensel T.G., Nestler E.J.;  
RT "Cloning and characterization of RG99-2: a striatal-enriched  
RT alternatively spliced product of the RG99 gene.";  
RL J. Neurosci. 19:2016-2026(1999).  
RN [3]

RP PHOSPHORYLATION OF ISOFORM 1.  
RX MEDLINE=21303582; PubMed=11292825;  
RA Hu G., Jang G.F., Cowan C.W., Wensel T.G., Palczewski K.;  
RT "Phosphorylation of RG99-1 by an endogenous protein kinase in rod  
RT outer segments.";  
RL J. Biol. Chem. 276:22287-22295(2001).  
CC -!- FUNCTION: INHIBITS SIGNAL TRANSDUCTION BY INCREASING THE GTPASE  
CC ACTIVITY OF G PROTEIN ALPHA SUBUNITS THEREBY DRIVING THEM INTO  
CC THEIR INACTIVE GDP-BOUND FORM. BINDS TO G(T)-ALPHA. INVOLVED IN  
CC PHOTOTRANSDUCTION; KEY ELEMENT IN THE RECOVERY PHASE OF VISUAL  
CC TRANSDUCTION.  
CC -!- SUBUNIT: HETERODIMER WITH GBETA5 (BY SIMILARITY).  
CC -!- ALTERNATIVE PRODUCTS:  
CC Event=Alternative splicing; Named isoforms=2;  
CC Name=2;  
CC IsoId=054828-1; Sequence=Displayed;  
CC Name=1;  
CC IsoId=054828-2; Sequence=VSP 005678, VSP 005679.  
CC -!- TISSUE SPECIFICITY: ISOFORM 1 IS EXPRESSED IN PHOTORECEPTOR OUTER  
CC SEGMENTS. ISOFORM 2 IS EXPRESSED IN BRAIN STRIATUM.  
CC -!- PTM: RETINAL ISOFORM 1 IS LIGHT-DEPENDENT PHOSPHORYLATED AT SER-  
CC 475. PHOSPHORYLATION IS DECREASED BY LIGHT EXPOSITION.  
CC -!- SIMILARITY: Contains 1 RGS domain.  
CC -!- SIMILARITY: Contains 1 G protein gamma domain.  
CC -!- SIMILARITY: Contains 1 DEP domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
CC EMBL; AF011358; AAC99481.1; --  
CC DR EMBL; AF125046; AAD20014.1; --  
CC DR HSSP; P49795; ICNZ.  
CC DR MGD; MGI:133824; Rgs9.  
CC DR InterPro; IPR000591; DEP.  
CC DR InterPro; IPR001770; G-gamma.  
CC DR InterPro; IPR000342; Regl\_Gprotein.  
CC DR Pfam; PF00610; DEP; 1.  
CC DR Pfam; PF00631; G-gamma; 1.  
CC DR Pfam; PF00615; RGS; 1.  
CC DR PRINTS; PR01301; RGSPROTEIN.  
CC DR ProDom; PDC01580; Regl\_Gprotein; 1.  
CC DR SMART; SM00049; DEP; 1.  
CC DR SMART; SM00224; GGL; 1.  
CC DR SMART; SM00315; RGS; 1.  
CC DR PROSITE; PS00186; DEP; 1.  
CC DR PROSITE; PS00058; G-PROTEIN\_GAMMA; FALSE\_NEG.  
CC DR PROSITE; PS0132; RGS; 1.  
CC KW Signal transduction inhibitor; Alternative splicing; Phosphorylation.  
CC FT DOMAIN 30 105 DEP.  
CC FT DOMAIN 222 283 G-PROTEIN GAMMA-LIKE.  
CC FT DOMAIN 299 414 RGS.  
CC FT VARSPPLIC 467 484 PQHLAPSPHLAVYTGTC -> VMSKLDRLRSQKKEPPK  
CC (in isoform 1).  
CC FT VARSPPLIC 485 675 /FTId=VSP\_005678.  
CC FT VARSPPLIC 675 675 /FTId=VSP\_005679.  
CC SQ SEQUENCE 675 AA; 76971 MW; 0EC910D833FFD06D CRC64;  
Query Match 69.8%; Score 30; DB 1; Length 675;  
Best Local Similarity 71.4%; Pred. No. 3.6e+02;  
Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 2 LLMWITQ 8  
| | | | |  
Db 55 VLQWITQ 61

RESULT 25

KALM\_CHICK  
ID KALM\_CHICK STANDARD; PRT; 676 AA.  
AC P33005;  
DT 01-OCT-1993 (Rel. 27, Created)  
DT 01-OCT-1993 (Rel. 27, Last sequence update)  
DT 28-FEB-2003 (Rel. 41, Last annotation update)  
DE Anosmin 1 precursor (Kallmann syndrome protein homolog).  
GN KAL.  
OS Gallus gallus (Chicken).  
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
OC Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae;  
OC Gallus.  
OX NCBI\_TaxID=9031;  
RN [1]  
RP SEQUENCE FROM N.A.  
RC TISSUE=Brain;  
RX MEDLINE=94010957; PubMed=8406507;  
RA Legouis R., Cohen-Salmon M., del Castillo I., Levilliers J.,  
RA Capy L., Morron J.-P., Petit C.;  
RT "Characterization of the chicken and quail homologues of the human  
RT gene responsible for the X-linked Kallmann syndrome.";  
RL Genomics 17:516-518(1993).  
CC -!- FUNCTION: May be an adhesion-like molecule with anti-protease  
CC activity;  
CC -!- SUBCELLULAR LOCATION: Secreted. Localized at cell surface (By  
CC similarity).  
CC -!- SIMILARITY: Contains 4 fibronectin type III domains.  
CC -!- SIMILARITY: Contains 1 WAP-type domain.  
CC -----  
CC This SWISS-PROT entry is copyright. It is produced through a collaboration  
CC between the Swiss Institute of Bioinformatics and the EMBL outstation -  
CC the European Bioinformatics Institute. There are no restrictions on its  
CC use by non-profit institutions as long as its content is in no way  
CC modified and this statement is not removed. Usage by and for commercial  
CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>  
CC or send an email to [license@isb-sib.ch](mailto:license@isb-sib.ch)).  
CC -----  
DR EMBL; L12144; AA051435.1; -.  
DR F01; B47222; B47222.  
DR HSP; P19957; 2REL.  
DR InterPro; IPR008957; FN III-like.  
DR InterPro; IPR003961; FN III.  
DR InterPro; IPR008197; WAP.  
DR Pfam; PF00041; fn3; 3.  
DR Pfam; PF00095; wap; 1.  
DR PRINTS; PR00003; 4DISULPHCORE.  
DR SMART; SM00060; FN3; 3.  
DR SMART; SM00217; WAP; 1.  
DR PROSITE; PS00317; 4\_DISULFIDE\_CORE; 1.  
KW Cell adhesion; Glycoprotein; Serine protease inhibitor; Repeat;  
KW Signal.  
FT SIGNAL 1 21 POTENTIAL.  
FT CHAIN 22 676 ANOSMIN 1.  
FT DOMAIN 22 115 "CYSTEINE BOX".  
FT DOMAIN 125 171 WAP.  
FT DOMAIN 176 280 FIBRONECTIN TYPE-III 1.  
FT DOMAIN 281 397 FIBRONECTIN TYPE-III 2.  
FT DOMAIN 398 536 FIBRONECTIN TYPE-III 3.  
FT DOMAIN 537 657 FIBRONECTIN TYPE-III 4.  
FT DOMAIN 66 66 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 204 204 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 295 295 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 466 466 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 549 549 N-LINKED (GLCNAC. . .) (POTENTIAL).  
FT CARBOHYD 560 560 N-LINKED (GLCNAC. . .) (POTENTIAL).  
SQ SEQUENCE 676 AA; 76375 MW; 3FAC7ED82EA7E352 CRC64;

Query Match 69.8%; Score 30; DB 1; Length 676;  
Best Local Similarity 57.1%; Pred.No. 3.6e+02;  
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Oy 1 SLLMWIT 7  
:|:|:|



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: August 22, 2004, 10:55:43 ; Search time 39 Seconds

(without alignments)  
22.198 Million cell updates/sec

Title: US-10-706-475-10

Perfect score: 43

Sequence: 1 SLLMWITQX 9

Scoring table: BLOSUM62XX

Gapop 10.0 , Gapext 0.5

Searched: 283366 seqs, 96191526 residues

Total number of hits satisfying chosen parameters: 283366

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 50 summaries

Database :

1: pir1:\*

2: pir2:\*

3: pir3:\*

4: pir4:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	36	83.7	196	2 AE2876	conserved hypothet
2	36	83.7	198	2 G97652	hypothetical prote
3	35	81.4	861	2 S77086	hypothetical prote
4	34	79.1	122	2 S54492	probable membrane
5	34	79.1	299	2 D84519	probable endoxylg
6	33	76.7	479	2 E84179	hypothetical prote
7	32	74.4	145	2 A64469	hypothetical prote
8	32	74.4	278	2 G81139	hypothetical prote
9	32	74.4	456	1 I40516	spaf protein - Bac
10	32	74.4	724	2 A38748	3-phosphatidylinos
11	32	74.4	724	2 A38749	3-phosphatidylinos
12	32	74.4	724	2 A38747	phosphatidylincis
13	32	74.4	999	2 AG2413	hypothetical prote
14	32	74.4	1076	2 E96882	protein FLR22.14 (
15	32	74.4	2330	1 RRIWNV	genome polyprotein
16	32	74.4	2331	2 S44054	genome polyprotein
17	31	72.1	151	2 E69786	ribosomal-protein-
18	31	72.1	213	2 T07603	NADH2 dehydrogenas
19	31	72.1	228	2 S45677	proteinase inhibit
20	31	72.1	311	2 T11362	NADH2 dehydrogenas
21	31	72.1	349	2 E83434	translocation prot
22	31	72.1	437	2 C49274	protein farnesyltr
23	31	72.1	437	2 B49274	protein farnesyltr
24	31	72.1	437	2 A40037	protein farnesyltr
25	31	72.1	752	2 H96603	unknown protein Fl
26	31	72.1	897	2 G89923	hypothetical prote
27	31	72.1	1092	2 T12320	hypothetical prote
28	31	72.1	1398	2 T20434	hypothetical prote
29	30	69.8	53	2 H82027	hypothetical prote

30 30 69.8 83 1 WSWLHS  
31 30 69.8 121 1 K4HU  
32 30 69.8 129 2 S40347  
33 30 69.8 132 2 S46373  
34 30 69.8 133 1 K4HU1  
35 30 69.8 134 1 K4HU17  
36 30 69.8 134 2 S21917  
37 30 69.8 134 2 S49531  
38 30 69.8 135 2 P86756  
39 30 69.8 136 2 A49137  
40 30 69.8 138 2 A53261  
41 30 69.8 168 2 S77282  
42 30 69.8 170 2 T00221  
43 30 69.8 192 2 D90464  
44 30 69.8 231 2 B64711  
45 30 69.8 237 2 D83407  
46 30 69.8 240 2 S06084  
47 30 69.8 247 1 E50521  
48 30 69.8 262 2 H64623  
49 30 69.8 262 2 C71891  
50 30 69.8 281 2 T29825

E5 protein - human  
Ig kappa chain pre  
Ig kappa chain - h  
Ig kappa chain V-J  
Ig kappa chain pre  
Ig kappa chain pre  
Ig kappa chain V r  
anti-Sm antibody V  
prophage pi2 prote  
Ig kappa chain pre  
Ig kappa chain pre  
hypothetical prote  
type II secretion  
conserved hypothet  
conserved hypothet  
probable transcrip  
Ig kappa chain pre  
conserved hypothet  
spermidine synthas  
probable spermidin  
hypothetical prote

#### ALIGNMENTS

##### RESULT 1

AE2876

conserved hypothetical protein Atu2439 [imported] - Agrobacterium tumefaciens (strain C)  
C:Species: Agrobacterium tumefaciens  
C:Date: 11-Jan-2002 #sequence\_revision 11-Jan-2002 #text\_change 09-Dec-2002

A:Accession: AE2876

R:Wood, D.W.; Setubal, J.C.; Kaul, R.; Monks, D.; Chen, L.; Wood, G.E.; Chen, Y.; Woo, J.; Karp, P.; Romero, P.; Zhang, S.  
Science 294, 2317-2323, 2001

A:Authors: Yoo, H.; Tao, Y.; Biddle, P.; Jung, M.; Krespan, W.; Perry, M.; Gordon-Kamm,

seer, E.W.

A:Title: The Genome of the Natural Genetic Engineer Agrobacterium tumefaciens C58.

A:Reference number: AE2577; MUID:21608550; PMID:11743193

A:Accession: AE2876

A:Status: preliminary

A:Molecule type: DNA

A:Residues: 1-196 <KUP>

A:Cross-references: PIDN:AAL43427.1; PID:g17740928; GSPDB:GN00186

A:Experimental source: strain C58 (Dupont)

C:Genetics:

A:Gene: Atu2439

A:Map position: circular chromosome

C:Superfamily: uncharacterized conserved protein

Query Match 83.7%; Score 36; DB 2; Length 196;

Best Local Similarity 85.7%; Pred. No. 15;

Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY

1 SLLMWIT 7

Db 23 SLLMWIT 29

##### RESULT 2

G97652

hypothetical protein AGR\_C\_4424 [imported] - Agrobacterium tumefaciens (strain C58, Cer)

C:Species: Agrobacterium tumefaciens

C:Date: 30-Sep-2001 #sequence\_revision 30-Sep-2001 #text\_change 09-Dec-2002

A:Accession: G97652

R:Goodner, B.; Hinkle, G.; Gattung, S.; Miller, N.; Blanchard, M.; Qurollo, B.; Goldman

A.; Liu, F.; Wollam, C.; Allinger, M.; Doughty, D.; Scott, C.; Lappas, C.; Markelz, B.

Science 294, 2323-2328, 2001

A:Title: Genome Sequence of the Plant Pathogen and Biotechnology Agent Agrobacterium tu

A:Reference number: A97359; MUID:21608551; PMID:11743194

A:Accession: G97652

A:Status: preliminary

A:Molecule type: DNA  
 A:Residues: 1-198 <KUR>  
 A:Cross-references: GB:AB007869; PIDN:AAK88176.1; PID:g15157620; GSPDB:GN00169  
 C:Genetics:  
 A:Gene: AGR\_C\_4424  
 A:Map position: circular chromosome  
 C:Superfamily: uncharacterized conserved protein

Query Match 83.7%; Score 36; DB 2; Length 198;  
 Best Local Similarity 85.7%; Pred. No. 15;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
 |||||  
 DB 25 SLLMWIT 31

## RESULT 3

S77086  
 hypothetical protein sll0737 - Synecocystis sp. (strain PCC 6803)  
 C:Species: Synecocystis sp.  
 A:Variety: PCC 6803  
 C:Date: 25-Apr-1997 #sequence\_revision 25-Apr-1997 #text\_change 20-Jun-2000  
 C:Accession: S77086  
 R:Kaneko, T.; Sato, S.; Kotani, H.; Tanaka, A.; Asamizu, E.; Nakamura, Y.; Miyajima, N.; O, K.; Okumura, S.; Shimpo, S.; Takeuchi, C.; Wada, T.; Watanabe, A.; Yamada, M.; Yasuda  
 DNA Res. 3, 109-136, 1996  
 A:Title: Sequence analysis of the genome of the unicellular cyanobacterium Synecocystis  
 s.  
 A:Reference number: S74322; MUID:97061201; PMID:8905231  
 A:Accession: S77086  
 A:Status: nucleic acid sequence not shown; translation not shown  
 A:Molecule type: DNA  
 A:Residues: 1-861 <KAN>  
 A:Cross-references: EMBL:D64005; GB:AB001339; NID:g1001779; PIDN:BAA10778.1; PID:g100662  
 A:Note: the nucleotide sequence was submitted to the EMBL Data Library, June 1996  
 C:Superfamily: Synecocystis hypothetical protein sll0737

Query Match 81.4%; Score 35; DB 2; Length 861;  
 Best Local Similarity 75.0%; Pred. No. 95;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 |||||  
 DB 157 SLLWFTQ 164

## RESULT 4

S54492  
 probable membrane protein YMR123w - yeast (Saccharomyces cerevisiae)  
 N:Alternate names: hypothetical protein YMR564.05  
 C:Species: Saccharomyces cerevisiae  
 C:Date: 08-Jul-1995 #sequence\_revision 17-Nov-1995 #text\_change 19-Apr-2002  
 C:Accession: S54492  
 R:Lye, G.; Churcher, C.M.  
 submitted to the EMBL Data Library, May 1995  
 A:Reference number: S54014  
 A:Accession: S54492  
 A:Molecule type: DNA  
 A:Residues: 1-122 <LYE>  
 A:Cross-references: EMBL:Z49273; NID:g809577; PID:g809582; GSPDB:GN00013; MIPS:YMR123w  
 C:Genetics:  
 A:Gene: SGD:PKR1; MIPS:YMR123w  
 A:Cross-references: SGD:S0004730  
 A:Map position: 13R  
 C:Superfamily: Saccharomyces cerevisiae probable membrane protein YMR123w  
 C:Keywords: transmembrane protein  
 F;21-37/Domain: transmembrane #status predicted <TM1>  
 F;51-67/Domain: transmembrane #status predicted <TM2>

Query Match 79.1%; Score 34; DB 2; Length 122;  
 Best Local Similarity 85.7%; Pred. No. 22;  
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
 |||||  
 DB 56 SLLMWIT 62

## RESULT 5

D84519  
 Probable endoxylglucan glycosyltransferase [imported] - Arabidopsis thaliana  
 C:Species: Arabidopsis thaliana (mouse-ear cress)  
 C:Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 16-Feb-2001  
 C:Accession: D84519  
 R:Lin, X.; Kaul, S.; Rounsley, S.D.; Shea, T.P.; Benito, M.I.; Town, C.D.; Fujii, C.Y.; M.; Koo, H.; Moffat, K.S.; Cronin, L.A.; Shen, M.; VanAken, S.E.; Umayam, L.; Tallon, L.; euss, D.; Niernman, W.C.; White, O.; Eisen, J.A.; Salzberg, S.L.; Fraser, C.M.; Venter, J Nature 402, 761-769, 1999  
 A:Title: Sequence and analysis of chromosome 2 of the plant Arabidopsis thaliana.  
 A:Reference number: A84420; MUID:20083487; PMID:10617197  
 A:Accession: D84519  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-299 <STO>  
 A:Cross-references: GB:AE002093; NID:g3810598; PIDN:AAC69380.1; GSPDB:GN00139  
 C:Genetics:  
 A:Gene: At2g14620  
 A:Map position: 2  
 C:Superfamily: endoxylglucan transferase

Query Match 79.1%; Score 34; DB 2; Length 299;  
 Best Local Similarity 62.5%; Pred. No. 52;  
 Matches 5; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 |||||  
 DB 21 SLLWVSQ 28

## RESULT 6

F84179  
 hypothetical protein Vng0189c [imported] - Halobacterium sp. NRC-1  
 C:Species: Halobacterium sp. NRC-1  
 C:Date: 02-Feb-2001 #sequence\_revision 02-Feb-2001 #text\_change 02-Feb-2001  
 C:Accession: F84179  
 R:Ng, W.V.; Kennedy, S.P.; Mahairas, G.G.; Berquist, B.; Pan, M.; Shukla, H.D.; Lasky, S.; Leithauser, B.; Keller, K.; Cruz, R.; Danson, M.J.; Hough, D.W.; Maddocks, D.G.; Jablon  
 Jung, K.H.; Alam, M.; Freitas, T.  
 Proc. Natl. Acad. Sci. U.S.A. 97, 12176-12181, 2000  
 A:Authors: Hou, S.; Daniels, C.J.; Dennis, P.P.; Omer, A.D.; Ehardt, H.; Lowe, T.M.; Li  
 A:Title: Genome sequence of Halobacterium species NRC-1.  
 A:Reference number: A84160; MUID:20504483; PMID:11016950  
 A:Accession: F84179  
 A:Status: preliminary  
 A:Molecule type: DNA  
 A:Residues: 1-479 <STO>  
 A:Cross-references: GB:AE004437; NID:g10579836; PIDN:AAG18802.1; GSPDB:GN00138  
 C:Genetics:  
 A:Gene: VNG0189C

Query Match 76.7%; Score 33; DB 2; Length 479;  
 Best Local Similarity 62.5%; Pred. No. 1.3e+02;  
 Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
 - : |||||  
 DB 263 ALYMWVITQ 270

## RESULT 7

A64469  
 hypothetical protein MJ1354 - Methanococcus jannaschii  
 C:Species: Methanococcus jannaschii  
 C:Date: 13-Sep-1996 #sequence\_revision 13-Sep-1996 #text\_change 21-Jul-2000  
 C:Accession: A64469

R;Bult, C.J.; White, O.; Olsen, G.J.; Zhou, L.; Fleischmann, R.D.; Sutton, G.G.; Blake, A.; Reich, C.I.; Overbeek, R.; Kirkness, E.F.; Weinstock, K.G.; Merrick, J.M.; Glodek, A.; Ison, J.D.; Sadow, P.W.; Hanna, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A. Science 273, 1058-1073, 1996

A;Authors: Kaine, B.P.; Borodovsky, M.; Klenk, H.P.; Fraser, C.M.; Smith, H.O.; Woese, C. A;Title: Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii A;Reference number: A64300; MUID:96337999; PMID:868087

A;Accession: A64469

A;Status: preliminary; nucleic acid sequence not shown; translation not shown

A;Molecule type: DNA

A;Residues: 1-145 <BUL>

A;Cross-references: GB:U67575; GB:L77117; NID:g1591992; PIDN:AAB99366.1; PID:g1591997; I C;Genetics:

A;Map position: FOR1304340-1304777

Query Match 74.4%; Score 32; DB 2; Length 145;  
Best Local Similarity 71.4%; Pred. No. 60;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
|||||

Db 106 SLLVWVT 112  
|||||

RESULT 8  
G81139  
hypothetical protein NMB0938 [imported] - Neisseria meningitidis (strain MC58 serogroup C;Species: Neisseria meningitidis  
C;Date: 31-Mar-2000 #sequence\_revision 31-Mar-2000 #text\_change 19-Jan-2001  
C;Accession: G81139  
R;Tettelin, H.; Saunders, N.J.; Heidelberg, J.; Jeffries, A.C.; Nelson, K.E.; Eisen, J.A. Hickey, E.K.; Haft, D.H.; Salzberg, S.L.; White, O.; Fleischmann, R.D.; Dougherty, B.A.; Ri, H.; Qin, H.; Vamathevan, J.; Gill, J.; Scarlato, V.; Maignani, V.; Pizza, M. Science 287, 1809-1815, 2000

A;Authors: Grandi, G.; Sun, L.; Smith, H.O.; Fraser, C.M.; Moxon, E.R.; Rappuoli, R.; V A;Title: Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. A;Reference number: A81000; MUID:20175755; PMID:10710307

A;Accession: G81139

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-278 <TET>

A;Cross-references: GB:AE002445; GB:AE002098; NID:g7226173; PIDN:AAF41344.1; PID:g722617 A;Experimental source: serogroup B, strain MC58

C;Genetics:

A;Gene: NMB0938

Query Match 74.4%; Score 32; DB 2; Length 278;  
Best Local Similarity 71.4%; Pred. No. 1.1e+02;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
|||||

Db 7 SLLJLWT 13  
|||||

RESULT 9  
I40516  
spaf protein - Bacillus subtilis  
C;Species: Bacillus subtilis  
C;Date: 10-Sep-1999 #sequence\_revision 10-Sep-1999 #text\_change 19-Jan-2001  
C;Accession: I40516  
R;Klein, C.; Entian, K.D. Appl. Environ. Microbiol. 60, 2793-2801, 1994

A;Title: Genes involved in self-protection against the lantibiotic subtilin produced by A;Reference number: I40511; MUID:94368094; PMID:8085823

A;Accession: I40516

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-456 <RES>

A;Cross-references: EMBL:U09819; NID:g9595315; PID:g9595321

C;Genetics:

A;Gene: spaf

C;Superfamily: Bacillus subtilis spaf protein; ATP-binding cassette homology

C;Keywords: ATP; nucleotide binding; P-loop  
F;30-214/Domain: ATP-binding cassette homology <ABC>  
F;47-54/Region: nucleotide-binding motif A (P-loop)

Query Match 74.4%; Score 32; DB 1; Length 456;  
Best Local Similarity 71.4%; Pred. No. 1.8e+02;  
Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
|||||

Db 378 SLLJLWT 384  
|||||

RESULT 10  
A38748  
3-phosphatidylinositol kinase (EC 2.7.1.-) 85K chain - human  
C;Species: Homo sapiens (man)  
C;Date: 24-Jan-1992 #sequence\_revision 24-Jan-1992 #text\_change 16-Jul-1999  
C;Accession: A38748; S28402  
R;Skolnik, E.Y.; Margolis, B.; Mohammadi, M.; Lowenstein, E.; Fischer, R.; Drepps, A.; Cell 65, 83-90, 1991

A;Title: Cloning of p13 kinase-associated p85 utilizing a novel method for expression/c A;Reference number: A38748; MUID:91191565; PMID:1849461

A;Accession: A38748

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-724 <SKO>

A;Cross-references: GB:M61906  
R;Panayotou, G.; Bax, B.; Gout, I.; Federwisch, M.; Wrzblowski, B.; Dhand, R.; Fry, M.J. EMBO J. 11, 4261-4272, 1992

A;Title: Interaction of the p85 subunit of PI 3-kinase and its N-terminal SH2 domain wi A;Reference number: S28402; MUID:93049176; PMID:1330535

A;Accession: S28402

A;Status: preliminary

A;Molecule type: protein

A;Residues: 301-311,315-319,424-439 <PAN>

C;Genetics:

A;Gene: GDB:PIK3R1

A;Cross-references: GDB:I27604; OMIM:171833

A;Map position: 5q12-5q13

C;Superfamily: SH2 homology

C;Keywords: Phosphotransferase  
F;333-428/Domain: SH2 homology <SH2A>  
F;624-718/Domain: SH2 homology <SH2>

Query Match 74.4%; Score 32; DB 2; Length 724;  
Best Local Similarity 83.3%; Pred. No. 2.9e+02;  
Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 3 LMWITQ 8  
|||||

Db 581 LMWLTQ 586  
|||||

RESULT 11  
A38749  
3-phosphatidylinositol kinase (EC 2.7.1.-) 85K chain alpha - bovine  
C;Species: Bos primigenius taurus (cattle)  
C;Date: 14-Feb-1992 #sequence\_revision 14-Feb-1992 #text\_change 05-Nov-1999  
C;Accession: A38749  
R;Otsu, M.; Hiles, I.; Gout, I.; Fry, M.J.; Ruiz-Larrea, F.; Panayotou, G.; Thompson, A. Cell 65, 91-104, 1991

A;Title: Characterization of two 85 kd proteins that associate with receptor tyrosine k A;Reference number: A38749; MUID:91191567; PMID:1707345

A;Accession: A38749

A;Status: preliminary

A;Molecule type: mRNA

A;Residues: 1-724 <OTS>

A;Cross-references: GB:M61746; GB:M61745; NID:g163476; PIDN:AAA79511.1; PID:g163477

C;Superfamily: SH2 homology

C;Keywords: phosphotransferase  
F;333-428/Domain: SH2 homology <SH2A>

F:624-718/Domain: SH2 homology <SH2>

Query Match 74.4%; Score 32; DB 2; Length 724;

Best Local Similarity 83.3%; Pred. No. 2.9e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 LLMWITQ 8

|||:|

Db 581 LLMWITQ 586

RESULT 12

A38747

phosphatidylinositol 3-kinase (EC 2.7.1.1-) 85K chain - mouse

C:Species: Mus musculus (house mouse)

C:Date: 03-Aug-1992 #sequence\_revision 03-Aug-1992 #text\_change 16-Jul-1999

C:Accession: A38747

R:Escobedo, J.A.; Navankasattusas, S.; Kavanaugh, W.M.; Milfay, V.A.; William

Cell 65, 75-82, 1991

A:Title: cDNA cloning of a novel 85 kd protein that has SH2 domains and regulates binding

A:Reference number: A38747; MUID:91191564; PMID:1849460

A:Accession: A38747

A:Molecule type: mRNA

A:Residues: 1-724 <ESC>

A:Cross-references: GB:M60651

C:Comment: This protein binds a phosphotyrosine-containing sequence of ligand-activated phosphatidylinositol at position 3 of the inositol ring.

C:Superfamily: SH2 homology

C:Keywords: phosphotransferase

F:333-428/Domain: SH2 homology <SH2A>

F:624-718/Domain: SH2 homology <SH2>

Query Match

Best Local Similarity 83.3%; Pred. No. 2.9e+02;

Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 3 LLMWITQ 8

|||:|

Db 581 LLMWITQ 586

RESULT 13

AG2413

hypothetical protein alr4863 [imported] - Nostoc sp. (strain PCC 7120)

C:Species: Nostoc sp. PCC 7120

A:Note: Nostoc sp. strain PCC 7120 is a synonym of Anabaena sp. strain PCC 7120

C:Date: 14-Dec-2001 #sequence\_revision 14-Dec-2001 #text\_change 09-Dec-2002

C:Accession: AG2413

R:Kaneko, T.; Nakamura, Y.; Wolk, C.P.; Kuritz, T.; Sasamoto, S.; Watanabe, A.; Iriguchi

Nakazaki, N.; Shimpo, S.; Sugimoto, M.; Takazawa, M.; Yamada, M.; Yasuda, M.; Tabata, S

DNA Res. 8, 205-213, 2001

A:Title: Complete Genomic Sequence of the Filamentous Nitrogen-fixing Cyanobacterium Ana

A:Reference number: AB1807; MUID:21595285; PMID:11759840

A:Accession: AG2413

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-999 <KUR>

A:Cross-references: GB:BA000019; PIDN:BA076562.1; PID:G17134000; GSPDB:GN00179

A:Experimental source: strain PCC 7120

C:Genetics:

A:Gene: alr4863

Query Match

Best Local Similarity 62.5%; Pred. No. 3.9e+02;

Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8

|||:|

Db 11 SLLQWVSQ 18

RESULT 14

B96682

genome polypeptide - Marburg virus (strain Popp)

N:Alternate names: structural protein L

N:Contains: RNA-directed RNA polymerase (EC 2.7.7.48)

protein F1E22.14 [imported] - Arabidopsis thaliana

C:Species: Arabidopsis thaliana (mouse-ear cress)

C:Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 31-Mar-2001

R:Accession: B96682

R:Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso, Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.; ansen, N.F.; Hughes, B.; Huizar, L.

Nature 408, 816-820, 2000

A:Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.

C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Lueros, J.S.; Maiti, R.; Marziali,

Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.

A:Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,

ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.

A:Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.

A:Reference number: A66141; MUID:21016719; PMID:11130712

A:Accession: B96682

A>Status: preliminary

A:Molecule type: DNA

A:Residues: 1-1076 <STO>

A:Cross-references: GB:AB005173; NID:G6686403; PIDN:AAF23837.1; GSPDB:GN00141

C:Genetics:

A:Gene: F1E22.14

A:Map position: 1

Query Match

Best Local Similarity 74.4%; Score 32; DB 2; Length 1076;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2 LLMWITQ 8

:|:|

Db 1016 LLMWITQ 1022

RESULT 15

RRIMV

genome polypeptide - Marburg virus (strain Musoke)

N:Alternate names: L protein

N:Contains: RNA-directed RNA polymerase (EC 2.7.7.48)

C:Species: Marburg virus

A:Note: host Homo sapiens (man)

C:Date: 31-Mar-1993 #sequence\_revision 31-Mar-1993 #text\_change 11-Jun-1999

C:Accession: A42450

R:Muehlberger, E.; Sanchez, A.; Randolph, A.; Wall, C.; Kiley, M.P.; Klenk, H.D.; Feldman

Virolology 187, 534-547, 1992

A:Title: The nucleotide sequence of the L gene of Marburg virus, a filovirus: homologues

A:Reference number: A42450; MUID:92188528; PMID:1546452

A:Accession: A42450

A:Molecule type: genomic RNA

A:Residues: 1-2330 <MOE>

A:Cross-references: GB:M92834; NID:G332178; PIDN:AAA46562.1; PID:G332179

C:Genetics:

A:Gene: L

C:Superfamily: parainfluenza virus RNA-directed RNA polymerase

C:Keywords: ATP; nucleotidyltransferase; RNA biosynthesis

F:1325-1360/Domain: ATP binding #status predicted <ATL>

F:1390-1420/Domain: ATP binding #status predicted <AT2>

F:1560-1593/Domain: ATP binding #status predicted <AT3>

F:1932-1961/Domain: ATP binding #status predicted <AT4>

Query Match 74.4%; Score 32; DB 1; Length 2330;

Best Local Similarity 62.5%; Pred. No. 8.9e+02;

Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SLLMWITQ 8

|:|:|

Db 1249 SLLMWITQ 1256

C:Species: Marburg virus  
A:Variety: strain Popp  
C:Date: 13-Jan-1995 #sequence\_revision 13-Jan-1995 #text\_change 18-Jun-1999  
C:Accession: S44054; S32776 V.E.; Blinov, V.M.; Dryga, S.A.; Netesov, S.V.  
R:Bukreyev, A.A.; Volchikov, V.E.; Blinov, V.M.; Dryga, S.A.; Netesov, S.V.  
Submitted to the EMBL Data Library, January 1994  
A:Description: Full-length nucleotide sequence of Marburg virus Popp strain: The complete  
A:Reference number: S44049  
A:Accession: S44054  
A:Molecule type: genomic RNA  
A:Residues: 1-2331 <BUK>  
A:Cross-references: EMBL:Z293337; NID:g450908; PIDN:CAA82542.1; PID:g450915  
A:Experimental source: strain Popp  
R:Bukreyev, A.A.; Netesov, S.V.  
Submitted to the EMBL Data Library, September 1992  
A:Description: The partial nucleotide sequence of Marburg virus genome.  
A:Reference number: S32775  
A:Accession: S32776  
A:Molecule type: genomic RNA  
A:Residues: 1-2331 <BUW>  
A:Cross-references: EMBL:X68494; NID:g296962; PIDN:CAA48508.1; PID:g296963  
A:Experimental source: strain Popp  
C:Genetics:  
A:Gene: L  
C:Superfamily: parainfluenza virus RNA-directed RNA polymerase  
C:Keywords: ATP; nucleotidyltransferase

Query Match 74.4%; Score 32; DB 2; Length 2331;  
Best Local Similarity 62.5%; Pred. No. 8.9e+02;  
Matches 5; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWITQ 8  
| | | | |  
DB 1249 SRLJWITQ 1256

RESULT 17  
E69786  
ribosomal-protein-alanine N-acetyltransfer homolog ydiD - Bacillus subtilis  
C:Species: Bacillus subtilis  
C:Date: 05-Dec-1997 #sequence\_revision 05-Dec-1997 #text\_change 20-Jun-2000  
C:Accession: E69786  
R:Kunst, F.; Ogasawara, N.; Moszer, I.; Albertini, A.M.; Alloni, G.; Azevedo, V.; Berter  
C.; Bron, S.; Bouilliet, S.; Brusch, C.V.; Caldwell, B.; Capuano, V.; Carter, N.M.; Cho  
A.; Ehrlich, S.D.; Emmerson, P.T.; Entian, K.D.; Errington, J.; Fabret, C.; Ferrati, B.  
Nature 390, 249-256, 1997  
A:Authors: Foulger, D.; Fritz, C.; Fujita, M.; Fujita, Y.; Fuma, S.; Galizzi, A.; Gallen  
lech, J.; Harwood, C.R.; Henaut, A.; Hilbert, H.; Holsappel, S.; Hosono, S.; Hullo, M.F.  
Koetter, P.; Koningstein, G.; Krogh, S.; Kumano, M.; Kurita, K.; Lapidos, A.; Lardinois,  
A:Authors: Lauber, J.; Lazarevic, V.; Lee, S.M.; Levine, A.; Liu, H.; Masuda, S.; Maueel  
Y, M.; Ogawa, K.; Ogilwara, A.; Oudega, B.; Park, S.H.; Parro, V.; Pohl, T.M.; Portetelle  
Rieger, M.; Rivolta, C.; Rocha, B.; Roche, B.; Rose, M.; Sadaie, Y.; Sato, T.; Scanlon,  
A:Authors: Schleich, S.; Schroeter, R.; Scoffone, P.; Sekiguchi, J.; Sekowska, A.; Seron  
akeuchi, M.; Tamakoshi, A.; Tanaka, T.; Terpstra, P.; Tognoni, A.; Tosato, V.; Uchiyama,  
T.; Winters, P.; Wipat, A.; Yamamoto, H.; Yamane, K.; Yasumoto, K.; Yata, K.; Yoshida, K  
A:Authors: Yoshikawa, H.F.; Zumstein, E.; Yoshikawa, H.; Danchin, A.  
A:Title: The complete genome sequence of the Gram-positive bacterium Bacillus subtilis.  
A:Reference number: A69580; MUID:98044033; PMID:9384377  
A:Accession: E69786  
A:Status: Preliminary; nucleic acid sequence not shown; translation not shown  
A:Molecule type: DNA  
A:Residues: 1-151 <RUN>  
A:Cross-references: GB:Z99107; GB:AL009126; NID:g2632866; PIDN:CAB12412.1; PID:g2632906  
A:Experimental source: strain 168  
C:Genetics:  
A:Gene: ydiD  
C:Superfamily: Escherichia coli ribosomal-protein-alanine N-acetyltransferase rimi

Query Match 72.1%; Score 31; DB 2; Length 151;  
Best Local Similarity 57.1%; Pred. No. 95;  
Matches 4; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
| | | | |

Db 142 ALIMWVT 148  
| | | | |

RESULT 18  
T07603  
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) 22K chain - potato  
C:Species: Solanum tuberosum (potato)  
C:Date: 14-May-1999 #sequence\_revision 14-May-1999 #text\_change 03-Jun-2002  
C:Accession: T07603  
R:Heiser, V.; Grolmann, L.; Brennicke, A.  
Plant Mol. Biol. 31, 1195-1204, 1996  
A:Title: The plant mitochondrial 22 kDa (PSST) subunit of respiratory chain complex I  
A:Reference number: Z16044; MUID:97071689; PMID:8914535  
A:Accession: T07603  
A:Status: preliminary; translated from GB/EMBL/DDBJ  
A:Molecule type: mRNA  
A:Residues: 1-213 <HEI>  
A:Cross-references: EMBL:X96671; NID:g1235606; PIDN:CAA65451.1; PID:g1235607  
A:Experimental source: cv. Desiree; green leaves  
C:Genetics:  
A:Gene: PSST  
A:Genome: nuclear  
A:Superfamily: psbG protein  
C:Keywords: electron transfer; membrane-associated complex; mitochondrion; NAD; oxidore

Query Match 72.1%; Score 31; DB 2; Length 213;  
Best Local Similarity 85.7%; Pred. No. 1.3e+02;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2 LLMWITQ 8  
| | | | |

Db 207 LLMWWTQ 213  
| | | | |

RESULT 19  
S45677  
proteinase inhibitor - signal crayfish  
C:Species: Pacifastacus leniusculus (signal crayfish)  
C:Date: 07-Oct-1994 #sequence\_revision 10-Nov-1995 #text\_change 03-Feb-2003  
C:Accession: S45677  
R:Johansson, M.W.; Keyser, P.; Soederhaell, K.  
Eur. J. Biochem. 223, 389-394, 1994  
A:Title: Purification and cDNA cloning of a four-domain Kazal proteinase inhibitor from  
A:Reference number: S45677; MUID:94333326; PMID:8055907  
A:Accession: S45677  
A:Molecule type: mRNA  
A:Residues: 1-228 <JOH>  
A:Cross-references: EMBL:X79512; NID:9498784; PIDN:CAA56043.1; PID:g498785  
C:Keywords: serine proteinase inhibitor  
F:21-66/Domain: Kazal proteinase inhibitor homology <KP1>  
F:72-119/Domain: Kazal proteinase inhibitor homology <KP2>  
F:123-170/Domain: Kazal proteinase inhibitor homology <KP3>  
F:174-221/Domain: Kazal proteinase inhibitor homology <KP4>

Query Match 72.1%; Score 31; DB 2; Length 228;  
Best Local Similarity 85.7%; Pred. No. 1.4e+02;  
Matches 6; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWIT 7  
| | | | |

Db 4 SLLTWIT 10  
| | | | |

RESULT 20  
T11362  
NADH2 dehydrogenase (ubiquinone) (EC 1.6.5.3) chain 1 - Daphnia pulex mitochondrion  
C:Species: mitochondrion Daphnia pulex  
C:Date: 16-Jul-1999 #sequence\_revision 16-Jul-1999 #text\_change 03-Jun-2002  
C:Accession: T11362  
R:Crease, T.J.  
Gene 233, 89-99, 1999  
A:Title: The complete sequence of the mitochondrial genome of Daphnia pulex (Cladocera:

A;Reference number: Z17264; MUID:99307147; PMID:10375625

A;Accession: T11362

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: DNA

A;Residues: 1-311 <CRE>

A;Cross-references: EMBL:AF117817; NID:g4927669; PID:g4927682; PIDN:AAD33242.1

C;Genetics:

A;Gene: NDI

A;Genome: mitochondrion

A;Genetic code: SGC4

C;Superfamily: NADH dehydrogenase (ubiquinone) chain 1

C;Keywords: membrane-associated complex; mitochondrion; NAD; oxidative phosphorylation;

Query Match

Best Local Similarity 72.1%; Score 31; DB 2; Length 311;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7

DB 83 SLLMWLS 89

RESULT 21

B83434

A;Title: translocation protein in type III secretion PA1690 [imported] - Pseudomonas aeruginosa

C;Species: Pseudomonas aeruginosa

C;Date: 15-Sep-2000 #sequence\_revision 15-Sep-2000 #text\_change 31-Dec-2000

A;Accession: B83434

R;Stover, C.K.; Pham, X.Q.; Erwin, A.L.; Mizoguchi, S.D.; Warren, P.; Hickey, M.J.; B

adman, S.; Yuan, Y.; Brady, L.L.; Coulter, S.N.; Folger, K.R.; Kas, A.; Larbig, K.; Lim,

; Lory, S.; Olson, M.V.

Nature 406, 959-964, 2000

A;Title: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic patho

A;Reference number: A82950; MUID:20437337; PMID:10984043

A;Accession: B83434

A;Status: preliminary

A;Molecule type: DNA

A;Residues: 1-349 <SPO>

A;Cross-references: GB:AE004596; GB:AE004091; NID:g9947658; PIDN:AAG05079.1; GSPDB:GN001

A;Experimental source: strain PA01

C;Genetics:

A;Gene: pscU; PA1690

C;Superfamily: flagellar biosynthetic protein flhB; flhB carboxyl-terminal homology

Query Match

Best Local Similarity 72.1%; Score 31; DB 2; Length 349;

Matches 5; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1 SLLMWIT 7

DB 151 SLLWVLT 157

RESULT 22

C49274

A;Title: protein farnesyltransferase (EC 2.5.1.1-) beta subunit - bovine

N;Alternate names: farnesyl-protein transferase beta subunit; FTPase beta subunit; preny

C;Species: Bos primigenius taurus (cattle)

C;Date: 25-Feb-1994 #sequence\_revision 18-Nov-1994 #text\_change 20-Sep-1999

A;Accession: C49274

R;Omer, C.A.; Kral, A.M.; Diehl, R.E.; Prendergast, G.C.; Powers, S.; Allen, C.M.; Gibbs

Biochemistry 32, 5167-5176, 1993

A;Title: Characterization of recombinant human farnesyl-protein transferase: cloning, ex

A;Reference number: A49274; MUID:93264431; PMID:8494894

A;Accession: C49274

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: mRNA

A;Residues: 1-437 <ONE>

A;Experimental source: brain

A;Note: sequence extracted from NCBI backbone (NCBIP:132834)

C;Superfamily: DPPI protein

C;Keywords: transferase

Query Match

Best Local Similarity 72.1%; Score 31; DB 2; Length 437;

Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWIT 7

DB 272 SLLQWVT 278

RESULT 23

B49274

A;Title: protein farnesyltransferase (EC 2.5.1.1-) beta subunit - human

N;Alternate names: farnesyl-protein transferase beta subunit; FTPase beta subunit; preny

C;Species: Homo sapiens (man)

C;Date: 25-Feb-1994 #sequence\_revision 18-Nov-1994 #text\_change 01-Dec-2000

A;Accession: B49274; I60951

R;Omer, C.A.; Kral, A.M.; Diehl, R.E.; Prendergast, G.C.; Powers, S.; Allen, C.M.; Gibbs

Biochemistry 32, 5167-5176, 1993

A;Title: Characterization of recombinant human farnesyl-protein transferase: cloning, ex

A;Reference number: A49274; MUID:93264431; PMID:8494894

A;Accession: B49274

A;Status: preliminary; not compared with conceptual translation

A;Molecule type: mRNA

A;Residues: 1-437 <ONE>

A;Experimental source: Placenta

A;Note: sequence extracted from NCBI backbone (NCBIP:132829)

R;Andres, D.A.; Milatovich, A.; Ozcelik, T.; Wenzlau, J.M.; Brown, M.S.; Goldstein, J.L.

Genomics 18, 105-112, 1993

A;Title: cDNA cloning of the two subunits of human CAAX farnesyltransferase and chromoso

A;Reference number: A47659; MUID:94102736; PMID:8276393

A;Accession: I60951

A;Status: preliminary; translated from GB/EMBL/DBJ

A;Molecule type: mRNA

A;Residues: 51-282, 'L', 284-437 <RES>

A;Cross-references: GB:L10414; NID:g3988757; PIDN:AAA86286.1; PID:g3988758

C;Genetics:

A;Gene: GDB:FNTB

A;Cross-references: GDB:L138174; OMIM:134636

A;Map position: 14q23-14q24

C;Superfamily: DPPI protein

C;Keywords: transferase

Query Match

Best Local Similarity 72.1%; Score 31; DB 2; Length 437;

Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 SLLMWIT 7

DB 272 SLLQWVT 278

RESULT 24

A40037

A;Title: protein farnesyltransferase (EC 2.5.1.1-) beta chain - rat

C;Species: Rattus norvegicus (Norway rat)

C;Date: 16-Oct-1992 #sequence\_revision 16-Oct-1992 #text\_change 05-Nov-1999

A;Accession: A40037

R;Chen, W.J.; Andres, D.A.; Goldstein, J.L.; Russell, D.W.; Brown, M.S.

Cell 66, 327-334, 1991

A;Title: cDNA cloning and expression of the peptide-binding beta subunit of rat p21(ras)

A;Reference number: A40037; MUID:91309145; PMID:1855253

A;Accession: A40037

A;Molecule type: mRNA

A;Residues: 1-437 <CHE>

A;Cross-references: GB:M69056; NID:G204185; PIDN:AAA41176.1; PID:G204186

C;Comment: This protein attaches farnesyl residues to a cysteine near the carboxyl termi

C;Superfamily: DPPI protein

C;Keywords: heterodimer; transferase

Query Match

Best Local Similarity 72.1%; Score 31; DB 2; Length 437;

Matches 5; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1 SLLMWIT 7  
 ||| |:  
 Db 272 SLLQWVT 278

## RESULT 25

H96603  
 unknown protein F14G9.16 [imported] - Arabidopsis thaliana  
 C/Species: Arabidopsis thaliana (mouse-ear cress)  
 C/Date: 02-Mar-2001 #sequence\_revision 02-Mar-2001 #text\_change 31-Mar-2001  
 C/Accession: H96603  
 R/Theologis, A.; Ecker, J.R.; Palm, C.J.; Federspiel, N.A.; Kaul, S.; White, O.; Alonso,  
 Chin, C.W.; Chung, M.K.; Conn, L.; Conway, A.B.; Conway, A.R.; Creasy, T.H.; Dewar, K.;  
 anser, N.F.; Hughes, B.; Huizar, L.  
 Nature 408, 816-820, 2000  
 A/Authors: Hunter, J.L.; Jenkins, J.; Johnson-Hopson, C.; Khan, S.; Khaykin, E.; Kim, C.  
 C.A.; Li, J.H.; Li, Y.; Lin, X.; Liu, S.X.; Liu, Z.A.; Luros, J.S.; Maiti, R.; Marziani,  
 Rizzo, M.; Rooney, T.; Rowley, D.; Sakano, H.  
 A/Authors: Salzberg, S.L.; Schwartz, J.R.; Shinn, P.; Southwick, A.M.; Sun, H.; Tallon,  
 ker, M.; Wu, D.; Yu, G.; Fraser, C.M.; Venter, J.C.; Davis, R.W.  
 A/Title: Sequence and analysis of chromosome 1 of the plant Arabidopsis.  
 A/Reference number: A86141; MUID:21016719; PMID:11130712  
 A/Accession: H96603  
 A/Status: preliminary  
 A/Molecule type: DNA  
 A/Residues: 1-752 <STO>  
 A/Cross-references: GB:AE005173; NID:g11094723; PIDN:RAG29658.1; GSPDB:GNC00141  
 C/Genetics:  
 A/Gene: F14G9.16  
 A/Map position: 1

Query Match : 72.1%; Score 31; DB 2; Length 752;  
 Best Local Similarity 83.3%; Pred. No. 4.5e+02;  
 Matches 5; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 2 LLMWIT 7  
 ||| |:  
 Db 223 LLMWLT 228

Search completed: August 22, 2004, 11:03:08  
 Job time : 40 secs

This Page Blank (uspro)